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ABC: ATP-binding cassette 
ACYP2: acylphosphatase 2, muscle type 
ADA: adenosine deaminase 
ADME: drug absorption, distribution, metabolism and elimination 
ADR: adverse drug reaction 
AFR: 1000 Genomes Project African population 
AMPK: AMP-activated protein kinase 
AMR: 1000 Genomes Project admixed American population 
AP: alkaline phosphatase 
AQP: aquaporin 
ARE: antioxidant response element 
Arntl: aryl hydrocarbon receptor nuclear translocator-like 
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ASN: 1000 Genomes Project East Asian population 
ATP: adenosine triphosphate 
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BCL2: B-cell CLL/lymphoma 2 
bp: base pairs 
C: cytosine 
C2: complement component 2 
C3: complement component 3 
C5: complement component 5 
CAF: Central Analytical Facility 
cAMP: cyclic adenosine monophosphate 
CAT: catalase 
Cau: Caucasian 
CCND1: cyclin D1 
CDH13: cadherin 13 
CFB: complement factor B 
CFTR: cystic fibrosis transmembrane conductance regulator 








CREB: cAMP response element-binding protein 
CREBBP: CREB binding protein 
CTCAE: Common Terminology Criteria for Adverse Events 
CTR1: copper transporter 1 
CUBN: cubilin 
dB: decibel 
dB HL: decibels hearing loss 
DFNA: deafness, autosomal dominant 
DFNB: deafness, autosomal recessive 
DFNX: deafness, X-linked 
DNA: deoxyribonucleic acid 
dNTP: 2`-deoxynucleotide-5`-triphosphate 
DP: read depth 
DPYD: dihydropyrimidine dehydrogenase 
DYX1C1: dyslexia susceptibility 1 candidate 1 
EDTA: ethylenediamine tetra-acetic acid 
EIF3A: eukaryotic translation initiation factor 3, subunit A 
EP300: E1A binding protein p300 
ERBB: Erb-B2 receptor tyrosine kinase 
ERCC: excision repair cross-complementation group 
ERK: extracellular signal-regulated kinase 
EUR: 1000 Genomes Project European population 
ExoI: exonuclease I 
FDA: Food and Drug Administration of America 
FLII: flightless I homologue (Drosophila) 
FRAS1: Fraser extracellular matrix complex subunit 1 
FREM2: FRAS1 related extracellular matrix protein 2 
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G: guanine 
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GJB2: gap junction protein, beta 2 
GO: gene ontology 
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GRB7: growth factor receptor-bound protein 7 
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GST: glutathione S-transferase 
GWAS: genome-wide association study 
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HER2: human epidermal growth factor receptor 2 
HO-1: haem oxygenase 1 
HREC: Human Research Ethics Committee 
HWE: Hardy-Weinberg Equilibrium 
Hz: hertz 
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ID: identifier 
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JNK: c-Jun N-terminal kinase 
KEAP1: kelch-like ECH-associated protein 1 
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LARP1B: La ribonucleoprotein domain family, member 1B 
LD: linkage disequilibrium 
LRP2: low-density lipoprotein receptor-related 2 
LRR: leucine rich repeat 
LRRC3B: leucine rich repeat containing 3B 
LRRFIP1: leucine rich repeat interacting protein 1 
MA: mixed ancestry 
MAF: minor allele frequency 




MMR: mismatch repair 
mRNA: messenger RNA 
MRP: multidrug resistance associated protein 
mtDNA: mitochondrial DNA 
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MT-RNR1: mitochondrially encoded 12S RNA 
n: number of individuals 
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Cisplatin, a potent chemotherapeutic agent, is widely used in the treatment of numerous 
soft-tissue cancers. Although high cure rates can be achieved when cisplatin is incorporated 
in chemotherapy regimens, the therapeutic utility of the drug may be limited by the 
development of dose-limiting adverse reactions in patients. A prevalent reaction to cisplatin 
is ototoxicity, or drug-induced hearing loss, which occurs when the drug accumulates in and 
damages cells of the inner ear, leading to permanent and progressive hearing impairment. In 
this investigation, two approaches were employed to explore the role of genetics in cisplatin 
response amongst South African cancer patients (n = 214). Using a candidate gene 
approach, which investigated variants in six genes which are involved in drug transport and 
processing, potential modifiers in the genes nuclear factor, erythroid 2-like 2 (NFE2L2) and 
solute carrier family 22, member 2 (SLC22A2) were identified. SLC22A2 encodes a known 
transporter of cisplatin, and the variant rs316019 conferred potentially protective effects 
against Chang- and TUNE-graded ototoxicity through a reduced transport of the drug (p = 
0.039 and p = 0.031, respectively). Similarly, the variant NFE2L2 rs6721961 was possibly 
protective, as it occurred more frequently in patients who did not develop hearing impairment 
according to four different ototoxicity grading scales during high-dose (≥ 200 mg/m2) cisplatin 
treatment (ASHA, p = 0.001; Chang, p = 0.022; CTCAE, p = 0.001; TUNE, p = 0.028). When 
supplementing the prospective cohort with retrospective patient data, an increased 
susceptibility of indigenous African patients to Chang grade > 0 ototoxicity was observed (p 
= 0.001). For this reason, whole-exome sequencing was conducted on a subset of the 
patient cohort (n = 11), focussing on individuals of African origin who represented the 
phenotype extremes. Potential genetic modifiers were identified in genes involved in various 
biological processes, including transmembrane transport, development, hearing, the 
response to DNA damage, immune reactions and signalling pathways, implicating many 
previously unreported genes in the cellular response to cisplatin as well as its ototoxicity. 
The results reported in this study indicate that genetic information can improve predictive 
models of cisplatin response, although there are many novel genes which should be 
explored in the South African population. Identifying these genetic modifiers, such as those 
in SLC22A2 and NFE2L2, has the potential to further our understanding of this adverse drug 












Non-communicable diseases (NCDs) can affect individuals from any age group and any 
geographical region. It is noteworthy then that up to 80% of all NCD-related deaths, and 90% 
of those before the age of 60 years, occur in developing countries (World Health 
Organisation [WHO], 2012). One of the most prevalent NCDs is cancer, a disease 
characterised by uncontrolled cell division and growth, leading to the development of 
tumours (Marx, 1994).  
 
While the causes of cancer are diverse, chromosomal instability (Boyer et al, 1995) and 
genetic mutations (Salk et al, 2010) are usually involved, and lead to the formation of 
immortal neoplastic cells. These cells are able to evade cell death pathways and the human 
immune system, and may metastasise to other organs in the body (Hanahan and Weinberg, 
2011). Although tumorous tissue can be surgically removed in some instances, a multimodal 
approach to therapy is usually required in the treatment of locally advanced cancers. These 
antineoplastic regimens may include the utilisation of chemotherapy and radiation therapy 
(RT) to target and destroy the cancerous cells.  
 
Despite advances in our knowledge of the disease and the development of new methods to 
treat various tumour types, neoplasia remains a leading cause of mortality worldwide. 
Approximately 8.2 million deaths in 2012 were cancer-related, 65% of which occurred in 
developing countries (Globocan, 2012). It is estimated that 12.7 million new cases were 
diagnosed in 2008 (WHO, 2012) and 14.1 million in 2012 (WHO, 2014). This is projected to 
reach 22 million new cancer diagnoses by 2030 (WHO, 2012). Cancer is a significant 
disease burden in South Africa (SA), with more than 100,000 diagnoses and an estimated 
40,000 cancer-related deaths every year (Mayosi et al, 2009). Aspects involved in 
addressing the global cancer burden may include prevention and early detection, but one 
focus of research is improving the management of newly diagnosed patients. Because the 
incidence of neoplasia is still increasing, part of this research must explore optimising the 
use of already existing therapies, for example by targeting treatment to those patients who 







1.2 Adverse drug reactions  
 
An important consideration in the optimisation of therapy is the development of adverse drug 
reactions (ADRs), which illustrate an aspect of heterogeneity in drug response amongst 
patients. ADRs are detrimental and unintended reactions to therapy which occur within the 
approved dosage recommendations (Su et al 2014), and may or may not be accompanied 
by success of treatment. Adverse reactions to medications have been reported to affect 
between 6.5% and 14.7% of all patients in international hospitals (Lazarou et al, 1998; 
Pirmohamed et al, 2004; Davies et al, 2009). Although there is less published data from 
developing countries such as SA, the prevalence of ADRs can be expected to be 
comparable (Mehta et al, 2007). ADRs range from relatively mild, reversible reactions to 
severe, irreversible and, in some instances, fatal drug reactions (Pirmohamed et al, 2004). In 
addition to an increase in morbidity and mortality amongst patients, severe ADRs can lead to 
permanent disability and have other consequences on patient quality-of-life (Su et al, 2014). 
The impact of ADRs in healthcare systems can therefore be considerable, as treatment 
regimens may require additional methods of monitoring, preventing, or treating ADRs, and 
they can alter the treatment or lead to its discontinuation.  
 
Most ADRs are influenced by both clinical and demographic factors such as patient age and 
drug dosages (Alomar, 2014); however, there is still variability in the response to numerous 
therapeutics which cannot be explained by these factors. Increasing evidence suggests that 
genetics plays a role in modifying the risk of ADR development (Su et al, 2014), but much of 
this genetic influence remains uninvestigated. In the prioritisation of ADRs for future genetic 
research, factors which should be considered include the severity and burden of the ADR, its 
irreversibility, expected incidence rate, tendency to cause life-long disability, and economic 
impact (Shaw et al, 2013). Ototoxicity is an adverse reaction to cisplatin therapy which 
meets many of these prioritisation criteria (Shaw et al, 2013), and is the subject of 




Cisplatin (cis-diamminedichloroplatinum(II), trade name Platinol) is a potent antineoplastic 
agent. Platinum-based compounds were originally discovered to have chemotherapeutic 
properties in the 1970s, when they were able to successfully regress large sarcoma tumours 
in mouse models (Rosenberg and VanCamp, 1970). Since its introduction into clinical 
practice, cisplatin has been effectively administered in the first-line treatment and 
management of a diversity of soft-tissue cancer types (McKeage, 1995).  
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In treatment regimens, cisplatin is often combined with RT and other chemotherapeutics 
such as etoposide, bleomycin, vincristine, doxorubicin and 5-fluorouracil (5-FU) (Homesley 
et al, 1999; Ortega et al, 2000). The incorporation of cisplatin into combination therapies 
improved the cure rate of testicular cancer from 5% to over 90% (Einhorn, 2002), and 
significantly lengthened progression-free survival in advanced cervical cancer patients (Rose 
et al, 1999). Cisplatin-containing regimens have been successfully used in the treatment of 
many other neoplasms, such as ovarian, lung, head and neck, bladder, and oesophageal 
cancers, where high cure rates are often achieved (McKeage, 1995). 
 
1.3.1 Cisplatin’s mechanism of action 
 
Cisplatin is administered intravenously to patients and is circulated throughout the body by 
the cardiovascular system. In the blood, cisplatin remains a neutral molecule, but is 
converted into an aquated and cytotoxic form upon entry into cancer cells. The uptake of 
cisplatin occurs largely via passive diffusion (Gale et al, 1973), although transporters such as 
copper transporter 1 (CTR1) have been demonstrated to actively facilitate this process 
(Holzer et al, 2004). The aquated form of cisplatin is cationic and highly reactive, and in this 
form induces extensive cellular damage, binding to proteins (Akaboshi et al, 1992; Neault et 
al, 2001), membrane phospholipids (Speelmans et al, 1997), cytoskeletal microfilaments 
(Christen et al, 1993), RNA (Hostetter et al, 2012), and DNA (Akaboshi et al, 1992), as well 
as causing mitochondrial dysfunction and calcium efflux (Aggarwal, 1993).  
 
Although the exact mechanism of cisplatin’s cytotoxicity has not yet been established, it is 
general consensus that genomic DNA is the primary target of the drug. Platinum-based 
compounds have been shown to interact strongly with DNA, causing the formation of inter- 
and intra-strand crosslinks by covalently binding to purine bases (Plooy et al, 1984; 
Fichtinger-Schepman et al, 1985). These platinum-DNA adducts distort and induce structural 
damage to the DNA helix, including bending (Rice et al, 1988), unwinding (Scovell and 
Collart, 1985), and the formation of double-stranded breaks (Sorenson and Eastman, 1988). 
The inhibition of DNA replication and transcription has also been reported after cisplatin 
treatment (Johnson et al, 1980; Sorenson and Eastman, 1988), and may be due to the 
inability of polymerase enzymes to circumvent cisplatin-DNA adducts, or the interaction 
between cisplatin and proteins involved in these processes. Although the response to 
platinum-induced DNA damage is so far unclear, numerous proteins recognise and bind to 
the DNA adducts. These include those involved in DNA repair processes, namely nucleotide 
excision repair (NER) and mismatch repair (MMR) proteins, as well as those which play a 
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role in the regulation of transcription and replication, signal transduction and apoptosis (Jung 
and Lippard, 2007).  
 
These effects in the nucleus lead to arrest of the cell cycle in the G2 phase (Cullinane et al, 
1999), and the activation of cell death pathways (Persons et al, 1999). Cisplatin retains its 
cytotoxicity in enucleated cells, implying that nucleus-independent pathways may also be 
involved in the drug’s mechanism of action (Yu et al, 2008). Although cisplatin has been 
reported to induce necrosis at high concentrations in vitro (Lieberthal et al, 1996), the drug 
exerts its chemotherapeutic properties primarily through the activation of apoptosis (Persons 
et al, 1999). The mitogen-activated protein kinase (MAPK), extracellular signal-regulated 
kinase (ERK) and c-Jun N-terminal kinase (JNK) pathways are stimulated following cisplatin 
treatment, and may mediate the decision between two different cell fates: DNA repair and 
cell survival, or the induction of apoptosis (Wang et al, 2000; Mansouri et al, 2003; Bragado 
et al, 2007).  
 
1.3.2 Adverse reactions to cisplatin therapy 
 
The effective use of cisplatin in chemotherapy can be limited by the development of ADRs in 
the patient, which include nephrotoxicity, neurotoxicity, and ototoxicity (McKeage, 1995), as 
well as anaemia, nausea, and acute, delayed or anticipatory emesis (Levi et al, 1981; 
McKeage, 1995). These ADRs occur when cells other than cancer cells accumulate the drug 
and are damaged. Nephrotoxicity, once the major dose-limiting ADR of cisplatin, can be 
largely prevented by hydration 24 hours before treatment (Santoso et al, 2003), while 
nausea and emesis can be ameliorated with antiemetic therapy (Hu et al, 2014a). For 
cisplatin-induced ototoxicity, however, no effective methods of prevention or treatment 
currently exist. 
 
1.3.2.1 Cisplatin-induced ototoxicity 
 
Ototoxicity is the progressive cellular degeneration of inner ear structures due to the 
cytotoxic effects of therapeutic agents in the region. This results in the development of 
sensorineural hearing loss (cochleotoxicity) and/or vestibular dysfunction (vestibulotoxicity) 
in patients, and is a known ADR of many drugs such as aminoglycoside antibiotics (Xie et al, 
2011), loop diuretics (Gallagher and Jones, 1979), antimalarials (Jourde-Chiche et al, 2012) 




Cisplatin is considered the most ototoxic of the platinum-based chemotherapeutics 
(McKeage, 1995; Ding et al, 2012). Reported incidences of hearing loss range between 25% 
and 100% of patients affected (Kopelman et al, 1988; Bokemeyer et al, 1998; De Jongh et 
al, 2003; Knight et al, 2005; Kushner et al, 2006; Coradini et al, 2007; Arora et al, 2009; 
Yancey et al, 2012; Choeyprasert et al, 2013; Yang et al, 2013; Peleva et al, 2014), 
depending on the audiometric criteria used, the sensitivity of the tests performed and, 
possibly, on the age of the patients being treated. Using conventional audiometry (0.25-8 
kHz), significant hearing loss typically affects less than 50% of adult cancer patients 
(Bokemeyer et al, 1998; De Jongh et al, 2003). However, up to 100% of patients may 
develop some degree of hearing loss when more sensitive hearing tests (8-16 kHz) are 
employed (Kopelman et al, 1988; Arora et al, 2009). A retrospective analysis of SA cisplatin-
receiving cancer patients at Groote Schuur Hospital (GSH) by our research group indicated 
an ototoxicity incidence rate of 55% using standard audiometry (Whitehorn et al, 2014a).  
 
Hearing impairment due to cisplatin chemotherapy is typically progressive, bilateral, and 
irreversible in nature, and may present with other symptoms such as ear pain and tinnitus 
(Arora et al, 2009). In cisplatin-induced ototoxicity, the higher frequencies of hearing (6-8 
kHz) are initially affected, but over repeated doses this hearing loss can progress into lower 
frequencies (Kopelman et al, 1988), including the speech frequencies of hearing (0.5-4 kHz) 
(de Andrade et al, 2013). Notably, as many as 50% of consonants spoken in the English 
language are heard in the 4-8 kHz range, and these are required for the understanding of 
spoken language (Grewal et al, 2010). As a result, the development of ototoxicity can have 
long-term impacts on patient quality-of-life. Hearing loss can impair verbal-auditory 
communication and have educational, social and economic consequences (Knight et al, 
2005; Einarsson et al, 2011). These effects are particularly pronounced in paediatric 
patients, in whom hearing impairment can cause difficulty in language acquisition and the 
ability to thrive, both academically and socially (Bess et al, 1998; Al-Khatib et al, 2010).  
 
Because of these quality-of-life considerations, ototoxicity can have an impact on the 
success of treatment. When hearing loss occurs, the dose of cisplatin may be reduced, or 
cisplatin treatment may be discontinued in favour of a less ototoxic, but often less effective 
drug, such as carboplatin. Carboplatin has demonstrated inferiority in terms of both overall 
and progression-free survival, response rate and the incidence of relapse when compared to 
cisplatin in the treatment of bladder, head and neck, lung, and germ cell cancers (Lokich and 
Anderson, 1998; Hotta et al, 2004; Sanborn, 2008). For other cancers, such as those of the 
ovaries, the efficacy of carboplatin may be equivalent, although less established (Lokich and 
Anderson, 1998).  
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1.3.2.2 Mechanism of cisplatin-induced ototoxicity 
 
The inner ear is composed of the cochlea and the vestibular apparatus (Figure 1.1). The 
vestibular apparatus is involved in balance, while the cochlea functions in auditory 
perception. Both of these structures are sensitive to cisplatin, and ototoxicity may occur 




Figure 1.1: Diagram of inner ear structures. The inner ear is composed of the cochlea and the 
vestibular apparatus. The cochlea, involved in hearing, has a basal (B) and an apical (A) turn. High 
frequencies are detected at the basal turn of the cochlea, and progressively lower frequencies are 
perceived at the more apical regions (adapted from Willems, 2000).  
 
 
Experiments in guinea pigs demonstrated an early accumulation and rapid saturation of the 
drug in the cochlea, as well as its delayed elimination from inner ear structures (Hellberg et 
al, 2013). Cochlear cells which display the greatest sensitivity to cisplatin are those in the 
organ of Corti (particularly the outer hair cells and supporting cells), the spiral ganglion, the 
stria vascularis, and the spiral ligament (Alam et al, 2000; Van Ruijven et al, 2005) (Figure 
1.2). The vestibular apparatus contains a population of localised stem cells, and although 
these provided promise for curative interventions (for example, the stimulation of these stem 
cells to differentiate and replace damaged cells), it has been demonstrated that these cells 













Figure 1.2: Cross-section through the human cochlea. Cells which are sensitive to cisplatin are 
indicated. These include the outer hair cells as well as those of the spiral ganglion, spiral ligament and 




Cisplatin exerts its cytotoxic effects in these cells through the mechanisms already 
discussed (Section 1.3.1). However, cisplatin-induced oxidative stress is an important 
contributor to apoptosis in the inner ear. Oxidative stress occurs when the redox balance in 
cells is disturbed, for example by the accumulation of reactive oxygen species (ROS) and 
free radicals such as superoxide anions, hydroxyl radicals, and hydrogen peroxide and its 
derivatives. These compounds can cause extensive damage to DNA, proteins, lipids, and 
organelles in the cell (Yakes and Van Houten, 1997). Consequently, prolonged oxidative 
stress results in DNA strand breaks, lipid and protein peroxidation, mitochondrial dysfunction 
and other cellular insults, which ultimately lead to the initiation of apoptotic cell death 
pathways (Roberg and Öllinger, 1998). These include mitochondria-dependent and                
-independent pathways, such as the release of pro-apoptotic factors from mitochondria and 
the activation of JNK and p38 pathways (Yamashita et al, 2004; Kamata et al, 2005; 
Matsuzawa and Ichijo, 2008). 
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Cellular sources of ROS include the mitochondria and NADPH oxidase (NOX) enzymes. 
NOX3 is a protein which is expressed in the inner ear and has been associated with the 
generation of cisplatin-induced oxidative stress, when silencing cochlear expression of 
NOX3 attenuated apoptosis and the development of ototoxicity in rat models (Mukherjea et 
al, 2010). The hair cells are hypothesised to be particularly vulnerable to ROS accumulation 
due to a reduced concentration of glutathione and other antioxidants (Sha et al, 2001). 
Demonstrations that oxidative stress causes significant changes to hair cell morphology 
(Clerici et al, 1995), and that application of ROS to guinea pig inner ears resulted in 
significant hearing loss (Clerici and Yang, 1996), indicate the sensitivity of the cochlea to 
oxidative stress. The generation of ROS and free radicals has been demonstrated in the 
cochlea following exposure to cisplatin (Clerici et al, 1996); hair cells and cells of the spiral 
ganglion seem to be most susceptible to ROS excess, while supporting cells in the organ of 
Corti tend to be more resistant to oxidative stress (Sha et al, 2001; Bánfi et al, 2004).    
 
Hair cells are sensory, detecting sound as vibrations in the endolymph (Hibino et al, 2010), 
and the spiral ganglion consists of neurons responsible for the transduction of auditory 
signals from the cochlear hair cells to the brain. Consequently, the loss of these cell types 
can contribute directly to hearing impairment. Upon treatment with cisplatin, cells in the spiral 
ganglion become detached from their myelin sheaths (Van Ruijven et al, 2005), and undergo 
apoptosis (Alam et al, 2000). The organisation of hair cells in the cochlea is such that those 
in different regions of the cochlea confer sensitivity to a specific range of sound frequencies 
(Figure 1.1). Cisplatin initially accumulates in the basal turn of the cochlea (Hellberg et al, 
2013), inducing apoptosis in these cells (Alam et al, 2000), which is why the high 
frequencies are initially affected (Grewal et al, 2010). Lower frequencies of hearing are 
affected more gradually, as the drug concentration increases in more apical regions of the 
cochlea (Helberg et al, 2013). 
 
Together, the stria vascularis and spiral ligament form the lateral wall of the cochlea (Figure 
1.2). The spiral ligament consists of fibrocytes and connective tissue and is largely 
unaffected by cisplatin treatment, although evidence of drug-induced apoptosis has been 
noted in the region (Alam et al, 2000). Conversely, extensive damage to cells in the stria 
vascularis has been observed following exposure to cisplatin (Meech et al, 1998). This is an 
epithelial tissue which functions in the production of endolymph in the scala media (Hibino et 
al, 2010). Changes to the endolymph, such as a reduction in potassium ion concentration 
(Rozengurt et al, 2003) or alteration in pH (Stawicki et al, 2014), can adversely affect the 





Because there are no preventative or curative strategies for cisplatin-induced ototoxicity, 
current clinical practice involves monitoring patient hearing throughout treatment for signs of 
significant hearing loss, and altering the treatment regimen accordingly. Audiometric 
monitoring programmes are recommended to include a baseline audiogram performed 
before the first cycle of chemotherapy, and follow-up audiograms conducted before each 
subsequent treatment cycle, so that deterioration in hearing can be detected (American 
Speech-Language-Hearing Association [ASHA], 1994).  
 
Unfortunately, audiometric monitoring strategies have several limitations in their ability to 
preserve patient quality-of-life. The first is a lack of awareness of and compliance with the 
need for audiometric tests, particularly in the SA context (de Andrade et al, 2009). Secondly, 
although cognisance of ototoxicity is reportedly improving, with a 300% increase in the 
number of audiometric tests performed on cisplatin-receiving cancer patients attending GSH 
between 2006 and 2010 (Whitehorn et al, 2014a), these tests are not always sufficiently 
available in hospitals. Thirdly, due to the progressive nature of cisplatin’s ADRs, sometimes 
significant hearing loss is only detected after the cessation of treatment. For example, an 
analysis of 120 paediatric patients demonstrated that, although 5% of patients displayed 
signs of severe ototoxicity immediately following treatment, this increased to 44% of patients 
when audiometric tests were conducted two years after treatment (Bertolini et al, 2004). The 
progressivity of ototoxicity also implies that altering treatment due to the onset of ototoxicity 
will not necessarily mitigate any further deterioration in hearing. Finally, permanent hearing 
loss has been observed in some patients after a single cycle of treatment (Durrant et al, 
1990), illustrating the inability of audiometric monitoring to prevent ototoxicity.  
 
Due to these limitations, research into preventative measures is desirable. These include the 
development of otoprotective agents which could be administered concomitantly with 
cisplatin, and the characterisation of intrinsic risk factors which may affect the susceptibility 
of certain patients to ototoxicity. The identification of otoprotective compounds is an area of 
much research, and agents which have been investigated include antioxidants, channel 
blockers, and inhibitors of apoptosis (Rybak et al, 2009). However, many of these 
compounds have only been demonstrated as protective in vitro, or in animal models when 
using invasive methods of administration (Wimmer et al, 2004; Shafik et al, 2013). The 
translation of these results to clinical utility has been challenging because the inner ear is a 
relatively isolated organ, making localised delivery in patients problematic. While systemic 
delivery of these agents may be able to protect the inner ear from damage (Mohan et al, 
20 
 
2014), this method of administration carries the potential to interfere with cisplatin’s 
anticancer effects, and therefore the success of treatment (Wimmer et al, 2004). Knowledge 
of intrinsic risk factors, however, may enable the identification of at-risk patients prior to the 
initiation of chemotherapy. 
 
1.5 Risk factors of ototoxicity 
 
Investigations into clinical risk factors of cisplatin-induced ototoxicity consistently identify the 
dose of cisplatin as a predictor of hearing impairment. It is the cumulative dose, rather than 
individual cisplatin dose, which seems to influence the risk of ototoxicity, as evidenced in 
numerous studies. In paediatric patients receiving total cisplatin doses exceeding 400 
mg/m2, a 3.35-fold increased risk of ototoxicity has been calculated (Li et al, 2004), a dose at 
which up to 44% of patients were reported to develop significant hearing loss (Bertolini et al, 
2004). The dose-dependency of ototoxicity has also been demonstrated in adult patients 
(Bokemeyer et al, 1998), and has been replicated in the SA population (Whitehorn et al, 
2014a). In this population, the cancer diagnosis was also identified as a risk factor: patients 
presenting with cancers of the reproductive organs were at a reduced risk of hearing 
impairment, while differential risks were suggested for the head and neck, lymphoma and 
digestive system tumours, although these have not been replicated (Spracklen et al, 2014; 
Whitehorn et al, 2014a). This indicates that other factors such as the method of cisplatin 
administration and infusion rates, which are treatment-specific, may also have an effect. 
 
Despite the identification of cumulative cisplatin dose as a risk factor, it is evident that there 
are substantial inter-individual differences in patient susceptibility to ototoxicity. Certain 
treatment regimens and cisplatin dosages may prove highly ototoxic in one patient, while 
another may retain normal hearing throughout a similar treatment regimen. Additional risk 
factors which have been reported less consistently (and, in some instances, in isolation) 
include young patient age at the initiation of treatment (Li et al, 2004; Yancey et al, 2012), 
patient gender (Yancey et al, 2012; Kirkim et al, 2014), the use of cranial irradiation (Chen et 
al, 2006; Yang et al, 2013) or other ototoxic drugs during treatment (Bokemeyer et al, 1998; 
Harris et al, 2012), previous exposure to noise (Bokemeyer et al, 1998), pre-existing hearing 
loss (Bokemeyer et al, 1998), impaired renal function (Bokemeyer et al, 1998), anaemia (De 
Jongh et al, 2003) and diet (Lautermann et al, 1995). The roles of both patient age and 
gender in cisplatin-induced hearing loss have proved contentious. Although young age (< 5 
years) has been reported as a risk factor in independent investigations (Li et al, 2004; 
Yancey et al, 2012), other studies in similar populations have shown no association between 
age extremes and hearing loss (Bokemeyer et al, 1998; De Jongh et al, 2003; Choeyprasert 
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et al, 2013). Male paediatric patients have been reported to be at a greater risk of ototoxicity 
(Yancey et al, 2012), but this observation has not replicated in other studies, including adult 




Pharmacogenetics is the study of the effect of genetic variation on individual drug 
responses. These may include efficacy and toxicity of treatment, as well as the development 
of resistance to therapy. Genes which are of interest in pharmacogenetics include those 
involved in the action of drugs, as well as their metabolism, distribution and elimination from 
the body (Weng et al, 2013). Pharmacogenetic studies may therefore contribute to the 
understanding of drug action and pharmacokinetics, although their ultimate objective is to 
improve medical practice. The current approach to medicine is limited to the prescription of 
drugs based on standard procedures, in which patients with the same diagnosis tend to be 
prescribed the same drug at the same dose (Abul-Husn et al, 2014), and issues such as 
ADRs are only reacted to after their occurrence. However, research into pharmacogenetics 
may enable the future personalisation of treatment regimens (including drug choice and 
dosage schedule) based on a patient’s genotype, and has the potential to optimise therapy 
in a way that is impossible at present.  
 
Cellular sensitivity to cisplatin has been demonstrated to have a heritable component, 
estimated to be between 32% and 47% from two experiments using lymphoblastoid cell lines 
which were derived from 10 and 27 families (Dolan et al, 2004; Shukla et al, 2008). This 
indicates that a pharmacogenetic approach to cisplatin-induced ototoxicity is valid, and the 
role of genetics in predisposing certain individuals to cisplatin’s adverse effects is a 
developing area of research (Rybak et al, 2007). 
 
1.6.1 The pharmacogenetics of cisplatin-induced ototoxicity 
 
The role of genetics in the development of cisplatin-induced ototoxicity has been under 
investigation since 2000 (Peters et al, 2000). A diverse group of genes has been explored to 
date, including those which are involved in the metabolism, detoxification and transport of 
drugs, as well as DNA repair genes, deafness susceptibility loci and mitochondrial genes 
(Table 1.1). However, despite over a decade of research on the subject, there is little 





Table 1.1: Potential genetic modifiers of cisplatin-induced ototoxicity 
Gene Variant Effect on risk Sample size p-value Reference 
Drug metabolism and detoxification genes 
GSTM3 GSTM3*B Reduced 39 0.020 Peters et al (2000) 
GSTP1 rs1695 Reduced 173 < 0.001 Oldenburg et al (2007) 
  None 162 0.610 Ross et al (2009) 





Reduced 173 0.022 Oldenburg et al (2007) 
TPMT rs12201199 Increased 162 < 0.001 Ross et al (2009) 
  Increased 317 < 0.001 Pussegoda et al (2013) 
  None 213 0.500 Yang et al (2013) 
  None 100 0.175 Whitehorn et al (2014b) 
  None 63 0.483 Lanvers-Kaminsky et al (2014) 
  None 110 0.650 Hagleitner et al (2014) 
COMT rs9332377 Increased 162 0.001 Ross et al (2009) 
  Increased 317 0.043 Pussegoda et al (2013) 
  None 213 0.780 Yang et al (2013) 
  None 115 0.564 Whitehorn et al (2014b) 
  None 63 0.094 Lanvers-Kaminsky et al (2014) 






20 0.020 Whitehorn et al (2014b) 
DPYD rs6667550 Increased 155 0.0047 Pussegoda (2012) 
Membrane receptors and transporters 
LRP2 rs2075252 Increased 50 0.016 Riedemann et al (2008) 
  None 68 0.763 Choeyprasert et al (2013) 
  None 115 0.872 Whitehorn et al (2014b) 
 rs2228171 Increased 68 0.087 Choeyprasert et al (2013) 
  None 50 0.034 Riedemann et al (2008) 
  None 115 0.140 Whitehorn et al (2014b) 
ABCC3 rs1051640 Increased 317 0.0033 Pussegoda et al (2013) 
ABCB5 rs10950831 Increased 155 1.06×10-6 Pussegoda (2012) 
CTR1 rs10981694 Increased 204 0.01 Xu et al (2012a) 
SLC22A2 rs316019 Reduced 64 0.018 Lanvers-Kaminsky et al (2015) 
Deafness-associated genes 




Peters et al (2003) 
Knoll et al (2006) 
D-loop 
region 
Screened None 39 0.08 Peters et al (2003) 
GJB2 35delG None 11 0.35 Knoll et al (2006) 
SLC26A4 Screened None 11 NA Knoll et al (2006) 
Other genes 
XPC rs2228001 Increased 32 0.042 Caronia et al (2009) 
  None 115  Whitehorn et al (2014b) 
SOD2 rs4880 Increased 71 0.04 Brown et al (2015) 
EIF3A  rs77382849 Increased 282 0.01 Xu et al (2012b) 
OTOS rs77124181, 
rs2291767 
Reduced 100 0.022 Spracklen et al (2014) 
CDH13 rs17758876 Increased 27 families < 0.0001 Shukla et al (2008) 
ACYP2 rs1872328 Increased 238 3.9×10-8 Xu et al (2015) 
ABCB5, ATP-binding cassette, subfamily B, member 5; ABCC3, ATP-binding cassette, subfamily C, member 3; 
ACYP2, acylphosphatase 2, muscle type; CDH13, cadherin 13; COMT, catechol-O-methyltransferase; CTR1, 
copper transporter 1; DPYD, dihydropyrimidine dehydrogenase; EIF3A, eukaryotic translation initiation factor 3, 
subunit A; GJB2, gap junction protein, beta 2; GST, glutathione S-transferase; LRP2, low-density lipoprotein 
receptor-related 2; MT-RNR1, mitochondrially encoded 12S RNA; NA, not applicable; SLC22A2, solute carrier 
family 22, member 2; SLC26A4, solute carrier family 26 (anion exchanger), member 4; SOD2, superoxide 
dismutase 2; TPMT, thiopurine S-methyltransferase; XPC, xeroderma pigmentosum, complementation group C 
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1.6.1.1 Genes involved in drug metabolism and detoxification 
 
1.6.1.1.1 The glutathione S-transferases (GSTs) 
 
The GSTs are an important superfamily of detoxifying enzymes which act by catalysing the 
conjugation of reduced glutathione to various substrates, including drugs and their 
metabolites. Three of the most ubiquitous GST isoforms are GSTM1, GSTT1 and GSTP1, 
which are expressed in many cell types, including the cochlear hair cells (el Barbary et al, 
1993). Chemotherapeutics such as cisplatin are detoxified by GSTP1 (Ban et al, 1996; Goto 
et al, 2002). The GST genes were of initial interest in the study of cisplatin-induced 
ototoxicity because, in addition to their role in drug detoxification, they are involved in 
antioxidant processes in cells (Baez et al, 1997). Therefore there are two mechanisms 
whereby GST polymorphisms may influence susceptibility to ototoxicity: by altering the 
detoxification of cisplatin (and therefore vulnerability to its toxic effects), and by modifying the 
ability of cells to respond to cisplatin-induced oxidative stress.  
 
The GST genes are highly polymorphic in humans (Garte et al, 2001), and polymorphisms 
within GSTM1, GSTT1 and GSTP1 are the most frequently investigated regarding hearing 
loss. The variants GSTM1*0 and GSTT1*0 are homozygous deletions yielding null alleles.  
The GSTP1 c.313A>G (rs1695) single nucleotide polymorphism (SNP), which encodes a 
reduced-function variant (Watson et al, 1998), has a minor allele frequency of approximately 
30% in Caucasian populations. Functional effects of the G-allele include an altered substrate 
specificity and capacity for detoxification (Allan et al, 2001; Hohaus et al, 2005). This allele 
encodes a better detoxifier of cisplatin, which improved protection against the drug in E. coli 
cells (Ishimoto and Ali-Osman, 2002). 
 
The first GST polymorphism which associated with cisplatin-induced ototoxicity, however, 
was the GSTM3*B allele, which was suggested to be protective against hearing impairment 
in 39 paediatric cancer patients (Peters et al, 2000). This allele encodes an intronic deletion 
which could potentially alter expression of the gene (Inskip et al, 1995), although evidence 
for this hypothesis is lacking. The authors failed to associate variation within other GST 
genes, including GSTP1, GSTT1 and GSTM1, with cisplatin-induced ototoxicity. However, a 
subsequent analysis of 173 testicular cancer survivors demonstrated the protective effect of 
variants within these genes. Particularly, presence of the GSTP1 c.313 G-allele, as well as 
the GSTM1*0 and GSTT1*0 alleles, potentially reduced the risk of hearing loss (Oldenburg 
et al, 2007). 





Methyltransferase enzymes catalyse the conjugation of methyl groups in the cellular 
metabolism of xenobiotic compounds such as pharmaceutical drugs. After assaying 220 
genes involved in drug absorption, distribution, metabolism and elimination (ADME), two 
methyltransferase variants were identified in association with significant hearing loss in 
Canadian paediatric patients (Ross et al, 2009). The genes, thiopurine S-methyltransferase 
(TPMT) and catechol-O-methyltransferase (COMT), had not been associated with ototoxicity 
before. However, the SNPs TPMT c.419+94T>A (rs12201199) and COMT c.466-367C>T 
(rs9332377) were both reported to increase the risk of ototoxicity in paediatric cancer 
patients (Ross et al, 2009). 
 
Because there is as yet no evidence that these genes play a role in the metabolism of 
cisplatin, the functional basis for these associations is unclear. Two hypotheses have been 
proposed by the authors. Reduction or abolition of methyltransferase activity may alter the 
formation of DNA cross-links, and thus affect the ability of cisplatin to damage DNA and 
induce apoptosis. Alternatively, these variants may cause the accumulation of S-
adenosylmethionine (SAM) in cells, since SAM is a substrate for methyltransferase 
enzymes. While SAM itself is not toxic to cells, it has been demonstrated to increase the 
incidence of cisplatin-induced ADRs in mouse models (Ochoa et al, 2009). 
 
On the basis of this genetic association study alone, the Food and Drug Administration of 
America (FDA) altered the product label of cisplatin to incorporate the association of TPMT 
polymorphisms and ototoxicity risk in paediatric patients (Boddy, 2013). The clinical utility of 
this amendment is somewhat debateable, considering the lack of replication of the result at 
the time, and the lack of any clear functional link to cisplatin or its ototoxicity (Boddy, 2013). 
Although the association between the TPMT variant (and, indeed, the COMT variant) was 
subsequently replicated by the same research group (Pussegoda et al, 2013), neither gene 
could explain the development of ototoxicity in American or European cohorts of patients 
(Yang et al, 2013; Hagleitner et al, 2014; Lanvers-Kaminsky et al, 2014). The study by Yang 
et al (2013) further questioned the validity of the association by demonstrating that the 
variants did not alter cellular sensitivity to cisplatin in vitro. Both genes have also been 
investigated in the SA population, and while TPMT polymorphisms did not associate with 
ototoxicity, three variants in COMT were proposed to form a risk haplotype in Caucasian 
patients (Whitehorn et al, 2014b). Hagleitner et al (2014) performed a meta-analysis of all 
published data, together with their work in Dutch and Spanish patient cohorts, and 
concluded that the role of TPMT and COMT variants in ototoxicity has been largely 
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overstated. In the final analysis, which considered five gene variants in a total of 664 
patients, only one of the SNPs, COMT c.*217C>T (rs4646316), showed a weak association 
with ototoxicity (Hagleitner et al, 2014). Although this SNP was not identified as statistically 
significant in the studies by Ross et al (2009), Pussegoda et al (2013), and Yang et al 




Using the assay which identified the TPMT and COMT modifiers, but with an additional 95 
genes included in the analysis, the intronic polymorphism c.2623-43032A>G (rs6667550) 
within dihydropyrimidine dehydrogenase (DPYD) associated with cisplatin-induced 
ototoxicity in a similar cohort of patients (Pussegoda, 2012). The association has not yet 
been replicated and, again, there is no evidence that DPYD or other dehydrogenase 
enzymes are involved in the metabolism of cisplatin. Rather, DPYD metabolises 5-FU, which 
is often co-administered with cisplatin in chemotherapy regimens. Increased expression of 
DPYD was correlated with a reduced cellular sensitivity to both 5-FU and cisplatin in vitro 
(Minegaki et al, 2013). Conflictingly, the same study reported that inhibition of DPYD activity 
decreased the sensitivity of human carcinoma cells to cisplatin (Minegaki et al, 2013). 
Whether the enzyme is involved in the metabolism of cisplatin or is required for its toxicity 
remains to be investigated further.  
 
1.6.1.2 Membrane receptors and transporters 
 
Following the discovery of cell-surface receptors and transporters which contribute to the 
active uptake of cisplatin by cells (Holzer et al, 2004; Filipski et al, 2008), the role of these 
proteins in the accumulation of cisplatin in off-target regions in the body, such as the inner 
ear, has been under consideration. Megalin is a cell-surface receptor which is expressed in 
the stria vascularis of the inner ear, and has been implicated in the transport of 
aminoglycosides (Schmitz et al, 2002). Two non-synonymous SNPs within the gene 
encoding megalin, low-density lipoprotein receptor-related 2 (LRP2), have been investigated 
regarding their role in cisplatin-induced ototoxicity. Riedemann et al (2008) demonstrated a 
significant association between LRP2 c.12280A>G (rs2075252) and ototoxicity, and no 
association between LRP2 c.8614G>A (rs2228171) and hearing impairment. Contradictory 
findings were reported by Choeyprasert et al (2013), in which the LRP2 c.8614 C-allele 
potentially increased the risk of ototoxicity, while LRP2 c.12280A>G showed no significant 
association. These differences may be explained by the different hearing loss and grading 
criteria used in the studies, as well as differences in methodology and statistical analyses. 
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Regardless, the sample sizes in both studies were small (n = 50 and n = 68, respectively), 
and the role of megalin in ototoxicity cannot be ascertained with any confidence. Both 
variants failed to associate with hearing loss in a larger analysis of 115 patients (Whitehorn 
et al, 2014b). 
 
More recently, two potential genetic modifiers in the ATP-binding cassette (ABC) superfamily 
of transporters have been identified. These are a group of broad-specificity transporters 
which facilitate the ATP-dependent transport of various molecules across cell membranes. 
The variants ABCC3 c.*3180A>G (rs1051640) and ABCB5 c.1290+1532G>T (rs10950831) 
associated with ototoxicity in 155 paediatric cancer patients (Pussegoda, 2012). Limitations 
of the associations between the ABCs, as well as LRP2, and ototoxicity include the lack of a 
mechanistic link to cisplatin and its ototoxic effects. It is unknown whether any of these 
proteins actively transport cisplatin into or out of cells, and, apart from experiments 
correlating ABCC3 expression and resistance to cisplatin in lung cancer cells (Young et al, 
2001), these genes have not been functionally analysed regarding their role in the cellular 
response to cisplatin. 
 
Known transporters of cisplatin include copper transporters such as CTR1, members of the 
transient receptor potential (TRP) superfamily, and the organic cation transporters (OCTs) 
(Waissbluth and Daniel, 2013). CTR1 was reported to transport cisplatin into cancer cells 
(Holzer et al, 2004), and is highly expressed in the hair cells, spiral ganglion and stria 
vascularis of the cochlea (More et al, 2010). It is also involved in the cellular response to 
oxidative stress (Kuo et al, 2001). Twenty SNPs within CTR1 were genotyped in 204 
Chinese cancer patients, and the intronic variant c.-36+2451T>G (rs10981694) was 
associated with an increased risk of ototoxicity (Xu et al, 2012a). OCT2, encoded by the 
gene solute carrier family 22, member 2 (SLC22A2), is also expressed in the inner ear 
(Ciarimboli et al, 2010). The variant c.808T>G (rs316019) in SLC22A2 has been associated 
with protection against ototoxicity in a German cohort of cisplatin-receiving patients 
(Lanvers-Kaminsky et al, 2015).  
 
1.6.1.3 Deafness-associated genes 
 
Although numerous genetic loci have been identified as causative of hearing loss in the 
absence of cisplatin, research into the role of these genes in the development of cisplatin-
induced ototoxicity is limited. Because mitochondrial mutations such as those in the gene 
encoding 12S rRNA (MT-RNR1) have been associated with non-syndromic deafness as well 
as aminoglycoside-induced ototoxicity (Prezant et al, 1993; Estivill et al, 1998), Peters et al 
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(2003) screened patient mitochondrial DNA (mtDNA) for potential modifiers of cisplatin’s 
ototoxicity. The authors failed to identify any known mutations in their patient cohort (Peters 
et al, 2003). A second investigation considered the role of five hearing genes: three in the 
mtDNA and two genomic genes, gap junction protein, beta 2 (GJB2) and solute carrier family 
26 (anion exchanger), member 4 (SLC26A4). Apart from a single mutation in GJB2, no 
polymorphisms were detected, and the authors could not explain the development of hearing 
loss in these patients (Knoll et al, 2006). Due to the small number of patients included in 
these studies (n = 39 and n = 11, respectively), the involvement of deafness-associated 
genes in cisplatin-induced ototoxicity cannot be excluded at present.  
 
1.6.1.4 Other genes 
 
Alternative candidate genes have been explored based on the current knowledge of 
cisplatin’s mechanism of action. The NER pathway is involved in the repair of cisplatin-
induced DNA damage, by removing platinum-containing adducts. The xeroderma 
pigmentosum, complementation group C (XPC) gene encodes a component of this pathway. 
A weak association between the nonsynonymous variant XPC c.2815C>A (rs2228001) and 
increased hearing loss was reported in 32 osteosarcoma patients (Caronia et al, 2009). Due 
to a small sample size, this study was likely underpowered, and the variant did not associate 
with ototoxicity in a study of 115 SA patients (Whitehorn et al, 2014b). A gene which 
functions upstream of the NER pathway, eukaryotic translation initiation factor 3, subunit A 
(EIF3A), has also been implicated as a potential modifier of ototoxicity. Although EIF3A 
functions primarily in the initiation of protein synthesis, it is also involved in the regulation of 
the NER pathway (Yin et al, 2011). The nonsynonymous SNP EIF3A c.2408G>A 
(rs77382849) may modify the risk of cisplatin’s ADRs, including ototoxicity, in Chinese lung 
cancer patients (Xu et al, 2013).  
 
Apart from the GSTs, few genes involved in the response to oxidative stress have been 
explored to date. A novel gene, OTOS, was suggested to play a role in antioxidant defences 
and could protect cells from the cytotoxic effects of cisplatin (Zhuo et al, 2008). Two OTOS 
polymorphisms, c.-192-182C>G (rs77124181) and c.-192-22A>G (rs2291767), were shown 
to be protective against ototoxicity in 100 cancer patients (Spracklen et al, 2014). Variation in 
superoxide dismutase 2 (SOD2) has also been associated with noise-induced and, possibly, 
age-related hearing losses (Fortunato et al, 2004; Chang et al, 2009; Liu et al, 2010; Nolan 
et al, 2013). The variant SOD2 c.47T>C (rs4880) was associated with the incidence of 
hearing aid use following cisplatin exposure in a cohort of American paediatric cancer 
patients, suggesting a potential role for the gene in the development of ototoxicity (Brown et 
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al, 2015). In a linkage analysis of cell lines derived from 27 Caucasian families, Shukla et al 
(2008) identified five genes which may explain variability in cisplatin-induced cytotoxicity. 
The genes were La ribonucleoprotein domain family, member 1B (LARP1B), leucine rich 
repeat containing 3B (LRRC3B), paired-like homeodomain 2 (PITX2), zinc finger protein 
385D (ZFN385D), and cadherin 13 (CDH13). Of these, CDH13 is most likely to directly affect 
cisplatin cytotoxicity. Unlike other cadherins, it is not implicated in cell-cell adhesion, but is 
rather involved in numerous cellular functions, including cell survival and the regulation of 
apoptosis due to oxidative stress (Joshi et al, 2005). CDH13 is expressed in many cochlear 
cells and has been proposed to have a role in hearing (Girotto et al, 2014). To date, only one 
genome-wide association study (GWAS) has been conducted into cisplatin-induced 
ototoxicity. Using this approach, the intronic variant c.185+29374G>A (rs1872328) in the 
gene acylphosphatase 2, muscle type (ACYP2) was identified in association with the 
phenotype in 238 paediatric patients (Xu et al, 2015). Although ACYP2 expression has been 
demonstrated in the transcriptomes of murine inner and outer hair cells (Liu et al, 2014), its 
contribution to hearing or cisplatin response is currently unknown. 
 
1.7 Future considerations or directions 
 
Given the inconsistent results of the abovementioned genetic association studies, the 
importance of replication of these results cannot be overstated (Hirschhorn and Altshuler, 
2002). Previous work in the SA patient population could not replicate the association 
between ototoxicity and variants within GSTP1, TPMT, LRP2 and XPC, although a risk 
haplotype in COMT was reported in Caucasian patients (Whitehorn et al, 2014b). The 
protective OTOS variants were limited to Caucasian and mixed ancestry patients (Spracklen 
et al, 2014). Notably, the role of genetics in ototoxicity amongst indigenous Africans is 
unknown. 
 
From these studies, it is also evident that the reported genetic factors cannot explain the 
total variation in the incidence of cisplatin-induced ototoxicity. Therefore, in addition to 
replication, new genes need to be explored for their involvement in ototoxicity. Such 
candidates may be chosen based on current knowledge of the pathway whereby cisplatin 
causes ototoxicity. For instance, variants in genes involved in the transport of cisplatin into or 
out of cells may be involved, as might variants which affect the cellular response to cisplatin 
treatment. However, it should be noted that current understanding of these pathways is 
limited and, consequently, so too is our ability to choose and analyse specific candidate 
genes. The study of ototoxicity may be benefitted by the utilisation of next-generation 
sequencing (NGS) techniques to analyse genome-scale regions of DNA for potential genetic 
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modifiers. This has the potential not only to be hypothesis-generating (by identifying 
potentially causative variants in novel genes) but also to contribute to knowledge of the 
mechanism of cisplatin-induced ototoxicity. 
 
1.8 Research aim and objectives 
 
The aim of this study is to investigate the role of genetic variation in the development of 
cisplatin-induced ototoxicity, by identifying genetic variants in a population of adult cisplatin-
receiving SA cancer patients that may modify the risk of ototoxicity. The project aim will be 
addressed through the following objectives: 
 
 The identification of candidate genes from the literature, with specific variants which 
may be associated with the development of cisplatin-induced ototoxicity 
 The establishment of genotypic frequencies for each candidate gene variant in a 
cohort of SA cancer patients, comparison of these frequencies to other published 
populations, and analysis of the associations between given genotypes and specific 
drug response phenotypes  
 The analysis of clinical and demographic risk factors present in the local patient 
population and how these may be used to accurately assess the development of 
ototoxicity 
 The identification of clinically relevant patients and the utilisation of NGS approaches 
to investigate the total protein-coding region of patient DNA for potential genetic 
modifiers 
 The investigation of potential functional effects of the genetic variants in silico, 
including how they may contribute to the development of cisplatin-induced ototoxicity 
in patients 
 
In this submission, Chapter 2 contains a brief investigation of hospital data for the incidence 
of ototoxicity amongst the local cisplatin-receiving cancer patient population, as well as the 
presence of clinical and demographic risk factors for the ADR. The role of genetics in 
cisplatin-induced ototoxicity is subsequently explored in Chapters 3 and 4. This includes the 
recruitment of a prospective patient cohort, which is described in Chapter 3, together with 
the results of a candidate gene investigation where seven genetic variants were analysed for 
their association with cisplatin response. Chapter 4 discusses a pilot NGS investigation 
which was conducted on a subset of the patient cohort, and was used to prioritise novel 
genes for future molecular investigations.  
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As one of the most effective and widely used antineoplastic agents currently in clinical use, 
cisplatin remains the drug of choice in the treatment of numerous cancers (Desari and 
Tchounwou, 2014). Cisplatin is frequently employed in first-line chemotherapy regimens, 
contributing to the successful treatment of a variety of lymphomas, sarcomas and 
carcinomas, including cancers of the lungs, oesophagus, head and neck regions, testes, 
ovaries, and cervix (Desari and Tchounwou, 2014). Its widespread use can be attributed to 
the improved success rates which are often achieved when incorporating cisplatin in 
treatment plans; cure rates as high as 85% have been reported in some instances 
(McKeage, 1995; Einhorn, 2002).  
 
The therapeutic utility of cisplatin, however, may be restricted by the development of dose-
limiting ADRs such as ototoxicity (McKeage, 1995). Ototoxicity is an adverse reaction to 
cisplatin which presents as irreversible, bilateral, and high-frequency hearing loss. It has the 
potential to be a disabling drug reaction, particularly when hearing impairment progresses 
into lower ranges of hearing (0.5-4 kHz) which are required for the recognition of spoken 
language (de Andrade et al, 2013). Therefore, the development of ototoxicity presents an 
important challenge in healthcare, as continuing optimal chemotherapy may then 
compromise patient quality-of-life. Although the protective effects of antioxidant compounds, 
channel blockers and apoptosis inhibitors have been extensively investigated in animal 
models of cisplatin response (Rybak et al, 2007), there are currently no methods of treating, 
attenuating or preventing ototoxicity in a clinical setting. Other platinum-based 
chemotherapeutics such as carboplatin and oxaliplatin may be less ototoxic than cisplatin, 
but these agents have their own toxicity profiles and are typically not as effective in the 
treatment of cancer (Lokich and Anderson, 1998; Hotta et al, 2004; Sanborn, 2008; Fakhrian 
et al, 2015). The lack of a safer alternative to cisplatin, with an efficacy which is comparable 
and well established, has contributed to the continued use of cisplatin in first-line 
chemotherapy regimens despite the risk of ototoxicity and other ADRs.  
 
Dosage reductions or the discontinuation of cisplatin treatment may occur in patients who 
display signs of hearing impairment, which may then reduce the efficacy of chemotherapy. 
This is significant when considering that the reported prevalence of ototoxicity amongst 
cisplatin-receiving cancer patients ranges from 25% to 100% (Kopelman et al, 1988; 
Bokemeyer et al, 1998; De Jongh et al, 2003; Knight et al, 2005; Kushner et al, 2006; 
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Coradini et al, 2007; Arora et al, 2009; Yancey et al, 2012; Choeyprasert et al, 2013; Yang et 
al, 2013; Peleva et al, 2014). One factor which may influence this incidence is the sensitivity 
of the audiometric tests employed during treatment. Using standard audiometry (0.25-8 
kHz), up to 50% of adult patients may develop hearing impairment over the course of 
chemotherapy (Bokemeyer et al, 1998; De Jongh et al, 2003). In a retrospective analysis of 
SA cancer patients, an ototoxicity prevalence of 55% was reported, indicating that hearing 
loss is a frequent adverse reaction to cisplatin in the local patient population (Whitehorn et 
al, 2014a). While numerous studies have demonstrated that the risk of ototoxicity is 
influenced by the cumulative dose of cisplatin to which the patient is exposed (Bokemeyer et 
al, 1998; Li et al, 2004; Oldenburg et al, 2007; Choeyprasert et al, 2013), there is still much 
inter-individual variation in sensitivity to cisplatin’s ototoxic effects. Indeed, patients who 
receive the same dose of cisplatin may have very different drug responses, and these 
differences have not yet been accounted for. Additional factors which have been explored for 
their role in ototoxicity include patient age, sex, the presence of pre-existing hearing loss or 
exposure to noise, reduced renal function, anaemia, a protein-poor diet, and genetic risk loci 
(Lautermann et al, 1995; Bokemeyer et al, 1998; De Jongh et al, 2003; Li et al, 2004; 
Mukherjea and Rybak, 2011; Yancey et al, 2012), but their contribution to drug-induced 
hearing loss remains inconclusive. 
 
Current clinical practice involves monitoring patient hearing throughout treatment and 
reacting to any impairment accordingly. This approach is limited to the detection of hearing 
loss and is unable to prevent it. However, considering the progressive and permanent nature 
of cisplatin-induced hearing loss, prevention of this ADR is preferable in order to better 
preserve patient quality-of-life. Understanding the role of intrinsic risk factors in ototoxicity 
may enable the identification of high-risk patients prior to the initiation of chemotherapy, and 
minimise this morbidity. The objective of the present investigation is to assess the influence 
of clinical and demographic variables on hearing sensitivity changes in response to cisplatin 






Between 2012 and 2015, cisplatin-receiving cancer patients were recruited into a molecular 
investigation of cisplatin-induced ototoxicity (Chapters 3 and 4), for which ethical approval 
was obtained from the Human Research Ethics Committee (HREC), University of Cape 
Town (UCT) (HREC reference no.: 389/2012 and 220/2014) (Appendix A). Recruitment was 
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conducted by a registered research nurse from the Division of Human Genetics, UCT, after 
obtaining written informed consent from each potential participant (Appendix B, Appendix C, 
Appendix D). This prospective cohort was supplemented with retrospective patient data to 
form a cross-sectional study of the patients who attended GSH for cisplatin-based 
chemotherapy between January 2006 and April 2015. All patients who were managed by the 
Department of Radiation Oncology, GSH, and referred to the Audiology Clinic, UCT/GSH, 
were potentially eligible. Only those who had sufficient audiometric data were included in the 
analysis. Audiometric requirements were the presence of both baseline and follow-up 
audiometric tests, so that hearing function before and after treatment could be assessed. 
Approval for the review of patient records was obtained from GSH (Appendix E) as well as 
the HREC (Appendix A).  
 
In addition to audiometric data, information relating to the treatment, such as cancer 
diagnosis, individual and cumulative cisplatin doses, and the use of cranial irradiation was 
recorded for each patient when available. Demographic data included patient age at the start 
of treatment, sex and ethnicity. For patients attending GSH between 2012 and 2015 (n = 
217), ethnicity was self-reported. For those identified retrospectively (n = 78), ethnicity was 
assigned according to race and linguistic group. The patients in the study were Caucasian, 
indigenous (Xhosa-speaking) African, Indian, or of mixed ancestry.  
 
2.2.2 Treatment details 
 
In each treatment cycle for testicular, ovarian and cervical (reproductive) cancers, cisplatin 
was administered in a low dose (25-60 mg/m2) every day for three days, together with 160 
mg/m2 etoposide and 15 000 IU bleomycin. The treatment of all the other cancer types 
consisted of a single high dose (> 60 mg/m2) of cisplatin per cycle, administered in a bolus, 
together with 8 mg ondansetron, 8 mg dexamethasone, 1 000 mg/m2 5-FU, and 500 ml 
mannitol. Patients were pre-treated by saline hydration 24 h prior to each cycle of 
chemotherapy.  
 
2.2.3 Audiometric monitoring 
 
Patient hearing thresholds were determined at frequencies between 0.25 kHz and 8.0 kHz 
using a GSI 61 audiometer (Grason-Stadler, Eden Prairie, MN USA) before each cycle of 
treatment. Hearing thresholds ≥ 25 dB at any test frequency in the baseline audiogram were 
recorded as pre-existing hearing loss. Ototoxicity was defined and graded using the Chang 
ototoxicity grading scale, in which grade 0 indicates that hearing remained unchanged during 
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treatment, and grade 1A (≥ 40 dB change in threshold at frequencies ≥ 6.0 kHz) upwards 
indicates a treatment-induced decrease in hearing sensitivity (Chang and Chinosornvatana, 
2010). Grade 2A (≥ 40 dB change in threshold at ≥ 4.0 kHz) and greater hearing loss was 
regarded as clinically significant (Chang and Chinosornvatana, 2010). To assess the impact 
of treatment on the patients’ hearing, changes in sensitivity threshold were calculated at 
each test frequency for the worst affected ear. 
 
2.2.4 Statistical analyses 
 
Associations between categorical variables and ototoxicity were assessed using Chi-
squared tests, or Fisher’s exact tests when any expected values were less than 5. 
Differences in the distribution of numerical variables between groups were analysed with 
Mann-Whitney U tests and Kruskal-Wallis tests. In all the analyses, any missing data was 
excluded from these tests. The ability of demographic and clinical factors to predict 
ototoxicity was analysed using binary forward logistic regression. Kaplan-Meier survival 
analysis was used to assess the time to develop hearing loss, in which the onset of 
ototoxicity was regarded as an event. The time of event-free survival was calculated as the 
number of days between the first audiogram and the date at which ototoxicity was first noted. 
Final dates on which no hearing loss was detected were censored in the analysis. All 
statistical analyses were performed using the IBM® SPSS® software version 22.0.0.0 (IBM® 




2.3.1 Patient cohort 
 
A total of 430 potentially eligible patients received cisplatin treatment at GSH during the 
study period, of whom 295 met the audiometric inclusion criteria (Table 2.1). The 295 
patients were predominantly (70.8%) male, and the primary cancer site recorded was the 
head and neck regions. Using the Chang ototoxicity grading scale, the incidence of hearing 
impairment in these patients was 39.7%. While patient age and gender did not show any 
significant associations with hearing loss, ethnicity did show significant differences. In 
particular, the indigenous Africans were significantly over-represented in Grades > 0 (OR: 
2.52, 95% CI: 1.43; 4.43). However, the anatomical site of cancer also differed significantly 
between the two groups, with reproductive cancer patients at a reduced risk of ototoxicity 
(OR: 0.34, 95% CI: 0.15; 0.76), and head and neck cancer patients at an increased risk (OR: 
1.84, 95% CI: 1.14; 2.97). 
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Table 2.1: Characteristics of eligible patients 
Variable Grade 0 (n = 178) Grade > 0 (n = 117) p-value 
Age (years) 
Median 



















    
Ethnicity (n,%) 
Caucasian  
Mixed ancestry  




















    
Cancer diagnosis (n,%) 


























    










    










    
Cranial irradiation (Gy) 
Median dose 








* Excluded from analysis; a Mann-Whitney U test; b Chi-squared test; c Fisher exact test 
max, maximum; min, minimum; n, number of individuals 
 
 
2.3.2 Association of clinical characteristics with ototoxicity 
 
Both the individual and cumulative cisplatin doses were significantly higher in patients who 
developed ototoxicity during treatment (Table 2.1). This dosage data associated with the 
anatomical site of the cancer, and there were significant differences in ethnicity distribution 
between the cancer diagnoses (Table 2.2). Caucasian patients were over-represented and 
black African patients were under-represented in the reproductive cancer group (Chi-
squared test, p = 0.001 and p = 0.011, respectively). Additionally, no significant differences 
in cisplatin dosage were detected between the head and neck cancers, lymphomas and 
osteosarcomas (Kruskal-Wallis test, p = 0.060). Although 48.2% of the head and neck 
cancer patients received cranial irradiation as part of their treatment, only a small proportion 
(37.0%) of these received their RT before or during cisplatin exposure. In these patients, the 




Table 2.2: Analysis of variables according to cancer diagnosis 
 Head and neck Lymphoma Osteosarcoma Reproductive Other p-value 













       














       





























       













a Kruskal-Wallis test; b Fisher’s exact test; c Chi-squared test  
BA, Black African; Cau, Caucasian; Ind, Indian; MA, mixed ancestry; n, number of individuals 
 
 
2.3.3 Association of demographic variables with ototoxicity 
 
Because head and neck cancers, lymphomas and osteosarcomas were treated using similar 
dosage regimens, the analysis of further covariates was restricted to this group of patients (n 
= 210), where the ototoxicity incidence rate was 44.8%. Again, the ethnicity of the patient 
was significantly associated with hearing impairment (Table 2.3). Indigenous Africans were 
significantly skewed towards the development of ototoxicity (OR: 2.43, 95% CI: 1.25; 4.73) 
as well as Grade ≥ 2A ototoxicity (OR: 2.46, 95% CI: 1.15; 5.26). Pre-existing hearing loss, 
age at the initiation of treatment, and patient sex did not associate with ototoxicity. 
 
Table 2.3: Demographics of head and neck cancer, lymphoma and osteosarcoma patients 































24 (16.2%)  
14 (22.6%) 
0.274b 
       

















       





























* Not included in analysis; a Mann-Whitney U test; b Chi-squared test; c Fisher’s exact test 
BA, Black African; Cau, Caucasian; HL, hearing loss; Ind, Indian; MA, mixed ancestry; n, number of individuals; 
ND, not determinable 
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The different ethnic groups displayed significant differences in threshold shifts due to 
cisplatin treatment (Figure 2.1). In all patients, the higher frequencies (6.0-8.0 kHz) were 
subject to greater changes as a result of treatment; however, indigenous Africans tended to 
experience the greatest shifts in hearing, and Caucasians the lowest. These differences 
were maintained between 3.0 kHz and 8.0 kHz (Table 2.4). There were also significant 
differences in the time to develop ototoxicity in the sub-population groups (Figure 2.2). 
Indigenous African patients developed hearing loss in a median time of 48 days, which was 
a significantly shorter time compared to the other patient sub-populations (Log-rank test, p = 
0.001). Caucasian and mixed ancestry patients developed ototoxicity in median periods of 
































Figure 2.1: Average threshold changes at each test frequency in head and neck cancer, 
osteosarcoma and lymphoma patients of different ethnicities. Orange, purple and grey represent the 
Caucasians, indigenous Africans and mixed ancestry patients, respectively. The distributions of 
hearing sensitivity changes are represented by box-and-whisker plots, in which the boxes delineate 
the upper and lower quartiles, and the whiskers indicate the minimum and maximum values. Lines 
within the boxes are the median values. Statistical outliers are indicated by circles (1.5-3.0 
interquartile ranges from the whisker) and stars (> 3.0 interquartile ranges from the whisker). Hearing 
sensitivity changes are measured on the y-axis, in which a greater value indicates more hearing 




Table 2.4: Median threshold shifts per test frequency in the different ethnic groups 
Test frequency 
(kHz) 
Caucasian Mixed ancestry Indigenous African p-valuea 
0.25 5.00 0.00 5.00 0.221 
0.5 0.00 0.00 5.00 0.969 
1.0 0.00 0.00 0.00 0.408 
2.0 0.00 0.00 0.00 0.678 
3.0 5.00 5.00 10.00 0.037 
4.0 10.00 10.00 30.00 0.023 
6.0 10.00 20.00 40.00 0.001 
8.0 17.50 30.00 40.00 0.007 































Figure 2.2: Kaplan-Meier survival analysis plot of ototoxicity-free survival between the different ethnic 
groups in head and neck cancer, lymphoma and osteosarcoma patients. Start dates were the date of 
first exposure to cisplatin, and end points were taken as the date at which ototoxicity was first 
observed in the patient. The time between these two dates, in days, is on the x-axis. The fraction of 
patients without ototoxicity is on the y-axis. Patients who did not develop Grade > 0 ototoxicity were 
censored at the date of their last recorded audiogram (crossed lines).  
 
 
2.3.4 Statistical modelling of cisplatin-induced ototoxicity 
 
The ability of cumulative dose, individual dose and ethnicity to predict ototoxicity was 
modelled using forward logistic regression. When investigating the head and neck, 
lymphoma and osteosarcoma patients, each of the covariates was retained as a significant 
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predictor of hearing loss (cumulative cisplatin dose: p < 0.001; African ethnicity: p = 0.012; 
individual cisplatin dose: p = 0.041). In comparison, only ethnicity was identified as a 
predictor of clinically relevant (Grade ≥ 2A) ototoxicity using forward logistic regression (p = 
0.006). Cumulative dose (p = 0.171) and individual dose (p = 0.170) could not predict Grade 
≥ 2A ototoxicity. Similar results were obtained when considering all the patients, regardless 
of cancer diagnosis: forward logistic regression identified the cumulative dose of cisplatin (p 
< 0.001), as well as black African ethnicity (p = 0.005) and individual dose (p = 0.003) as 
predictors of ototoxicity. Regarding clinically significant ototoxicity, ethnicity was the most 
significant predictor of hearing impairment (p = 0.001); however, when analysing the total 
cohort, both the cumulative dose (p = 0.014) and the individual dose (p = 0.042) were 




Ototoxicity is a severe, potentially disabling ADR which can affect a large proportion of 
cisplatin-receiving cancer patients, and can alter treatment outcomes due to quality-of-life 
considerations. The characterisation of risk factors is therefore of interest, as this could 
enable the a priori identification of patients who are more susceptible to ototoxicity, and play 
a role in the future personalisation of treatment regimens. The only conclusive risk factor 
which has been identified to date, however, is a high cumulative dose of cisplatin 
(Bokemeyer et al, 1998; Li et al, 2004), which was a predictor of ototoxicity in this study. In 
addition, this investigation has described a previously unreported association between 
geographic ethnicity and ototoxicity.  
 
Due to significant differences in the distribution of ethnicity between the cancer diagnoses, 
patients diagnosed with head and neck cancers, lymphomas and osteosarcomas were 
focussed on in order to reduce the effect of possible confounding clinical factors. This is 
because it was evident that different modalities of treatment presented different risks of 
ototoxicity to patients. In particular, those with cancers of the reproductive system (i.e. 
testes, cervix and ovaries) were at a 2.9-fold reduced risk of hearing impairment, possibly 
due to the lower dose of cisplatin administered in the treatment of these cancers (median 
dose: 35.00 mg/m2). The data also suggested that osteosarcoma, lymphoma, and head and 
neck cancer patients were exposed to similar treatment regimens, and there was no 
significant difference in dosage between these regimens (median dose: 100.00 mg/m2). In 
this group of patients, the ethnicity of the patient remained in significant association with 
ototoxicity, with indigenous Africans at a 2.4 times greater risk of hearing impairment. These 
patients were also 2.5 times more susceptible to the development of ototoxicity in Grades 
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2A, 2B and 3, the grades of hearing loss at which clinical interventions such as hearing aids 
are usually required (Chang and Chinosornvatana, 2010).  
 
Analysis of audiograms from indigenous African patients indicated significantly greater 
cisplatin-induced hearing loss across a wide range of frequencies; all test frequencies 
between 3.0 kHz and 8.0 kHz were subject to greater shifts due to treatment. These results 
were also observed in the total cohort of patients (Appendix F). Notably, audiometric 
thresholds in the speech frequencies (0.5-4.0 kHz) were more likely to be affected in 
indigenous Africans, while hearing impairment tended to be limited to the high frequencies 
(4.0-8.0 kHz) in the Caucasian and mixed ancestry patients. This indicates that ototoxicity 
tends to be more severe in indigenous Africans, and has a greater potential to affect quality-
of-life. In addition, this patient population developed hearing loss at a significantly faster rate. 
In the United States of America (USA), it has been reported that individuals of African 
ancestry usually maintain better hearing across all ages compared to Caucasians (Agrawal 
et al, 2008; Lin et al, 2011). Melanin is present in the cochlea, at a density which is 
proportional to pigmentation of the skin, and may play a role in otoprotection and antioxidant 
function (Murillo-Cuesta et al, 2010; Xiong et al, 2011). Pigmented animals have displayed 
more resistance to aminoglycoside ototoxicity than albino animals (Wu et al, 2001), although 
the protective effects of melanin are equivocal. Melanin has been demonstrated to bind 
drugs such as aminoglycosides and anthracyclines, which may potentiate their toxic effects 
(Svensson et al, 2003). Although this may explain the increased incidence of hearing loss 
observed amongst the black African individuals in this cohort of cisplatin-receiving patients, 
melanin has not shown any affinity for cisplatin in vitro (Svensson et al, 2003). 
 
No other demographic variables associated with ototoxicity in this group of patients. While 
young paediatric patients may be more susceptible to the ototoxic effects of cisplatin (Li et 
al, 2004), there is currently no suggestion that the effect of young age is maintained in adults 
(Oldenburg et al, 2007), or even other paediatric populations (Bertolini et al, 2004; Ross et 
al, 2009). It has been reported that male patients are at a greater risk of hearing impairment 
in response to chemotherapy than female patients (Yancey et al, 2012), although similarly 
this association has not been replicated (De Jongh et al, 2003; Bertolini et al, 2004; Li et al, 
2004). In contrast, few human correlational investigations into cisplatin-induced ototoxicity 
have considered the role of ethnicity. Those which have did not report any association with 
the condition (Li et al, 2004; Pussegoda et al, 2013; Yang et al, 2013). This is likely due to 
the high proportion (> 75%) of Caucasian patients included in these analyses; it is unclear 
what proportion of the remainder consisted of indigenous Africans. Of the patients with an 
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assigned ethnicity in this study, a total of 84.3% were non-Caucasian, of whom 26.6% were 
indigenous Africans.  
 
It should be noted that information regarding co-medications and co-morbidities was not 
available in this investigation, and therefore the role of these potential covariates in 
ototoxicity cannot be ascertained. Additionally, data regarding the use of cranial irradiation 
amongst head and neck cancer patients was limited, and has been identified as a potential 
risk factor, particularly at doses exceeding 48 Gy (Chen et al, 2006). While this may explain 
why head and neck cancer patients seemed more likely to develop ototoxicity in this study, 
the majority (63.0%) of patients who received RT to the head and neck regions did so after 
cisplatin therapy, and therefore after audiological monitoring had ceased. There was no 
indication that the use of RT during treatment increased the risk of hearing loss. The 
concurrent administration of RT and cisplatin has failed to associate with ototoxicity in other 
investigations (Ilveskoski et al, 1996; Knight et al, 2005; Ross et al, 2009; Choeyprasert et 
al, 2013) and may be due to the dose of radiation used: in this study, the average dose 
(median dose: 45 Gy) was less than the reported threshold of 48 Gy (Chen et al, 2006).   
 
A previous epidemiological investigation focussing on the prevalence of ototoxicity in a 
similar patient cohort reported an ototoxicity incidence of 55.1% (Whitehorn et al, 2014a). In 
the present study, however, 39.7% of all patients were affected. Although 188 more patients 
were included in this study compared to the previous, the difference should rather be 
attributed to the different definitions of ototoxicity employed in the analyses. The Chang 
ototoxicity grading scale is a modification of the Brock criteria which are widely used in 
studies of ototoxicity (Brock et al, 1991), and accounts for the fact that ototoxicity initially 
affects the higher ranges of hearing before progressing into the lower frequencies (Chang 
and Chinosornvatana, 2010). It is therefore possible that non-ototoxic shifts in hearing were 
included in the 55.1% originally reported, as the less stringent ASHA criteria of ototoxicity 
were used (ASHA, 1994). When analysing the head and neck cancer, lymphoma and 
osteosarcoma patients with the Chang grading scale, an ototoxicity incidence of 44.8% was 
observed, although 61.7% of indigenous Africans developed hearing impairment at these 
doses. These results suggest that the indigenous African population of SA may be a sub-




The increased susceptibility of indigenous Africans to hearing loss in this investigation 
indicates a new potential risk group of patients. Since all patients were attending the same 
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hospital and were subjected to a similar standard of care, the discrepancy between the 
ethnicities cannot be attributed to differences in healthcare. Previous studies have identified 
genetic variants which may modify the risk of ototoxicity in Caucasian cancer patients 
(Oldenburg et al, 2007; Riedemann et al, 2008; Caronia et al, 2009; Ross et al, 2009; 
Pussegoda et al, 2013; Spracklen et al, 2014; Lanvers-Kaminsky et al, 2015). It is therefore 
probable that the increased susceptibility of the indigenous African population may be due to 
unique underlying genetic influences. Recent population genomic studies have shown that 
relatively few populations, even those in Africa, have remained free of admixture (Lachance 
et al, 2012; Pickrell et al, 2014). Consequently, detailed genomic studies of these sub-
populations may be valuable in elucidating the contribution of genetics to ototoxicity. 
 
Genetic variations in the pathways which metabolise cisplatin and modulate cell response 
after exposure to the drug may be involved, as might variants affecting the normal 
functioning of the inner ear. Although a previous investigation of the SA population identified 
novel modifiers of cisplatin-induced ototoxicity in the gene OTOS, these results were limited 
to Caucasian and mixed ancestry patients, and could not explain hearing loss in indigenous 
Africans (Spracklen et al, 2014). Further analysis of this genetically unique population may 
therefore reveal new genes in association with ototoxicity, contributing to our knowledge of 










Platinum-based chemotherapy is prevalently employed in the treatment of various soft-tissue 
neoplasias. Cisplatin exerts its cytotoxic properties through the induction of apoptotic 
pathways in cancer cells, and it is thought that cell death is primarily triggered by damage to 
DNA (Wang and Lippard, 2005). Other molecular targets such as proteins and RNA have 
been suggested, as nucleus-independent pathways may also contribute to cell death 
(Akaboshi et al, 1992; Neault et al, 2001; Yu et al, 2008). Although the incorporation of 
cisplatin into chemotherapy regimens has proved to be a largely successful strategy in the 
management of cancer (McKeage, 1995; Einhorn, 2002), the effective use of the drug may 
be compromised when these apoptotic pathways are activated in noncancerous cells in the 
body, leading to the development of severe ADRs such as ototoxicity, nephrotoxicity, and 
neurotoxicity in the patient (McKeage, 1995).  
 
Ototoxicity, or drug-induced hearing loss, is a potentially disabling reaction to cisplatin. It 
occurs when the drug accumulates in and damages cells of the inner ear, resulting in 
hearing loss which typically affects the higher frequencies of hearing (6-8 kHz) before 
progressing into the lower frequencies (0.5-4 kHz) (Kopelman et al, 1988; de Andrade et al, 
2013). Ototoxicity is a prevalent adverse reaction to cisplatin chemotherapy, causing 
permanent hearing impairment in between 25% and 100% of patients treated with the drug 
(Kopelman et al, 1988; Bokemeyer et al, 1998; De Jongh et al, 2003; Knight et al, 2005; 
Kushner et al, 2006; Coradini et al, 2007; Arora et al, 2009; Yancey et al, 2012; 
Choeyprasert et al, 2013; Yang et al, 2013; Peleva et al, 2014). The reported incidences of 
ototoxicity vary depending on the sensitivity of hearing tests employed in the analyses, as 
well as the audiometric definition of ototoxicity used. Indeed, there are as yet no universally 
accepted audiological criteria for drug-induced hearing loss, which may complicate the 
comparison of different study populations.  
 
There are numerous ototoxicity classifications and scales, including the ASHA guidelines 
(ASHA, 1994), the Brock criteria (Brock et al, 1991), the Chang ototoxicity grading scale 
(Chang and Chinosornvatana, 2010), and the Common Terminology Criteria for Adverse 
Events (CTCAE) published by the National Cancer Institute (NCI) (NCI, 2010). Two more 
recently proposed criteria are the International Society of Paediatric Oncology Boston (SIOP) 
ototoxicity grading scale (Brock et al, 2012), and the TUNE criteria, which were developed 
specifically for use in adult patients (Theunissen et al, 2014). These scales (Table 3.1) differ 
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both in terms of how the test frequencies are ranked in order of significance, as well as 
which threshold changes are considered markers of drug-induced hearing loss. For 
example, the ASHA and CTCAE criteria do not place any emphasis on lower or higher 
frequencies in the audiogram, whereas the other grading scales do account for the fact that 
ototoxicity initially affects higher frequencies of hearing (> 6 kHz); the higher grades of the 
Chang, Brock, SIOP and TUNE scales all reflect progression of hearing impairment to the 
lower frequencies of hearing. Nevertheless, the CTCAE are still largely used in studies of 
ototoxicity and have demonstrated superiority over the Brock criteria, which may 
underestimate hearing loss incidence due to the high threshold change it requires (Landier 
et al, 2014). The ASHA, Brock, Chang, SIOP and CTCAE ototoxicity grading scales have all 
shown a degree of concordance with one another in their abilities to detect hearing loss 
(Bass et al, 2014; Landier et al, 2014). However, no data on the comparability of the TUNE 
grading system is available as yet. 
 
Table 3.1: Different grading scales of ototoxicity 
Scale Grade 1a Grade 2 Grade 3 Grade 4 
ASHA ≥ 20 dB at any freq or 
≥ 10 dB at any two 
adjacent freqs 
- - - 
     
Brock ≥ 40 dB at 8 kHz ≥ 40 dB at 4 kHz and 
above 
≥ 40 dB at 2 kHz and 
above 
≥ 40 dB at 1 kHz and 
above 
     
Chang 1A: ≥ 40 dB at 6 to 12 
kHz 
1B: > 20 and < 40 dB 
at 4 kHz 
2A: ≥ 40 dB at 4 kHz 
and above 
2B: > 20 and < 40 dB 
at any freq < 4 kHz 
≥ 40 dB at 2 or 3 kHz 
and above 
 
≥ 40 dB at 1 kHz and 
above 
     
CTCAE ≥ 15 and ≤ 25 dB 
averaged at any two 
adjacent freqs 
> 25 dB averaged at 
any two adjacent 
freqs 
> 25 dB averaged at 
any three adjacent 
freqs 
> 80 dB at 2 kHz and 
above 
     
SIOP > 20 dB at 6 or 8 kHz > 20 dB at 4 kHz and 
above 
> 20 dB at 2 or 3 kHz 
and above 
> 40 dB at 2 kHz and 
above 
     
TUNE 1A: ≥ 10 dB at 8 kHz 
or above 
1B: ≥ 10 dB at 1 to 4 
kHz 
2A: ≥ 20 dB at 8 kHz 
or above 
2B: ≥ 20 dB at 1 to 4 
kHz 
≥ 35 dB at 1 to 4 kHz  ≥ 70 dB at 1 to 4 kHz 
a Grade 0 (no hearing loss) omitted from all scales for clarity 
ASHA, American Speech-Language-Hearing Association; CTCAE, Common Terminology Criteria for Adverse 
Events; dB, decibels; freq, frequency; kHz, kilohertz; SIOP, International Society of Paediatric Oncology Boston 
 
 
Regardless of the audiometric criteria, there is much inter-individual variability in the 
development of hearing impairment amongst patients. One risk factor of ototoxicity which 
has been consistently and independently identified is the cumulative dose of cisplatin, in 
which patients exposed to greater total doses of the drug are more likely to develop 
significant hearing loss (Bokemeyer et al, 1998; Bertolini et al, 2004; Li et al, 2004; 
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Whitehorn et al, 2014b). Predictive predisposing factors would be more effective, however, if 
they were not related to the treatment plan itself, and are inherent to the patient. Non-clinical 
risk factors which have been suggested to date include patient gender, age extremes, pre-
existing audiological markers such as hearing loss and prior noise exposure, and impaired 
renal function. Unfortunately, none of these variables have been able to explain variability in 
patient response with much success (Bokemeyer et al, 1998; De Jongh et al, 2003; Li et al, 
2004; Chen et al, 2006; Yancey et al, 2012; Choeyprasert et al, 2013; Kirkim et al, 2014).  
 
A potential source of inter-individual variability in drug response is the patient genome. There 
has been increasing focus on the pharmacogenetics of cisplatin-induced ototoxicity, and 
several genetic polymorphisms have been reported in association with an altered risk of 
hearing impairment as a result of treatment (Rybak et al, 2007). Many of these results could 
not be replicated in independent investigations, indicating that they may be false positives or 
population-specific. Although the heritability of cisplatin sensitivity has been demonstrated at 
the cellular level (Dolan et al, 2004; Shukla et al, 2008), it is evident that pharmacogenetic 
studies into cisplatin response have so far been unable to identify reliable predictors of 
ototoxicity. While it can be expected that the effect sizes of genetic associations may 
decrease in replication studies (Boddy, 2013), genetic variants in TPMT, XPC, GSTP1, and 
LRP2 failed to associate with ototoxicity in populations alternative to those in which they 
were originally reported (Riedemann et al, 2008; Ross et al, 2009; Choeyprasert et al, 2013; 
Whitehorn et al, 2014b; Yang et al, 2013; Hagleitner et al, 2014; Lanvers-Kaminsky et al, 
2014). This reduces confidence in the role those markers play in the development of 
cisplatin-induced ototoxicity. With the exception of GSTP1 and OTOS, none of the genes 
which have been investigated so far have a known function in the pathway whereby cisplatin 
induces ototoxicity (Oldenburg et al, 2007; Spracklen et al, 2014). For example, TPMT, 
COMT, ABCC3, ABCB5 and DPYD were identified through a screen of all ADME-related 
genes (Ross et al, 2009; Pussegoda, 2012; Pussegoda et al, 2013), while LRP2 was chosen 
as a candidate by similarity, since its encoded product is a transporter of another class of 
ototoxic drugs, the aminoglycosides (Riedemann et al, 2007). 
 
In order to explain the pharmacogenetics of cisplatin-induced ototoxicity, new genes need to 
be investigated as potential sources of variability in drug response. Given the 
inconsistencies of the aforementioned genetic association studies, future candidate genes 
may be better chosen based on knowledge of the pathway by which cisplatin induces its 
ototoxicity, with an emphasis on functional variants. The aim of this investigation is to 
consider the role of new candidate genes in the development of cisplatin-induced ototoxicity 





3.2.1 Research design 
 
This project is the continuation of an investigation, initially started in 2012, into the 
pharmacogenetics of cisplatin-induced ototoxicity in adult SA cancer patients (HREC 
reference no.: 389/2012). It is a collaborative study involving the Division of Audiology 
(UCT/GSH) and the Department of Radiation Oncology (GSH), which previously identified 
two potential genetic modifiers of ototoxicity in the genes OTOS and COMT (Spracklen et al, 
2014; Whitehorn et al, 2014b).  
 
The present research will investigate new potential candidate genes that may modify patient 
susceptibility to hearing loss. This is a longitudinal investigation in which the participants are 
all exposed to cisplatin, and audiometric data that is collected throughout treatment is used 
to assess the development of ototoxicity.  
 
3.2.2 Patient recruitment  
 
Ethical approval for this study was obtained from the HREC (HREC reference no.: 220/2014; 
Appendix A), and patients who attended the Audiology Clinic and the Department of 
Radiation Oncology at GSH were recruited between 2012 and 2015. Potential participants 
were approached prospectively or retrospectively by a registered research nurse from the 
Division of Human Genetics, UCT, if the patients met the inclusion criteria of the study. 
Prospective recruitment involved contacting eligible patients in the wards when they were 
admitted for treatment, while previous GSH patients were identified retrospectively by 
compiling a list of those who met the inclusion criteria according to the hospital records. 
 
3.2.2.1 Inclusion and exclusion criteria 
 
Eligible patients were those whose primary diagnosis was cancer of the soft tissues, for 
which they were receiving cisplatin-based chemotherapy at GSH. Additional inclusion criteria 
were the presence of a baseline hearing test prior to treatment and at least one post-
treatment audiometric examination, so that the audiological response to cisplatin could be 
measured. Patients were ineligible if they did not have any recorded audiometric tests before 
or during treatment, as there would be insufficient data to determine the development of 
hearing impairment. Patients were also excluded if they were in the terminal stages of their 
diseases, did not consent to participate, or did not understand the project and its 
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implications. Patients with baseline hearing loss were included in the study, although its 
presence was noted as a possible confounding factor. 
 
3.2.2.2 Collection of data, biological samples, and informed consent 
 
Written informed consent was obtained from each patient during the recruitment process 
(Appendix B), as well as basic demographic information such as sex, date of birth, and self-
reported ethnicity. Additionally, a biological sample of either blood or saliva was acquired 
from each participant for use in molecular investigations (Appendix C). Informed consent 
was requested for access to patient folders (Appendix D), from which clinical information 
relating to cisplatin treatment, including the cancer diagnosis, drug dosages, cycle 
information and the results of audiometric tests were obtained. Approval for the retrieval of 
patient folders was obtained from GSH (Appendix E). The medical records were also 
reviewed for other relevant information such as the use of cranial irradiation during 
treatment, the development of tinnitus and vestibular problems, as well as whether the 
treatment regimen was altered due to an adverse reaction to cisplatin.  
 
3.2.2.3 Audiometric analysis 
 
Audiometry tests were conducted on patients at the Audiology Clinic, GSH, before each 
cycle of cisplatin treatment. A GSI 61 audiometer (Grason-Stadler, Eden Prairie, MN USA) 
was used to determine hearing thresholds by pure-tone audiometry, in which air and bone 
conduction thresholds were measured in each ear at frequencies between 0.25 kHz and 8.0 
kHz. 
 
Pre-treatment audiograms were analysed to determine patient baseline hearing thresholds, 
including the existence of any pre-existing hearing loss. This was defined as a hearing 
threshold of ≥ 25 dB at any frequency in the audiogram and classified as high-frequency, 
conductive, or noise-induced, according to the type of hearing loss presented. Changes in 
hearing during treatment were assessed using the follow-up audiometric data. Audiograms 
obtained before each subsequent cisplatin cycle were compared to the baseline audiograms 
to determine hearing threshold changes during treatment, relative to their baseline. 
Significant hearing loss was defined and graded using the Chang ototoxicity grading scale 
(Chang and Chinosornvatana, 2010), the ASHA guidelines (ASHA, 1994), CTCAE version 





3.2.3 DNA extraction and quality control 
 
Genomic DNA was extracted from the patients’ biological samples and archived at -4°C 
within the Division of Human Genetics, UCT. DNA was isolated from peripheral blood 
lymphocytes using a modified salting out method (Miller et al, 1988) (Appendix G), while the 
ORAgene (DNA Genotek Inc., Ontario, Canada) or Norgen Biotek Saliva DNA Collection, 
Preservation and Isolation (Norgen Biotek Corp., Ontario, Canada) kits were used for the 
isolation of DNA from peripheral salivary endothelial cells, as following the manufacturers’ 
recommendations (Appendix G). 
 
DNA extracts were quantified using a NanoDrop® 1000 spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, DE USA) and diluted to working concentrations of 100 ng/µl. 
The integrity of the DNA samples was interrogated by agarose gel electrophoresis on 1% 
(w/v) agarose gels (Appendix H) which were stained with 1X SYBR® Safe DNA gel stain 
(Life TechnologiesTM, Carlsbad, CA USA).  
 
3.2.4 Candidate selection and the amplification of target DNA regions 
 
Candidate genes and variants were selected based on the literature. Genes which have a 
reported role in the cellular response to cisplatin were prioritised, as variation within those 
genes may be more likely to influence patient responses to treatment. In order to focus on 
variants with possible functional effects, those with prior associations with modified disease 
susceptibility were selected for analysis in the cohort. Although SNPs within genes encoding 
drug metabolising enzymes such as TPMT and GSTP1 were previously investigated and 
found to have no role in ototoxicity in the SA population (Whitehorn et al, 2014b), two 
variants which had not been investigated in this population are ABCC3 c.4509A>G 
(rs1051640) and ABCB5 c.1290+1532G>T (rs10950831), and were included as variants of 
interest in the investigation. 
 
The polymerase chain reaction (PCR) was used to amplify genomic regions which contained 
the variants of interest. The target SNPs were SLC22A2 c.808T>G (rs316019), nuclear 
factor, erythroid 2-like 2 (NFE2L2) g.177265309C>A (rs6721961), EIF3A c.3527-704C>T 
(rs10787899) and g.119081149A>G (rs3824830), CDH13 g.82609046A>T (rs11646213), 
ABCC3 rs1051640 and ABCB5 rs10950831. PCR primers were synthesised by Integrated 
DNA Technologies (IDT) (IDT Inc., Coralville, IA USA) (Table 3.2) and resuspended in 1X 
Tris/EDTA (TE) buffer (Appendix H) following the manufacturer’s instructions. The optimum 
PCR conditions such as annealing temperature (Ta) and primer concentration were 
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established in singleplex for each primer pair, as well as in multiplex. The Ta was optimised 
by performing PCR over a gradient of increasing annealing temperatures between 50°C and 
60°C while other reaction conditions remained constant.  
 
 
Table 3.2: Properties of the primers used for amplification of target regions 
Target gene Variant Primer no. S/A Primer sequence (5`-3`) Expected product size 
(bp) 
ABCB5 rs10950831 
1 S gttgactctacatccaggtctt 
792 
2 A agtctgaggttgctctaatgat 
ABCC3 rs1051640 
3 S tgagcaagtacccagaagag 
196 
4 A ttaggcaagtccagcatc 
CDH13 rs11646213 
5 S tgtgacattcggaagaga 
583 
6 A ggagtaggcaagcactac 
EIF3A rs10787899 
7 S cacgcagatttcagcatagt 
983 
8 A gggtaacagtatagcagattc 
EIF3A rs3824830 
9 S cagttcacaggctcttca 
258 
10 A atgattgtctctcacggttg 
NFE2L2 rs6721961 
11 S aagagttgtttgcgaaggtc 
479 
12 A tttggtgggaagaggttc 
SLC22A2 rs316019 
13 S aatgggtctggagagtga 
263 
14 A ggagaacagtggggattttt 
A, antisense primer; ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-
family C, member 3; bp, base pairs; CDH13, cadherin 13; EIF3A, eukaryotic translation initiation factor 3, subunit 
A; NFE2L2, nuclear factor erythroid 2-like 2; no., number; S, sense primer; SLC22A2, solute carrier family 22, 
member 2  
 
 
3.2.4.1 PCR conditions 
 
Amplification of the target regions was performed in three multiplex PCRs (Table 3.3). Each 
reaction was performed in a final volume of 25 µl and contained 150 ng DNA template, 1X 
Colourless GoTaq® reaction buffer (Promega, Madison, WI USA), 0.24 mM dNTPs (Bioline, 
London, UK), 0.75 units GoTaq® DNA polymerase (Promega), and between 0.20 and 0.52 
µM of each primer (Table 3.3). To check for contamination of the PCR reagents, a no-
template control was included for each reaction, which contained water instead of DNA.  
 
The reactions were performed in a Bio-Rad T100TM thermal cycler (Bio-Rad Laboratories 
Inc., Hercules, CA USA). Thermal cycling conditions included an initial denaturation step of 
94°C for 3 mins, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at the 
optimised Ta (Table 3.3) for 30 s, and extension at 72°C for 1 min. A final extension step of 
72°C for 10 mins was also included. PCR products were visualised by agarose gel 
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electrophoresis on 2.5% (w/v) agarose gels stained with 1X SYBR® Safe DNA gel stain (Life 
TechnologiesTM). GeneRulerTM 100 bp Plus DNA ladder (Thermo Scientific, Waltham, MA 
USA) was included as a size standard in each electrophoresis experiment (Appendix H). 
 
 
Table 3.3: Optimised multiplex PCR conditions 
 Target gene Variant Primer pair Primer concentration 
(µM) 
PCR 1 (Ta = 56°C)    
 ABCB5 rs10950831 1/2 0.40 
EIF3A rs3824830 9/10 0.40 
PCR 2 (Ta = 56°C)    
 
ABCC3 rs1051640 3/4 0.40 
CDH13 rs11646213 5/6 0.52 
EIF3A rs10787899 7/8 0.52 
PCR 3 (Ta = 55°C)    
 
NFE2L2 rs6721961 11/12 0.40 
SLC22A2 rs316019 13/14 0.40 
ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-family C, member 3; 
bp, base pairs; CDH13, cadherin 13; EIF3A, eukaryotic translation initiation factor 3, subunit A; NFE2L2, nuclear 




3.2.4.2 Purification of PCR products 
 
PCR products were prepared for use in downstream molecular applications using alkaline 
phosphatase (AP) and exonuclease I (ExoI) purification. Each purification reaction contained 
1.5 units FastAPTM (Thermo Scientific) and 4 units ExoI (Thermo Scientific) in a final volume 
of 25 µl, and was conducted in a Bio-Rad T100TM thermal cycler (Bio-Rad Laboratories Inc.). 
The reaction conditions consisted of a 37°C incubation period of 1 h, followed by a 75°C 
step for 15 mins.  
 
3.2.5 SNaPshot® genotyping 
 
The variants of interest were genotyped using the SNaPshot® multiplex kit (Life 
TechnologiesTM). Primers for the single nucleotide extension sequencing reactions were 
synthesised by IDT (Table 3.4). Each reaction contained a total of 5 μl purified PCR product, 
2 μl reaction mix and 1 μl primer mix, to a total volume of 10 μl. The reaction conditions 
consisted of 25 cycles of 96°C for 10 s, 50°C for 5 s and 60°C for 30 s, conducted in a 




Table 3.4: Primers for SNaPshot® genotyping 
Target 
gene 




ABCB5 rs10950831 aaatgatgttaatatcctttatagtctgtatcacg S 35 36 
ABCC3 rs1051640 cctggtcctggacaaaggagtagtagctga S 30 31 
CDH13 rs11646213 aaagcatacagaaaacatatctttgaaagaagttgc S 36 37 
EIF3A rs10787899 ttggatatgaagggcttgaaaa S 22 23 
EIF3A rs3824830 gattcccaggctgga S 15 16 
NFE2L2 rs6721961 gggagatgtggacagc A 16 17 
SLC22A2 rs316019 gagcaagaagaagaagttgggcagag A 26 27 
A, antisense strand; ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-
family C, member 3; bp, base pairs; CDH13, cadherin 13; EIF3A, eukaryotic translation initiation factor 3A; 
NFE2L2, nuclear factor erythroid 2-like 2; S, sense strand; SLC22A2, solute carrier family 22, member 2  
 
 
3.2.5.1 Visualisation and analysis of SNaPshot® reaction products 
 
The reaction products were purified through the addition of 1 unit of FastAPTM (Thermo 
Scientific) to each. Purification reactions were incubated at 37°C for 1 h, after which they 
were heated to 75°C for 15 mins, and 95°C for 5 mins in a GeneAmp® 9700 thermal cycler 
(Applied Biosystems). 
 
In preparation for capillary electrophoresis, 5 µl of the purified SNaPshot® product was mixed 
with 4.7 µl Hi-DiTM formamide (Life TechnologiesTM) and 0.3 µl GeneScanTM 120 LIZ® size 
standard (Life TechnologiesTM) in a MicroAmp® 96-well reaction plate (Life TechnologiesTM). 
The products were heated to 95°C for 5 mins in a Hybaid touchdown thermal cycler (The 
Scientific Group, Johannesburg, SA) before separation and visualisation by capillary 
electrophoresis on an ABI PRISM® 3130xl genetic analyser (Applied Biosystems), using the 
3130xl Genetic Analyser Data Collection software version 3.1 (Applied Biosystems). 
SNaPshot® genotyping results were viewed and analysed using the GeneMapper® software 
version 4.1 (Applied Biosystems), with the default SNaPshot® analysis method selected. For 
each SNP of interest, the colour peak indicated the genotype at that position, with red 
labelling thymine, green labelling adenine, blue labelling guanine, and black labelling 
cytosine. 
 
3.2.6 Validation of genotyping 
 
The results of SNaPshot® genotyping were validated by direct cycle sequencing of PCR 




3.2.6.1 Direct cycle sequencing reaction conditions 
 
PCR products were sequenced using the BigDye® Terminator v3.1 Cycle Sequencing kit 
(Life TechnologiesTM). Sequencing reactions included 2 µl purified PCR product, 1X 
sequencing buffer, 0.25X Terminator Mix, and 2 µM primer, to a total volume of 10 µl. The 
reactions were conducted in a GeneAmp® 9700 thermal cycler (Applied Biosystems), and 
thermal cycling conditions consisted of initial denaturation at 98°C for 5 mins, followed by 30 
cycles of denaturation at 96°C for 30 s, annealing at 50°C for 15 s and extension at 60°C for 
4 mins. 
 
Sequencing products were purified by ethanol precipitation: 2.2 volumes of 100% ethanol 
(Sigma-Aldrich®, St Louis, MO USA) and 0.36 M sodium acetate (pH 5.21) (Merck 
Chemicals, Darmstadt, Germany) were added to each sequencing reaction. The reactions 
were then incubated at -22°C overnight and centrifuged at 10,000 rpm for 10 mins in a 
Centrifuge 5415D (Eppendorf AG, Hamburg, Germany), after which 30 µl of 70% ethanol 
was added to each precipitate. These were centrifuged again at 10,000 rpm for 10 mins, and 
the supernatant discarded. Once dry, the pellet was resuspended in 10 µl sdH2O (Adcock 
Ingram, Johannesburg, SA). 
 
To visualise the sequencing products, 5 µl of the resuspended reaction was mixed with 8 µl 
Hi-DiTM formamide (Life TechnologiesTM) in a MicroAmp® 96-well reaction plate (Life 
TechnologiesTM). Sequencing products were denatured at 95°C for 5 mins in a Hybaid 
touchdown thermal cycler (The Scientific Group), before separation and visualisation on an 
ABI PRISM® 3130xl Genetic Analyser (Applied Biosystems). The 3130xl genetic analyser 
data collection software version 3.1 (Applied Biosystems) was used for capture of the 
sequencing reaction output.  
 
3.2.6.2 Analysis of sequencing products 
 
The FinchTV software version 1.4.0 (http://www.geospiza.com/Products/finchtv.shtml; 
accessed 10.07.2014) was used to visualise and edit electropherograms. This involved 
removal of indistinct regions at the edges of the electropherograms, and confirming each 
base call in the remaining sequence. The edited sequences were aligned to a reference 
sequence downloaded from the Ensembl database (http://www.ensembl.org/index.html, 
accessed 30.03.2014, accession numbers: ABCB5, ESNG00000004846; ABCC3, 
ESNG00000108846; CDH13, ESNG00000140945; EIF3A, ESNG00000107581; NFE2L2, 
ESNG00000116044; SLC22A2, ESNG00000112499) using the ClustalW multiple sequence 
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alignment tool in the BioEdit Sequence Alignment Editor version 7.2.5 (http:// 
www.mbio.ncsu.edu/bioedit/bioedit.html; accessed 10.07.2014). The alignment was 
analysed at the position of the variant, to see if the genotyping call matched that of the 
sequence. 
 
3.2.7 Statistical analysis of data 
 
Observed genotypes were analysed for deviation from those expected under Hardy-
Weinberg Equilibrium (HWE) using Chi-squared analysis (www.tufts.edu/~mcourt01/ 
.../Court%20lab%20-%20HW%20calculator.xls, accessed 29.05.2013). All other statistical 
analyses were performed using the IBM® SPSS® Statistics programme, version 22.0.0.0 
(IBM® Corp.). Categorical variables such as patient ethnicity, sex, cancer diagnosis, and 
genotypic data were analysed individually for their associations with cisplatin-induced 
ototoxicity by Chi-squared tests, or Fisher’s exact tests when expected frequencies were 
less than 5. The distribution of numerical variables, which included patient age and dosage 
information, was examined using the Shapiro-Wilk test. Since all the numerical data was not 
normally distributed, Mann-Whitney U tests were applied to the data. The variables were 
also tested for their ability to predict ototoxicity using conditional forward logistic regression, 
in which all the data was included as potential covariates, and the development of ototoxicity 
was a binary dependent variable. Nondirectional binary logistic regression was used to 
adjust the observed allele frequency differences between patient groups for the identified 
non-genetic confounders. In all the analyses, p-values < 0.05 were considered significant. In 
the analysis of genetic data, this value was adjusted to 0.007 by Bonferroni correction to 
account for the seven SNPs analysed.  
 
Linkage disequilibrium (LD) between variants was tested for those which are located on the 
same chromosome. The online version of SHEsis (http://analysis2.bio-x.cn/myAnalysis.php; 
accessed 22.08.2015) was used to calculate and compare pair-loci r2 and D` values for each 
of the ethnic groups represented in this study (i.e. Black African, Caucasian, mixed ancestry, 
and Indian). For variants in LD, haplotypes were treated as categorical variables and tested 











3.3.1 Patient cohort 
 
During the study period, a total of 349 cancer patients were recruited from GSH. Of these, 
222 patients met the inclusion criteria and were considered for molecular investigations 
(Table 3.5). The remaining 127 patients were excluded mainly for audiological reasons: 22 
patients did not undergo any audiological testing during treatment, 58 received only a 
baseline examination with no follow-up audiometry performed, and three had audiological 
examinations during treatment but without any measure of pre-treatment hearing levels. Two 
patients who did meet the audiometric inclusion criteria were not included due to unreliable 
or unclear baseline audiometric readings, and six patients did not receive any cisplatin 
treatment. The hospital folders of 35 patients could not be accessed during the study period, 
and one patient withdrew from the study. 
 
Table 3.5: Characteristics of the patient cohort used in molecular investigations 
Demographic characteristics  
Age (years) 
Median 
































Clinical characteristics  


















Cumulative dose (mg/m2) 
Median 




Individual dose (mg/m2) 
Median 




Duration of audiometric follow-up (days) 
Median 




max, maximum; min, minimum 
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The cohort of 222 patients consisted of predominantly (71.2%) male individuals, and the 
primary ethnic group was Cape mixed ancestry (60.8%). Pre-existing hearing loss was 
observed in approximately half (53.1%) of the cohort: the most common form of hearing 
impairment was that limited to the high frequencies; conductive and noise-induced hearing 
losses were less commonly observed. Patients were also classified according to the 
anatomical site of cancer, and the most frequent cancer diagnoses were those of the head 
and neck (50.5%), testes and ovaries (14.7%) and lymphomas (14.0%). Cancers grouped 
under “other” included cancer of the bladder (n = 3), anus (n = 1), breasts (n = 1), skin (n = 
1), thymus gland (n = 1), and mixed cancers (n = 3). 
 
3.3.2 Incidence of ototoxicity in the cohort 
 
Four different audiometric definitions of ototoxicity were included in this investigation, 
yielding ototoxicity incidence rates which ranged between 39.2% and 74.8% (Figure 3.1). 
While the development of ototoxicity is already a binary variable in the ASHA guidelines, the 
grading scales used in the Chang, CTCAE and TUNE criteria were dichotomised by 
comparing grade 0 to the other grades. Using this approach, demographic and clinical 




Figure 3.1: The incidences of hearing loss according to each of the ototoxicity definitions used (A), as 
well as the relative distributions of ototoxicity grades 0-4 in the Chang, CTCAE and TUNE grading 
scales (B). 
 
A         B 
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Although the clinical and demographic risk factors of ototoxicity have been discussed in 
detail previously (Chapter 2), similar analyses were performed using the different ototoxicity 
definitions in the prospective cohort (Table 3.6). Clinical risk factors such as the cancer 
diagnosis and dosage information associated with ototoxicity despite the criteria used, while 
the demographic factors age, ethnicity and pre-existing hearing loss correlated less 
consistently at the level of α = 0.05 (Table 3.6). Patients who developed ASHA- and TUNE-
level ototoxicity were significantly older than those who did not, and individuals presenting 
with baseline hearing impairment were more likely to develop ototoxicity according to all the 
grading scales used, with the exception of the Chang grading scale. The gender of the 
patient, however, did not associate with an altered risk of ototoxicity for any of the definitions 
included (Table 3.6). 
 
Table 3.6: Demographic and clinical characteristics of patients with and without ototoxicity 
 No ototoxicity Ototoxicity p-value 





























































































































































a Mann-Whitney U test; b Chi-squared test 




3.3.3 Candidate gene study 
 
To explore potential genetic modifiers of cisplatin-induced ototoxicity, seven SNPs were 
genotyped in the patient cohort. Although 222 patients had audiometric phenotypes, 
genotyping experiments were conducted on 214 samples, because six samples had 
insufficient DNA, and two samples failed consistently during the analyses. One genotype 
could not be obtained due to lack of amplification at the ABCB5 rs1051640 locus; this 
genotype was estimated to be T/G based on the ethnicity of the patient. All genotype 
frequencies were in accordance with HWE (Table 3.7).  
 
Table 3.7: Observed genotype frequencies for each variant analysed 
Variant Genotype counts Minor allele frequency Hardy-Weinberg p-value 




ABCC3 rs1051640 A/A: 147 
A/G: 60  
G/G: 7 
0.17 0.773 




















ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-family C, member 3; 
CDH13, cadherin 13; EIF3A, eukaryotic translation initiation factor 3, subunit A; NFE2L2, nuclear factor erythroid 
2-like 2; SLC22A2, solute carrier family 22, member 2  
 
 
3.3.3.1 Single-site analysis 
 
The association of each of the SNPs with ototoxicity was explored in all patients with 
available clinical data (n = 196) without stratification (Appendix I). At the level of α = 0.05, the 
variant SLC22A2 rs316019 demonstrated potential protective effects against Chang- and 
TUNE-level ototoxicity, while NFE2L2 rs6721961 was similarly associated with reduced 









Figure 3.2: Presence of the SLC22A2 rs316019 (A) and NFE2L2 rs6721961 (B) variant alleles in the 
different ototoxicity classes. Green: ASHA; purple: Chang; red: CTCAE; blue: TUNE. Bars with 




Because the total dose of cisplatin is a well-demonstrated risk factor of ototoxicity, patients 
who were exposed to below-average cumulative doses (median dose: 200 mg/m2) were 
excluded in order to better identify SNPs with protective effects (Tables 3.8 – 3.11). When 
considering patients with cumulative doses greater than or equal to 200 mg/m2 (n = 113), the 
variant NFE2L2 rs6721961 was associated with ototoxicity regardless of the audiometric 
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criteria used (Tables 3.8 – 3.11). In all cases, the alternative A-allele associated with a 
reduced risk of ototoxicity. The association with ASHA- and CTCAE-grade ototoxicity 
retained significance after correction for multiple testing. However, the protective effects of 
the SLC22A2 rs316019 T-allele were not maintained, even at the pre-correction p-value of 
0.05 (Tables 3.9 and 3.11). 
 
Table 3.8: Association of variants with ASHA-grade ototoxicity in patients exposed to cumulative 
cisplatin doses ≥ 200 mg/m2 
Variant No ototoxicity Ototoxicity p-value Odds ratio (95% CI) 













0.419 (0.154; 1.139) 
1.710 (0.774; 3.779) 







a 0.706 (0.404; 1.233) 













2.101 (0.811; 5.442) 
0.419 (0.154; 1.139) 







a 1.702 (0.730; 3.969) 













1.378 (0.627; 3.032) 
0.745 (0.330; 1.681) 







a 1.237 (0.673; 2.273) 













0.650 (0.295; 1.435) 
0.884 (0.394; 1.980) 







a 1.101 (0.622; 1.949) 













0.809 (0.368; 1.776) 
1.383 (0.620; 3.084) 







a 0.932 (0.506; 1.717) 













0.128 (0.032; 0.507) 








b 0.129 (0.034; 0.484) 













1.330 (0.500; 3.537) 








a 1.108 (0.458; 2.681) 
a Chi-squared test; b Fisher’s exact test 
ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-family C, member 3; 
CDH13, cadherin 13; CI, confidence interval; EIF3A, eukaryotic translation initiation factor 3, subunit A; NFE2L2, 









Table 3.9: Association of variants with Chang-grade ototoxicity in patients exposed to cumulative 
cisplatin doses ≥ 200 mg/m2  
Variant No ototoxicity Ototoxicity p-value Odds ratio (95% CI) 













0.670 (0.290; 1.550) 
1.129 (0.538; 2.369) 






48 (46.2%) 0. 354
a 0.777 (0.460; 1.312) 













1.250 (0.551; 2.838) 
0.804 (0.349; 1.856) 







a 1.207 (0.582; 2.504) 













1.206 (0.575; 2.530) 
0.825 (0.388; 1.757) 







a 1.116 (0.636; 1.959) 













0.885 (0.417; 1.878) 
0.958 (0.450; 2.038) 







a 0.864 (0.505; 1.477) 













0.665 (0.315; 1.400) 
1.529 (0.708; 3.304) 







a 0.775 (0.433; 1.387) 













0.204 (0.043; 0.978) 








a 0.198 (0.043; 0.914) 













0.471 (0.184; 1.203) 








a 0.481 (0.200; 1.158) 
a Chi-squared test; b Fisher’s exact test 
ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-family C, member 3; 
CDH13, cadherin 13; CI, confidence interval; EIF3A, eukaryotic translation initiation factor 3, subunit A; NFE2L2, 
nuclear factor erythroid 2-like 2; SLC22A2, solute carrier family 22, member 2  
 
 
The ABCB5 rs10950831 T-allele did show a weak association with TUNE-defined ototoxicity 
(Table 3.11). Because one of these genotypes was estimated to be T/G, the statistical tests 
were repeated using both homozygous alternative genotype calls. While the inclusion of G/G 
strengthened the association of this variant with hearing loss (Chi-squared test, p = 0.021), 
changing the genotype to T/T abolished any significance (Chi-squared test, p = 0.074). This 
is likely because the patient did not develop significant hearing loss according to any of the 
ototoxicity definitions, and it is therefore more likely to influence analysis were the ototoxicity 
incidence rate is high, such as with the TUNE grading scale. In order to overcome this, the 
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patient was excluded and the analyses performed again. The ABCB5 rs10950831 T-allele 
remained in association with TUNE ototoxicity (Chi-squared test, p = 0.037, OR: 0.489, 95% 
CI: 0.248; 0.966). In all the statistical tests, the variant did not show any associations with 
the other ototoxicity grading scales (data not shown). 
 
Table 3.10: Association of variants with CTCAE-grade ototoxicity in patients exposed to cumulative 
cisplatin doses ≥ 200 mg/m2  
Variant No ototoxicity Ototoxicity p-value Odds ratio (95% CI) 













0.452 (0.181; 1.132) 
1.448 (0.679; 3.084) 







a 0.670 (0.392; 1.145) 













1.381 (0.589; 3.239) 
0.686 (0.286;1.645) 







a 1.254 (0.587; 2.682) 













1.176 (0.553; 2.500) 
0.867 (0.401; 1.878) 







a 1.116 (0.627; 1.986) 













0.952 (0.442; 2.052) 
1.012 (0.469; 2.185) 







a 0.958 (0.556; 1.651) 













0.595 (0.278; 1.271) 
1.830 (0.843; 3.972) 







a 0.757 (0.422; 1.357) 













0.106 (0.022; 0.511) 








a 0.107 (0.023; 0.496) 













0.991 (0.400; 2.453) 








a 0.890 (0.389; 2.038) 
a Chi-squared test; b Fisher’s exact test 
ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-family C, member 3; 
CDH13, cadherin 13; CI, confidence interval; EIF3A, eukaryotic translation initiation factor 3, subunit A; NFE2L2, 







Table 3.11: Association of variants with TUNE-grade ototoxicity in patients exposed to cumulative 
cisplatin doses ≥ 200 mg/m2  
Variant No ototoxicity Ototoxicity p-value Odds ratio (95% CI) 













0.211 (0.046; 0.962) 
1.554 (0.617; 3.910) 







a 0.502 (0.258; 0.977) 













2.145 (0.668; 6.890) 
0.350 (0.096; 1.277) 







a 1.575 (0.574; 4.323) 













0.615 (0.242; 1.564) 
1.209 (0.478; 3.054) 







a 0.649 (0.331; 1.273) 













1.797 (0.714; 4.520) 
0.462 (0.166; 1.280) 







a 1.279 (0.651; 2.514) 













0.514 (0.202; 1.310) 
2.600 (1.022; 6.614) 







a 0.795 (0.396; 1.597) 













0.304 (0.086; 1.066) 








b 0.270 (0.086; 0.846) 













0.571 (0.205; 1.597) 








a 0.528 (0.214; 1.304) 
a Chi-squared test; b Fisher’s exact test 
ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-family C, member 3; 
CDH13, cadherin 13; CI, confidence interval; EIF3A, eukaryotic translation initiation factor 3, subunit A; NFE2L2, 
nuclear factor erythroid 2-like 2; SLC22A2, solute carrier family 22, member 2  
 
 
3.3.3.2 Haplotype analysis 
 
Two of the analysed SNPs were located in the gene EIF3A, 42,006 bp apart. The variants 
EIF3A rs10787899 and rs3824830 were noted to be in some degree of LD in the Caucasian 
and Indian populations (Table 3.12); however, the sample size of the Indians was very 
limited (n = 3), and this cannot be considered an accurate representation of the amount of 
LD between these SNPs in this population group. The SNPs were not in any LD in the mixed 
ancestry and Black African population groups (Table 3.12).  
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Table 3.12: Analysis of linkage disequilibrium between the variants EIF3A rs10787899 and 
rs3824830 in the different ethnic population groups 
Population r2 value D` value 
Caucasian 0.520 0.840 
Mixed ancestry 0.087 0.547 
Black African 0.002 0.125 
Indian 1.000 1.000 
 
 
The role of the rs10787899-rs3824830 haplotype in ototoxicity was explored in the 
Caucasian and Indian populations. Similar to the single-site analysis of these variants, no 
significant associations between the EIF3A haplotypes and ototoxicity were observed (Table 
3.13).  
 
Table 3.13: Associations between the EIF3A rs10787899 and rs3824830 haplotypes and ototoxicity 
in Caucasian and Indian patients 






















0.902 (0.293; 2.774) 
0.818 (0.282; 2.371) 
1.933 (0.687; 5.443) 






















2.450 (0.494; 12.156) 
0.528 (0.161; 1.735) 
0.682 (0.181; 2.562) 






















1.333 (0.424; 4.193) 
0.778 (0.270; 2.243) 
1.000 (0.306; 3.266) 






















1.048 (0.340; 3.230) 
0.710 (0.240; 2.098) 
0.462 (0.129; 1.648) 
2.296 (0.811; 6.505) 
a Chi-squared test; b Fisher’s exact test 
ASHA, American Speech-Language-Hearing Association; CI, confidence interval; CTCAE, Common Terminology 
Criteria for Adverse Events 
 
 
3.3.3.3 Regression modelling of clinical, demographic and genetic variables 
 
The predictive value of each of the genetic and non-genetic factors was assessed by forward 
logistic regression. Using the development of ototoxicity as a binary dependent variable, 
data from the individual site analyses was entered as potential covariates in a step-wise 
model. This included the cumulative and individual cisplatin doses, the anatomical site of 
cancer (grouping the head, neck, oesophagus, lymphoma and/or osteosarcoma cancers and 
those of the testes or cervix into two separate groups), whether the patient was of black 
African ethnicity, the presence of baseline hearing impairment, as well as patient age, sex, 
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and genotypic information. Using this approach, various demographic, clinical, and genetic 
predictors of cisplatin-induced hearing loss were identified for each of the definitions of 
ototoxicity (Table 3.14). 
 
Table 3.14: Risk factors of ototoxicity identified by forward logistic regression 
Ototoxicity scale Identified risk factor p-value 
ASHA NFE2L2 rs6721961 A-allele 
Cumulative cisplatin dose 
Individual cisplatin dose 





   
Chang NFE2L2 rs6721961 A-allele 
Cumulative cisplatin dose 
Reproductive cancers 





   
CTCAE NFE2L2 rs6721961 A-allele 
Baseline hearing impairment 
Cumulative cisplatin dose 
Individual cisplatin dose 






   
TUNE Baseline hearing impairment 
Reproductive cancers 




ASHA, American Speech-Language-Hearing Association; CTCAE, Common Terminology Criteria for Adverse 
Events; NFE2L2, nuclear factor, erythroid 2-like 2 
 
 
Notably, the only risk factor identified across all the grading scales was black African 
ethnicity. Cumulative cisplatin dose and the NFE2L2 rs6721961 A-allele were retained as 
significant predictors of ASHA-, Chang-, and CTCAE-level ototoxicity (Table 3.14). 
Regression analysis was also used to adjust the genetic association results for patient 
ethnicity (Table 3.15). The association between NFE2L2 rs6721961 and ototoxicity amongst 
patients receiving total cisplatin doses ≥ 200 mg/m2 remained significant after this correction, 
for all the definitions of ototoxicity used. In addition, the CDH13 rs11646213 variant was 
significantly associated with TUNE-defined ototoxicity, despite not being identified in the 
prior analyses (Table 3.11). ABCB5 rs10950831 was identified again; however, this 
significance was lost when repeating the analyses with G/G and T/T replacing the estimated 
T/G genotype (logistic regression, p = 0.177 and p = 0.473, respectively). Exclusion of this 
patient from the model also abolished the significance (logistic regression, p = 0.265), while 
the association of NFE2L2 rs6721961 remained significantly associated with hearing loss 







Table 3.15: Genetic association results after adjustment for patient ethnicity 
Variant Allele No ototoxicity Ototoxicity p-value Odds ratio (95% CI) 
ASHA      
ABCB5 rs10950831 G 41 (55.4%) 71 (46.7%) 0.324 0.706 (0.404; 1.233) 
ABCC3 rs1051640 G 8 (10.8%) 26 (17.1%) 0.330 1.702 (0.730; 3.969) 
CDH13 rs11646213 T 21 (28.4%) 50 (32.9%) 0.763 1.237 (0.673; 2.273) 
EIF3A rs10787899 T 28 (37.8%) 61 (40.1%) 0.658 1.101 (0.622; 1.949) 
EIF3A rs3824830 G 22 (29.7%) 43 (28.3%) 0.551 0.932 (0.506; 1.717) 
NFE2L2 rs6721961 A 10 (13.5%) 3 (2.0%) 0.005 0.129 (0.034; 0.484) 
SLC22A2 rs316019 T 8 (10.8%) 18 (11.8%) 0.964 1.108 (0.458; 2.681) 
Chang      
ABCB5 rs10950831 G 64 (52.5%) 48 (46.2%) 0.409 0.777 (0.460; 1.312) 
ABCC3 rs1051640 G 17 (13.9%) 17 (16.3%) 0.803 1.207 (0.582; 2.504) 
CDH13 rs11646213 T 37 (30.3%) 34 (32.7%) 0.796 1.116 (0.636; 1.959) 
EIF3A rs10787899 T 50 (41.0%) 39 (37.5%) 0.178 0.864 (0.505; 1.477) 
EIF3A rs3824830 G 38 (31.1%) 27 (26.0%) 0.294 0.775 (0.433; 1.387) 
NFE2L2 rs6721961 A 11 (9.0%) 2 (1.9%) 0.028 0.198 (0.043; 0.914) 
SLC22A2 rs316019 T 18 (14.8%) 8 (7.7%) 0.038 0.481 (0.200; 1.158) 
CTCAE      
ABCB5 rs10950831 G 50 (55.6%) 62 (45.6%) 0.139 0.670 (0.392; 1.145) 
ABCC3 rs1051640 G 12 (13.3%) 22 (16.2%) 0.747 1.254 (0.587; 2.682) 
CDH13 rs11646213 T 27 (30.0%) 44 (32.4%) 0.916 1.116 (0.627; 1.986) 
EIF3A rs10787899 T 16 (34.8%) 73 (40.6%) 0.303 0.958 (0.556; 1.651) 
EIF3A rs3824830 G 29 (32.2%) 36 (26.5%) 0.277 0.757 (0.422; 1.357) 
NFE2L2 rs6721961 A 11 (12.2%) 2 (1.5%) 0.004 0.107 (0.023; 0.496) 
SLC22A2 rs316019 T 11 (12.2%) 15 (11.0%) 0.440 0.890 (0.389; 2.038) 
TUNE      
ABCB5 rs10950831 G 29 (63.0%) 83 (46.1%) 0.040 0.502 (0.258; 0.977) 
ABCC3 rs1051640 G 5 (10.9%) 30 (16.1%) 0.798 1.575 (0.574; 4.323) 
CDH13 rs11646213 T 18 (39.1%) 53 (29.4%) 0.036 0.649 (0.331; 1.273) 
EIF3A rs10787899 T 16 (34.8%) 73 (40.6%) 0.607 1.279 (0.651; 2.514) 
EIF3A rs3824830 G 15 (32.6%) 50 (27.8%) 0.309 0.795 (0.396; 1.597) 
NFE2L2 rs6721961 A 6 (13.0%) 7 (3.9%) 0.008 0.270 (0.086; 0.846) 
SLC22A2 rs316019 T 8 (17.4%) 18 (10.0%) 0.112 0.528 (0.214; 1.304) 
ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-family C, member 3; 
ASHA, American Speech-Language-Hearing Association; CDH13, cadherin 13; CI, confidence interval; CTCAE, 
Common Terminology Criteria for Adverse Events; EIF3A, eukaryotic translation initiation factor 3, subunit A; 
NFE2L2, nuclear factor erythroid 2-like 2; SLC22A2, solute carrier family 22, member 2  
 
 
3.3.3.4 Other markers of treatment response 
 
Although ototoxicity is the primary focus of this investigation, data about other toxic ADRs 
was collected because cisplatin is also a known nephro- and neurotoxin. Five of the included 
patients developed significant renal dysfunction during treatment, and five others showed 
signs of myelosuppresion, neutropaenia, hypokalaemia, hypomagnesaemia and/or 
hypocalcaemia after cisplatin treatment. Additionally, nine patients self-reported post-
chemotherapy tinnitus, which is another effect cisplatin may have in the inner ear. No 
patients were recorded as symptomatic of peripheral neurotoxicity. 
 
Notably, none of the patients who showed signs of nephrotoxicity had the variant SLC22A2 
rs316019 T-allele, and none of those who developed electrolyte deficiencies or 
myelosuppresion carried the NFE2L2 rs6721961 A-allele (Table 3.16). While these 
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differences did not reach statistical significance (data not shown), no such directionality was 
observed with any of the other potential risk factor SNPs (Table 3.16). 
 
Table 3.16: Select genotypes for each of the patients who developed other cisplatin-induced ADRs 








1 Nephrotoxicity T/G A/A C/C G/G 
2 Nephrotoxicity T/T A/A C/C G/G 
3 Nephrotoxicity G/G A/A A/A G/G 
4 Nephrotoxicity T/G T/T C/C G/G 
5 Nephrotoxicity T/T A/A C/C G/G 
6 Neutropaenia T/G A/T C/C G/G 
7 Neutropaenia T/G T/T C/C G/G 
8 Neutropaenia T/T A/A C/C G/G 
9 Nutrient deficiencyb G/G A/A C/C G/G 
10 Neutropaenia and nutrient deficiencyc G/G T/T C/C T/G 
11 Tinnitus T/T T/T C/C G/G 
12 Tinnitus T/G A/A A/C G/G 
13 Tinnitus G/G A/T C/C G/G 
14 Tinnitus NA A/T C/C G/G 
15 Tinnitus G/G A/A C/C T/G 
16 Tinnitus G/G A/T C/C G/G 
17 Tinnitus G/G A/T C/C G/G 
18 Tinnitus T/G A/T C/C G/G 
19 Tinnitus T/G A/T C/C T/G 
a patients given a numerical identifier which is unrelated to the cisplatin-induced ototoxicity study; b hypokalaemia 
and hypomagnesaemia; c hypocalcaemia and hypomagnesaemia 
ABCB5, ATP-binding cassette, sub-family B, member 5; CDH13, cadherin 13; NA, not available; NFE2L2, 





Cisplatin is a chemotherapeutic which is prevalently administered in the management of 
cancer. The use of the drug can be limited by the development of permanent hearing loss, 
which is a common adverse reaction to cisplatin chemotherapy. However, the efficacy of 
cisplatin as an antineoplastic agent means that it has remained the drug of choice in first-line 
chemotherapy regimens, despite the risk of ototoxicity as well as other severe ADRs which 
can impair patient quality-of-life. 
 
The incidence of ototoxicity observed in this cohort varied considerably depending on the 
audiometric definition of ototoxicity used. The TUNE grading system was the most 
conservative scale, with 74.8% of all patients displaying signs of hearing loss compared to 
39.2% according to the Chang ototoxicity scale. Both of these grading scales prioritise the 
progressivity of ototoxicity by limiting their higher grades to hearing loss occurring in the 
lower frequencies. However, the threshold shifts considered significant in the TUNE scale 
are a quarter that of in the Chang grading scale, which accounts for these very different 
results. The CTCAE, which are arguably the most prevalently used in studies of cisplatin-
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induced ototoxicity, yielded an ototoxicity rate of 57.7%, and the ASHA guidelines gave an 
incidence of 66.7%. Because the TUNE scale is relatively new, there is a paucity of literature 
regarding its usefulness and comparability; however, the incidence of ototoxicity in this study 
did not differ significantly from that reported by Theunissen et al (2014) (Chi-squared test, p 
= 0.136). The observed ototoxicity incidences were significantly higher compared to other 
study populations, graded using the Chang (Yang et al, 2013; Peleva et al, 2014) and 
CTCAE (De Jongh et al, 2003; Yang et al, 2013; Hagleitner et al, 2014) grading scales. 
Equally, however, there are study populations in which the prevalence of hearing loss did not 
differ significantly from those reported here (Knight et al, 2005; Lanvers-Kaminsky et al, 
2015); these inconsistencies are most likely due to inter-study differences regarding 
chemotherapy regimens, length of audiometric follow-up, and quality of audiological 
monitoring.  
 
Given the high incidence of ototoxicity, globally as well as amongst SA patients (Whitehorn 
et al, 2014a), the identification of individuals who are at an altered risk of hearing loss is 
preferable, so that quality-of-life issues can be considered in the selection of treatment 
strategies. While the role of various clinical and demographic factors has been discussed 
previously (Chapter 2), it is demonstrated here that predictive models are invariably 
improved by the inclusion of patient genotypic information. The SNP NFE2L2 rs6721961 
was identified as a possible predictor of ototoxicity in patients exposed to average or above-
average total doses of cisplatin, as it associated with ototoxicity regardless of definition 
before and after adjusting for patient ethnicity. The encoded protein product of NFE2L2, 
NRF2, is a transcription factor involved in the protection of cells against oxidative and other 
stresses (Venugopal and Jaiswal, 1998). Under normal cellular conditions, NRF2 is localised 
to the cytoplasm, where it is bound to and targeted for proteasomal degradation by kelch-like 
ECH-associated protein 1 (KEAP1) (Suzuki and Yamamoto, 2015). When ROS, 
electrophiles or xenobiotics accumulate in cells, the activity of KEAP1 is inhibited, allowing 
NRF2 to stabilise and translocate to the nucleus (Hybertson and Gao, 2014). There, NRF2 
binds to antioxidant response elements (AREs), activating the expression of numerous 
genes involved in cellular protection. AREs are located upstream of genes encoding, for 
example, haem oxygenase 1 (HO-1), various GST enzymes, peroxiredoxins, glutathione 
peroxidases, and ferroxidases, as well as drug metabolising enzymes and multidrug 
resistance transporters (Ishii et al, 2000; Thimmulappa et al, 2002; Vollrath et al, 2006; 
Malhotra et al, 2010). 
 
Since cisplatin acts in part through the induction of oxidative stress in cells (Clerici et al, 
1996), NRF2 may also be involved in the cellular response to cisplatin. Indeed, flunarizine, 
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an activator of the NRF2/HO-1 pathway, prevented cisplatin-induced apoptosis and reduced 
the production of pro-inflammatory cytokines in a human organ of Corti cell line (So et al, 
2008). Transfection of wild type NFE2L2 constructs into the cells had a similar effect, while 
inhibition of NFE2L2 expression by siRNA attenuated the protective effects of flunarizine (So 
et al, 2008). The protective role of NRF2 has also been demonstrated in mouse models of 
nephrotoxicity, where mice without a functional copy of Nrf2 showed greater signs of renal 
impairment following exposure to cisplatin compared to wild type mice, despite a similar 
accumulation of cisplatin-DNA adducts in the kidney cells of both experimental and control 
animals (Aleksunes et al, 2010). Further, various compounds which have been implicated as 
protectants against cisplatin-induced ototoxicity or nephrotoxicity have been found to exert 
their effects through the activation of NRF2-related pathways (Jin et al, 2015; Kim et al, 
2015a; Kim et al, 2015b; Ma et al, 2015; Sahu et al, 2015); conversely, inhibition of these 
pathways may sensitise cancerous cells to cisplatin treatment or reverse the development of 
cisplatin resistance (Shi et al, 2014a; Hou et al, 2015; Lee et al, 2015). 
 
The SNP rs6721961 occurs in the promoter of NFE2L2, 617 bp upstream of the transcription 
start site. The region contains a putative ARE-like transcription factor binding site, through 
which NRF2 may positively regulate its own expression in a positive feedback loop 
mechanism (Marzec et al, 2007). Promoter sequences which contain the rs6721961 A-allele 
were shown to bind NRF2 less efficiently than wild type promoters (Marzec et al, 2007), 
resulting in an approximately 40% reduction in NFE2L2 expression (Marczak et al, 2012; 
Suzuki et al, 2013). In the present investigation, this promoter region variant was associated 
with protection against ototoxicity. Given that a reduction in NFE2L2 expression increases 
cellular sensitivity to cisplatin, this association is in a direction which is opposite to that which 
might have been expected. Nevertheless, similar protective effects of the NFE2L2 
rs6721961 A-allele have been reported for various conditions which are influenced by 
oxidative stress, such as infection-induced asthma in children (Ungvári et al, 2012), 
bronchopulmonary dysplasia (Sampath et al, 2015), reduced responses to vasodilators 
(Marczak et al, 2012), and Parkinson’s disease (von Otter et al, 2010; Todorovic et al, 2015). 
Todorovic et al (2015) further demonstrated that olfactory cells which contained the 
alternative A-allele were significantly protected from pesticide-induced cell death, which may 
indicate that the SNP can play a protective role against toxic insults. Other conditions with 
which the SNP has been associated include breast and lung cancers (Hartikainen et al, 
2012; Suzuki et al, 2013), type 2 diabetes mellitus (Shimoyama et al, 2014; Wang et al, 
2015), defective spermatogenesis and poor semen quality (Yu et al, 2012; Yu et al, 2013), 
acute lung injury (Marzec et al, 2007), and acute respiratory distress syndrome (O’Mahony 
et al, 2012). 
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Another gene involved in the cellular antioxidant response is CDH13. Although its encoded 
protein, cadherin-13, primarily functions in the development and functioning of the nervous 
system, it is also involved in functions such as cell proliferation, migration, survival, and cell 
cycle progression (Rivero et al, 2013). CDH13 overexpression in endothelial cells increased 
their protection against oxidative stress-induced apoptosis, indicating its role as a promoter 
of cell survival (Joshi et al, 2005; Rivero et al, 2013). Immunohistochemistry experiments 
demonstrated cadherin-13 expression in multiple cell types in the murine cochlea, including 
the hair cells, spiral ganglion cells and stria vascularis (Girotto et al, 2014). In accordance 
with the authors’ hypothesis that the gene plays a role in hearing, variation in the gene was 
associated with sloping high frequency hearing loss in human subjects (Girotto et al, 2014). 
CDH13 genetic variation was also identified in association with cisplatin cytotoxicity using a 
genome-wide linkage approach (Shukla et al, 2008). The SNP CDH13 rs11646213, which is 
located upstream of the gene, has been linked to metabolic syndrome and obesity (Fava et 
al, 2011), hypertension (Org et al, 2009), and early-onset preeclampsia (Wan et al, 2013). 
While it did show a mild association with TUNE-grade ototoxicity in the present study, 
rs11646213 did not associate with any of the other ototoxicity scales used after adjustment 
for patient ethnicity. It is possible that the role of cadherin-13 in hearing may obscure its 
association with cisplatin-induced hearing loss; indeed, when examining only patients who 
had normal pre-treatment audiograms, CDH13 rs11646213 did associate weakly with Chang 
ototoxicity (data not shown). Notably, however, its association with TUNE ototoxicity was lost 
in the analysis. While its link to cisplatin-induced hearing impairment may be tenuous, the 
role of CDH13 in hearing and cellular protection may warrant further investigation of this 
gene for genetic markers of treatment response.  
 
In contrast, polymorphisms in EIF3A did not associate with ototoxicity in this study, despite a 
functional link between the gene and the cellular response to cisplatin. Primarily involved in 
the translation of mRNA into protein products, EIF3A has also been shown to regulate cell 
growth (Dong et al, 2004), cell cycle progression (Dong et al, 2009), differentiation (Liu et al, 
2007), and oncogenesis (Zhang et al, 2007). Levels of EIF3A expression may also affect 
individual responses to chemotherapy, as significantly greater survival rates were reported in 
cervical and oesophageal cancer patients with higher expression of the gene (Dellas et al, 
1998; Chen and Burger, 1999). Similarly, EIF3A levels were reportedly correlated with 
sensitivity to platinum-based and other chemotherapeutic drugs in the treatment of lung 
cancer (Yin et al, 2011). These results were only observed when investigating DNA-
damaging drugs such as cisplatin, and it was further demonstrated that EIF3A 
overexpression suppresses NER pathway activity by regulating the translation of various key 
NER proteins (Yin et al, 2011). In a pilot investigation in a Chinese lung cancer patient 
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cohort, the novel non-synonymous variant EIF3A rs77382849 was associated with an 
increased susceptibility to platinum-induced ototoxicity coupled with a reduced rate of 
nephrotoxicity (Xu et al, 2012b). Because of the SNP’s low frequency in non-Asian 
populations, it was not included in this study. The SNPs EIF3A rs3824830 and rs10787899, 
however, have been associated with an increased risk of breast cancer (Olson et al, 2010), 
and decreased survival in pancreatic cancer patients (Couch et al, 2010), and may therefore 
affect expression of the gene, although no studies have yet explored this hypothesis. Neither 
SNP associated with treatment response in the present investigation, and similar results 
were recently reported in Chinese ovarian and lung cancer patient populations (Yin et al, 
2015; Zhang et al, 2015). 
 
An alternative level at which functional genetic variants may be identified in association with 
cisplatin-induced ototoxicity is the transport of cisplatin into or out of cells. It was originally 
thought that cisplatin entered cells purely by passive diffusion, but there is now substantial 
evidence that the process of cisplatin uptake is actively facilitated by various transporter 
proteins (Waissbluth and Daniel, 2013). One such transporter is OCT2, which is encoded by 
the gene SLC22A2. Because OCTs are predominantly expressed in the kidney, initial 
interest concerned their role in nephrotoxicity. Homozygous deletion of SLC22A2 in mice 
reduced urinary excretion of cisplatin and conferred protection against cisplatin-induced 
kidney damage (Filipski et al, 2009). OCT2 is also expressed in the cochlea at a level 48.2 
times greater than CTR1, another known transporter of cisplatin (Ciarimboli et al, 2010). Co-
administration of cimetidine, an OCT2 substrate, with cisplatin, abolished ototoxicity and 
significantly reduced nephrotoxicity in mice (Ciarimboli et al, 2010). SLC22A2 rs316019 is a 
non-synonymous SNP which results in an altered substrate specificity and reduced transport 
activity (Kang et al, 2007; Song et al, 2008; Song et al, 2012). Patients with the T-allele had 
a reduced renal uptake of metformin (Song et al, 2008) and were shown to have significantly 
fewer signs of renal damage and nephrotoxicity following cisplatin treatment when compared 
to patients without the SNP (Filipski et al, 2009). More recently, the polymorphism was 
associated with protection against cisplatin-induced ototoxicity, graded with the CTCAE, in 
German paediatric and adult patients (Lanvers-Kaminsky et al, 2015). Although the 
association of variant with hearing loss was replicated here, this was limited to the Chang 
ototoxicity grading scale, and with a smaller effect size. Incidentally, none of the patients 
who developed significant renal dysfunction carried the SNP, further illustrating its potential 
as a protective SNP. This relationship did not reach statistical significance, presumably 
because of the small number of patients presenting with nephrotoxicity in this investigation 




Other transporter gene variants which have been associated as modifiers of cisplatin-
induced ototoxicity are ABCC3 rs1051640 and ABCB5 rs10950831, which were proposed to 
have an effect on the cellular efflux of cisplatin (Pussegoda, 2012). These polymorphisms 
were identified through a screen of all known ADME genes, and therefore may not have any 
direct links with the cellular response to cisplatin. Indeed, neither association was replicated 
in the present investigation, and although ABCB5 rs10950831 did associate with a 
decreased risk of TUNE ototoxicity, this association cannot be considered robust because 
one of the genotypes was estimated, and the significance could be abolished by changing 




Pharmacogenetic investigations have demonstrated the influence of patient genetic 
information in the response to numerous drugs, contributing not only to the understanding of 
the molecular basis of drug response, but also in developing models for patient risk profiling. 
It is likely that there are similar genetic modifiers which play a role in variable cisplatin 
responses. In the case of cisplatin-induced ototoxicity, the ability to identify patients who are 
at an altered risk of significant hearing loss is preferable, as this would allow the prediction of 
ototoxicity before treatment and circumvent the need to modify therapy in response to ADRs. 
It is this difference between predictive and responsive medicine that forms the basis of 
personalised therapy. The present investigation identified potential modifiers of cisplatin-
induced ototoxicity by exploring variation in genes known to play a role in cisplatin response. 
This approach yielded potential modifiers in NFE2L2 rs6721961, SLC22A2 rs316019, and 
CDH13 rs11646213. Of these, the variant in NFE2L2 demonstrated the greatest promise, as 
inclusion of this genotypic information improved predictive models of ototoxicity according to 
three commonly used ototoxicity grading scales. It is possible that this promoter region 
variant influences patient response by affecting the expression levels of NFE2L2, a gene 
important in the cellular response to oxidative stress, although this association should be 
replicated in an independent patient cohort. However, the functional effects of SLC22A2 and 
CDH13 may warrant further investigation into the role of rs316019 and rs11646213, or other 












Cisplatin is a potent anti-cancer drug which is used prevalently in chemotherapy regimens 
for various tumours, including those of the head and neck, lungs, testes, cervix and ovaries. 
Although high success rates can be achieved when incorporating cisplatin in treatment plans 
(Einhorn, 2002), this use can be limited by ADRs such as ototoxicity affecting the patient 
(McKeage, 1995). Ototoxicity is characterised by progressive, permanent and bilateral high-
frequency hearing loss, and can affect between 25% and 100% of patients. In the GSH 
patient population, an ototoxicity incidence of about 40% was reported using the Chang 
ototoxicity grading scale, although over 57% of patients developed hearing loss as defined 
by the CTCAE, which are more prevalently used in studies of ototoxicity (Chapter 3). Since 
other dose-limiting ADRs such as nephrotoxicity and nausea can be controlled (by pre-
hydration and anti-emetics, respectively), ototoxicity remains one of the most prevalent 
dose-limiting adverse reactions to cisplatin. In comparison to the high ototoxicity incidence, 
only five patients in the prospective cohort developed significant nephrotoxicity during 
treatment (Chapter 3). 
 
Due to quality-of-life considerations, research into predictive or preventative measures 
against ototoxicity is desirable. Numerous otoprotectant molecules have been explored to 
date, including antioxidants, apoptosis inhibitors, and channel blockers (Rybak et al, 2009); 
however, the promise of these agents is limited by issues concerning their delivery and 
neutralising effects on cisplatin (Wimmer et al, 2004). Predictive markers of ototoxicity, in 
contrast, would enable the identification of at-risk patients before treatment. Currently, the 
only risk factor which has been reported with any consistency is the cumulative dose of 
cisplatin, in which patients who are exposed to a higher total dose are more likely to develop 
significant hearing impairment (Bertolini et al, 2004; Li et al, 2004). In the SA population, 
patient ethnicity was a better predictor of ototoxicity, although clinical factors such as dose 
and treatment regimen also play a role (Chapter 2). The relative inability of other factors 
such as patient age, sex, and pre-existing hearing loss to predict ototoxicity has resulted in 
an increased interest in the pharmacogenomics of cisplatin-induced hearing impairment 
(Bokemeyer et al, 1998; De Jongh et al, 2003; Li et al, 2004; Chen et al, 2006; Yancey et al, 
2012; Choeyprasert et al, 2013; Kirkim et al, 2014). While numerous genetic risk factors 
have been suggested, including those in the genes encoding GSTs, methyltransferases and 
other drug metabolising and transporting genes, there is as yet little consensus as to the role 
these genetic variants may play in the development of ototoxicity. 
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Investigations into the pharmacogenomics of cisplatin-induced hearing loss have, to date, 
been largely candidate gene-based, in which genes are chosen based on prior knowledge of 
cisplatin and its mechanism of action. These candidate gene studies have yielded potential 
genetic modifiers in GSTP1, GSTT1, GSTM1 (Oldenburg et al, 2007), XPC (Caronia et al, 
2009), LRP2 (Riedemann et al, 2008; Choeyprasert et al, 2013) and, in the SA population, 
OTOS (Spracklen et al, 2015). Screening of 220 ADME-related genes in Canadian cancer 
patients has also identified potential modifiers in COMT, TPMT, DPYD, ABCC3 and ABCB5 
(Ross et al, 2009; Pussegoda, 2012; Pussegoda et al, 2013). However, many of these 
studies have yielded results which fail to replicate in subsequent studies, indicating 
population specificity or false positives. Regardless of the interpretation, this reduces the 
likelihood that these variants have any biological or functional relevance in the cellular 
response to cisplatin. 
 
The failings of candidate gene studies may be due to a lack of a clear understanding of the 
pathway whereby cisplatin induces its ototoxicity, leading to incorrect candidates being 
chosen, and false positives reported (Boddy, 2013). Work already conducted in the SA 
population has demonstrated that the candidate gene approach is a viable one, and variants 
in OTOS (Spracklen et al, 2014) and NFE2L2 (Chapter 3) have been identified as novel 
predictors of treatment response. However, candidate gene studies depend on knowledge of 
the pathways resulting in cisplatin-induced ototoxicity, which is limited. Therefore, the study 
of cisplatin-induced ototoxicity may be benefitted by hypothesis-free approaches such as 
GWAS and NGS projects. A pilot GWAS of 238 cisplatin-receiving paediatric patients 
revealed a new potential modifier of ototoxicity in the ACYP2 gene (Xu et al, 2015). Although 
the association was replicated in an additional 68 patients in the same investigation, the 
relatively small sample sizes restrict the clinical utility of this finding (Xu et al, 2015). 
Furthermore, GWAS is limited to the detection of variants which are already known. NGS 
approaches, in comparison, allow both common and novel variants to be analysed at the 
genome scale. The only NGS study into cisplatin response to date investigated whole-
exome sequencing (WES) data from 50 urothelial carcinoma patients’ tumour cells, which 
identified excision repair cross-complementation group 2 (ERCC2) somatic mutations as a 
potential marker of treatment response (Van Allen et al, 2014).   
 
WES is an NGS strategy which targets and sequences the coding regions of the genome 
only. This greatly reduces the amount of sequence data produced, while focussing on 
variants which are more likely to have a tangible functional effect. The aim of this pilot 
investigation is to utilise WES approaches to explore functional variants in a subset of the 
patient cohort. By investigating the exomes of patients who represent phenotype extremes 
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(i.e. increased sensitivity to cisplatin’s ototoxic effects, or heightened resistance to them), 
this may yield novel candidate genes for future studies, and provide an insight into potential 




4.2.1 Patients and samples 
 
Patients from the prospective cohort were eligible for WES if they displayed extreme 
susceptibility to cisplatin’s ototoxic effects, or extreme resistance to them. Extremely 
resistant patients were identified if they developed no hearing loss during treatment despite 
receiving multiple (≥ 3) cycles of chemotherapy, reaching a cumulative cisplatin dose which 
was above the average for the cohort (median cumulative dose: 200 mg/m2). Fifteen patients 
met these criteria. Conversely, extreme susceptibility was classified as the onset of clinically 
significant hearing impairment (Chang grade ≥ 2B) after a single cycle of chemotherapy, or 
the progression of hearing loss to clinical significance over two cycles of treatment; ten such 
patients were identified. The degree of hearing loss experienced by each patient was 
defined using ASHA classifications as mild (26 to 39 dB HL), moderate (40 to 54 dB HL), 
moderately severe (55 to 69 dB HL), severe (70 to 89 dB HL), or profound (≥ 90 dB HL) 
(Clark, 1981). Since all the patients were obtained from the prospective cohort, the 
contribution of previously genotyped markers (Whitehorn et al, 2014b; Spracklen et al, 2014) 
to variable cisplatin response was considered, when available. DNA samples from 11 
patients were prepared for exome sequencing by diluting them to solutions of 30 ng/µl in 1X 
TE buffer (Appendix H). Four DNA samples had a high 260/280 ratio, and a purification step 
was performed in order to decontaminate the DNA of proteins. This consisted of a repeat of 




Targeted sequencing of the exome was performed on each sample by the Central Analytical 
Facility (CAF) at Stellenbosch University, using the Ion TorrentTM platform. The Ion 
AmpliSeqTM Exome RDY-IC kit (Life TechnologiesTM) was used for exome capture, and 
sequencing libraries were constructed using the Ion ChefTM platform (Life TechnologiesTM). 
The sequences were read on an Ion ProtonTM sequencer (Life TechnologiesTM), producing 
BAM files which were aligned to the Homo sapiens reference genome sequence (UCSC 
version hg19) using the Ion Reporter software on the CAF servers, to generate sequence 
files in the variant call format (VCF). 
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4.2.3 Variant annotation 
 
The table_annotate.pl function of ANNOVAR (Wang et al, 2010) was used to annotate 
variants in the exomes with information regarding the type of variant, the affected gene, and, 
in the case of non-synonymous variants, the predicted pathogenicity. The annotation 
databases dbSNP version 138 (snp138), dbNFSP version 2.6 (ljb26_all), 1000 Genomes 
Project 2014 October version (1000g2014oct), NIH-NBBI 6500 exome database version 2 
(esp6500siv2_all), refGene, cytoBand, and genomicSuperDups were downloaded from the 
ANNOVAR website (http://annovar.openbioinformatics.org; accessed 20.02.2015). Each 
exome was annotated using chromosome build UCSC hg19 as a reference, which was 
downloaded as part of the Genome Analysis Toolkit (GATK) resource bundle 
(https://www.broadinstitute.org/gatk/; accessed 29.01.2015). Twelve pathogenicity predictors 
were included for the annotation of non-synonymous variants (Table 4.1). These were SIFT, 
PolyPhen 2 HumDiv, PolyPhen 2 HumVar, LRT, MutationTaster, MutationAssessor, 
FATHMM, RadialSVM, LR, GERP++, PhyloP, and SiPhy, all of which provide a 
pathogenicity score which was included in the ANNOVAR annotation. In addition, with the 
exception of GERP++, PhyloP and SiPhy, a pathogenicity prediction was provided for each, 
which converted the score into discreet groups to reflect their deleteriousness (Table 4.1). 
 
Table 4.1: LJB23 databases included in ANNOVAR table_annovar.pl annotation 
Pathogenicity prediction tool Score range Categorical prediction 




PolyPhen 2 HumDiv ≤ 0.452 
0.453 – 0.956 
≥ 0.957 
“Benign” (B) 
“Possibly damaging” (P) 
“Probably damaging” (D) 
PolyPhen 2 HumVar ≤ 0.446 
0.447 – 0.909 
≥ 0.909 
“Benign” (B) 
“Possibly damaging” (P) 
“Probably damaging” (D) 
LRT - “Neutral” (N) 
“Deleterious” (D) 
“Unknown” (U) 












RadialSVM - “Tolerated” (T) 
“Deleterious” (D) 
LR - “Tolerated” (T) 
“Deleterious” (D) 
GERP++, PhyloP, SiPhy - Higher scores are more deleterious 





4.2.4 Scoring and filtering of exonic variants 
 
The sequenced exomes were divided into two groups: group A contained the patients 
resistant to cisplatin-induced ototoxicity, and group B comprised the susceptible patients. To 
filter the results of exome sequencing, two pipeline approaches, which consisted of variant-
level and gene-level analyses, were applied to the sequence data. In both instances, the 
variants were initially assigned a score out of 8 based on the ANNOVAR annotation output. 
For non-synonymous single nucleotide variants (SNVs), this score was equal to the number 
of pathogenicity predictors, not including PolyPhen 2 HumVar, GERP++, PhyloP, or SiPhy, 
which classified the variant as deleterious, probably damaging or disease causing (Table 
4.1). Synonymous and non-frameshift insertions, deletions and substitutions were given a 
score of 0, while stop-gain, stop-loss and frameshift mutations were scored 8. All the 
variants with scores ≥ 4 were selected for the variant- and gene-level pipelines. Variants 
classified as unknown were excluded from any further analysis.  
 
4.2.4.1 Variant-level analysis 
 
In the identification of exonic variants enriched in one group of patients, all variants which 
were common to both patient groups were excluded. To further this enrichment, all the 
variants occurring in ≥ 3 patients in either group were investigated for functional links to 
cisplatin and its ototoxicity. These included the analysis of gene-disease relationships and 
gene prioritisation using online bioinformatics tools. 
 
4.2.4.1.1 Analysis of gene-disease relationships 
 
Each gene in which an enriched variant was identified was investigated for a potential 
functional link to cisplatin response by interrogating the diseases with which the gene has 
been associated. Searches were performed in the Online Mendelian Inheritance in Man® 
(OMIM®) (http://www.omim.org/; accessed 06.05.2015) and MalaCards (http:// 
www.malacards.org/; accessed 06.05.2015) databases. Genes were considered potentially 
significant if mutations in that gene have been linked to a disease in an organ or tissue which 








Table 4.2: Off-target organs which can be susceptible to cisplatin-induced ADRs 
Adverse drug event Affected organ or tissue 
Ototoxicity Inner ear (cochlea and/or vestibular apparatus) 
Nephrotoxicity Kidney 
Neurotoxicity (Peripheral) nervous system 
Nausea, emesis Gastrointestinal tract 
Electrolyte disturbance Kidney 
Myelosuppression Bone marrow 
Haemolytic anaemia Erythrocytes 
Adapted from McKeage, 1995  
 
 
4.2.4.1.2 Gene prioritisation 
 
The online gene prioritisation tool VarElect (LifeMap Sciences Inc., CA USA; 
http://varelect.genecards.org; accessed 14.06.2015) was used to assess the relationship 
between input genes and the phenotype of interest (in this instance, specified as “cisplatin 
AND ototoxicity”). VarElect incorporates the GeneCards® human gene database (http://www. 
genecards.org/), MalaCards human disease database (http://www.malacards.org/), and 
PathCards pathway unification database (http://pathcards.genecards.org/) to suggest genes 
which are directly or indirectly associated with the phenotype, providing a score which is 
used to rank the genes.   
 
4.2.4.2 Gene-level analysis 
 
Similar to the variant-level analysis, genes which were mutated in ≥ 3 patients in one group, 
and had no variation in the other patient group, were selected for gene-disease relationship 
analysis (4.2.4.1.1) and prioritisation (4.2.4.1.2). Additional analyses which were performed 
at the gene level were pathway and panel-based analyses.  
 
4.2.4.2.1 Pathway analysis 
 
All of the genes which were mutated in only one of the patient groups were analysed for the 
pathways in which they act using ConsensusPathDB (CPDB) (http://consensuspathdb.org/; 
accessed 27.06.2015). Initially, an over-representation gene set analysis was performed on 
each set of genes (i.e. the genes enriched in each group), to identify the pathways in which 
those genes have been implicated. Then, the gene sets for each of the enriched pathways 
were downloaded from CPDB, and searched against the total dataset to identify pathways 





4.2.4.2.2 Panel analysis 
 
Genes which were mutated more than once, and uniquely, in either patient group were 
interrogated against four separate gene panels (Appendix J). The panels included were a 
deafness gene panel of 87 genes (http://personalizedmedicine.partners.org/Laboratory-For-
Molecular-Medicine/Tests/Hearing-Loss/OtoGenome.aspx; accessed 31.03.2015), an ADME 
gene panel of 267 genes (http://pharmaadme.org/joomla/index.php?option=com_content 
&task=view&id=12&Itemid=27; accessed 23.02.2015), a DNA repair gene panel of 177 
genes (http://sciencepark.mdanderson.org/labs/wood/dna_repair_genes.html; accessed 
14.04.2015), and a custom cisplatin response gene panel, which was generated based on 
genes frequently associated with cisplatin toxicity or resistance (41 genes). 
 
4.2.5 Statistical analysis of patient demographic and genomic data 
 
Basic statistical tests were performed using the IBM® SPSS® Statistics programme, version 
22.0.0.0 (IBM® Corp.). These included descriptive analyses of numerical data between the 
patient groups, in which the normality of the distribution was first analysed by Shapiro-Wilk 
test. For normally distributed data, the t-test was employed, and for non-normal datasets, the 
Mann-Whitney U test was employed. Because of the small sample sizes, Fisher’s exact tests 
were utilised when examining differences in categorical variables between the two groups.  
 
Population structures in the extreme phenotype cohort were compared to the patients’ self-
reported ethnicities using principal component analysis (PCA). Bi-allelic PCA was performed 
in R version 3.0 (https://www.r-project.org/; accessed 28.04.2015) using the SNPRelate 
package version 0.9.19 (http://www.bioconductor.org/packages/release/bioc/html/SNPRelate 
.html; accessed 18.05.2015). Population controls were all individuals from the 1000 
Genomes Project: genomic information of each individual included in the 1000 Genomes 
Project was downloaded per chromosome (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/ 
release/2013 0502.html; accessed 29.04.2015) and exomic regions extracted. The 
experimental WES VCF files were merged with the 1000 Genomes Project exomes using 
GATK’s CombineVariants function. The gdsfmt package (http://www.bioconductor.org/ 
packages/release/bioc/html/gdsfmt/; accessed 18.05.2015) was used to convert the WES 









4.3.1 Extreme-phenotype cohort 
 
Out of the 25 eligible patients, 11 were chosen for WES: 6 patients developed severe 
hearing loss over a short time period (Group B), while 5 demonstrated increased resistance 
to cisplatin’s ototoxic effects (Group A) (Table 4.3). These groups differed significantly in 
terms of the cumulative cisplatin dose (Mann-Whitney U test, p = 0.004) and the number of 
cycles to the end of audiological monitoring (Mann-Whitney U test, p = 0.004). The median 
cumulative dose and number of cycles in Group B was 150.38 mg/m2 and 1.5 cycles 
respectively, compared to 338.24 mg/m2 and 4.0 cycles in Group A. There were no 
significant differences in age (independent samples t-test, p = 0.987) or sex (Fisher’s exact 
test, p = 0.567) distributions between the two groups. Group A was comprised of patients of 
mixed ancestry only, while group B was predominantly (66.7%) black African; this difference 
approached significance at α = 0.05 (Fisher’s exact test, p = 0.061). 
 
Table 4.3: Characteristics of patients selected for whole-exome sequencing 
Patient 
no. 








1 MA M 67 Head/Neck 338.24 3 0 
2 MA F 52 Head/Neck 297.22 4 0 
3 MA F 15 Head/Neck 431.65 6 0 
4 MA F 48 Head/Neck 304.35 3 0 
5 MA M 14 Osteosarcoma 431.21 4 0 
6 BA M 25 Lymphoma 100.00 1 3 
7 BA M 26 Osteosarcoma 202.15 2 3 
8 BA M 47 Head/Neck 200.00 2 3 
9 MA M 44 Lymphoma 100.00 1 2B 
10 MA F 43 Head/Neck 100.75 1 3 
11 BA F 49 Lymphoma 201.12 2 3 
a endpoint taken as the end of audiological monitoring 
BA, Black African; F, female; M, male; MA, mixed ancestry; no., number 
 
 
Each patient in Group A received ≥ 3 cycles of cisplatin therapy but maintained unchanged 
hearing throughout (Figure 4.1). For patients 3 and 4, hearing seemed to improve slightly 
during treatment (Figure 4.1 C and D), while for others, hearing sensitivities remained similar 
to the pre-treatment levels. In contrast, the patients in Group B developed significant hearing 
loss after a single cycle of treatment (Figure 4.2), but three patients received a second cycle 
of treatment, during which their hearing deteriorated further. Using the ASHA classifications, 
hearing sensitivities were indicative of moderately severe to severe deafness in all the 
patients, although patient 11 developed profound deafness in the left ear despite having a 









Figure 4.1: Patient audiograms showing hearing levels in each Group A ear before treatment (solid 
black line) compared to hearing at the last audiogram (dashed black line). For patient 1 (A), patient 4 
(D), and patient 5 (E), this was 4 cycles of cisplatin, while for patient 2 (B) and patient 3 (C), this was 
5 and 6 cycles, respectively. Audiograms on the left depict hearing levels in the left ear, while those 
from the right ear are opposite. In each audiogram, the x-axis (top of the graph), designates the test 
frequency (Hz) and the y-axis indicates the hearing sensitivity at each test frequency. ASHA hearing 












Figure 4.1 (cont.): Patient audiograms showing hearing levels in each Group A ear before treatment 
(solid black line) compared to hearing at the last audiogram (dashed black line). For patient 1 (A), 
patient 4 (D), and patient 5 (E), this was 4 cycles of cisplatin, while for patient 2 (B) and patient 3 (C), 
this was 5 and 6 cycles, respectively. Audiograms on the left depict hearing levels in the left ear, while 
those from the right ear are opposite. In each audiogram, the x-axis (top of the graph), designates the 
test frequency (Hz) and the y-axis indicates the hearing sensitivity at each test frequency. ASHA 




For each Group B patient, the hearing impairment showed the expected pattern of 
ototoxicity, in which higher frequencies were affected more than lower frequencies. 
However, the implication of frequencies < 6.0 kHz in all Group B patients indicates 
progression and severity of hearing impairment experienced by these patients. With the 
exception of patient 8, who displayed audiometric signatures typical of sloping high-
frequency (age-related) hearing loss (Figure 4.2C), all of the Group B patients had normal 
pre-treatment audiograms (Figure 4.2). In all cases, the development of hearing impairment 










Figure 4.2: Patient audiograms showing hearing levels in each Group B ear before treatment (solid 
black line) compared to hearing at the last audiogram (dashed black line). For patient 9 (D) and 
patient 10 (E), this was one cycle of cisplatin, while for patient 6 (A), patient 7 (B), patient 8 (C) and 
patient 11 (F), this was two cycles. Audiograms on the left depict hearing levels in the left ear, while 
those from the right ear are opposite. In each audiogram, the x-axis (top of the graph), designates the 
test frequency (Hz) and the y-axis indicates the hearing sensitivity at each test frequency. ASHA 
hearing loss severity classifications are included in the grey boxes for comparison. 
 
 










Figure 4.2 (cont.): Patient audiograms showing hearing levels in each Group B ear before treatment 
(solid black line) compared to hearing at the last audiogram (dashed black line). For patient 9 (D) and 
patient 10 (E), this was one cycle of cisplatin, while for patient 6 (A), patient 7 (B), patient 8 (C) and 
patient 11 (F), this was two cycles. Audiograms on the left depict hearing levels in the left ear, while 
those from the right ear are opposite. In each audiogram, the x-axis (top of the graph), designates the 
test frequency (Hz) and the y-axis indicates the hearing sensitivity at each test frequency. ASHA 





The results of previous genetic investigations were explored for all of the patients in the 
extreme phenotype cohort, to see if their extreme response could be explained in part by 
these reported genetic modifiers (Table 4.4). Three patients in the extreme phenotype cohort 
carried the NFE2L2 rs6721961 A-allele, two of whom were in Group B. Only one patient 
carried the SLC22A2 rs316019 T-allele, and this patient was also in Group B. Both of the 
OTOS variant alleles for rs2291767 and rs77124181 only occurred in Group A patients; 
however, some of these genotypes were missing.  
 
Table 4.4: Genotypes of previously associated genetic variants in the extreme phenotype cohort 
Gene variant Group A Group B 1 2 3 4 5 6 7 8 9 10 11 
ABCB5 rs10950831 T/G T/T T/G T/G T/G T/T T/G T/T T/T T/G T/G 
ABCC3 rs1051640 A/A A/G A/A A/A A/A A/A A/A A/A A/A G/G A/G 
CDH13 rs11646213 A/A A/A A/A A/A A/T A/A A/A T/T A/T A/T A/A 
COMT rs4646316 C/C C/C C/C C/C C/C C/T C/C C/T C/C C/C - 
COMT rs4818 C/C C/C C/C G/G C/C C/C C/G C/G G/G C/C - 
COMT rs9332377 C/C C/C C/T C/C C/C C/C C/T T/T T/T C/C - 
EIF3A rs10787899 T/T C/T C/C C/C C/T T/T C/C C/T T/T C/T C/C 
EIF3A rs3824830 T/T C/T C/T T/T T/T T/T C/C C/T T/T C/T T/T 
GSTP1 rs1695 A/G A/G A/G A/G A/G A/G A/A A/G A/A A/G - 
LRP2 rs2075252 A/G A/G G/G G/G A/G G/G G/G A/G G/G G/G - 
LRP2 rs2228171 G/G G/A G/A G/G G/A G/G G/G G/A G/G G/A - 
NFE2L2 rs6721961 C/C C/C C/C C/C C/A C/C C/C C/A C/C C/A C/C 
OTOS rs2291767 A/A A/A A/G - - A/A A/A A/A A/A A/A - 
OTOS rs77124181 C/G C/C C/G - - C/C C/C C/C C/C C/C - 
SLC22A2 rs316019 G/G G/G G/G G/G G/G G/G G/G G/G G/T G/G G/G 
TPMT rs1142345 A/A A/A A/A A/A A/A A/A A/A A/A A/A A/A - 
TPMT rs1800460 G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G - 
TPMT rs12201199 T/A T/A T/T T/A T/T T/A T/T T/A T/T T/T - 
XPC rs2228001 C/A C/A C/C C/A C/A C/A C/A A/A A/A C/A - 
ABCB5, ATP-binding cassette, sub-family B, member 5; ABCC3, ATP-binding cassette, sub-family C, member 3; 
CDH13, cadherin 13; COMT, catechol O-methyltransferase; EIF3A, eukaryotic translation initiation factor 3, 
subunit A; GSTP1, glutathione S-transferase; LRP2, low density lipoprotein receptor-related protein 2; NFE2L2, 
nuclear factor, erythroid 2-like 2; OTOS, otospiralin; SLC22A2, solute carrier family 22, member 2; TPMT, 





Exomic regions of DNA were successfully captured and sequenced in all 11 patients, with a 
median coverage of 113X (Table 4.5). Target coverage was higher in Group A compared to 
Group B (median coverage 135X and 99X, respectively; Mann-Whitney U test p < 0.001). 
Similarly, the median Phred-based quality scores in Group A were significantly greater than 
in Group B (358.46 and 296.77 respectively; Mann-Whitney U test p < 0.001). The mean 
mutation rate was 4.3 mutations/Mb in both patient groups; the distribution of mean mutation 






Table 4.5: Depth of coverage and quality scores obtained from WES 
Patient 
no. 








1 227.00 4.00 2740.00 604.62 13.00 3904.15 A 
2 113.00 6.00 2284.00 317.98 10.00 3853.70 A 
3 156.00 6.00 1730.00 431.60 15.04 3886.63 A 
4 98.00 5.00 1603.00 280.08 10.00 3898.10 A 
5 119.00 5.00 1541.00 348.40 10.00 3861.25 A 
6 121.00 6.00 1271.00 344.54 10.00 3911.17 B 
7 100.00 5.00 1226.00 300.25 12.00 3853.65 B 
8 73.00 6.00 838.00 219.49 15.00 3832.87 B 
9 72.00 5.00 973.00 219.20 15.04 3853.15 B 
10 118.00 5.00 2524.00 357.24 13.00 3873.98 B 
11 135.00 6.00 1547.00 377.81 10.00 3853.83 B 
Overall 113.00 - - 334.82 - - - 
DP, read depth; no., number; max, maximum; min, minimum 
 
 
The sequencing files were annotated using the table_annovar.pl function of ANNOVAR. 
According to the annotation output, a total of 257,831 variants were identified in the patient 
exomes, the majority (96.09%) of which were synonymous or non-synonymous SNVs 
(Figure 4.3A). The remaining 3.91% of the variants consisted of frameshift and non-
frameshift insertions, deletions, and substitutions, stop-gain and stop-loss mutations, or 
variants with unknown consequences. The ratio of the different mutation types appeared 






Figure 4.3: Proportion of the different variant consequences in the patient exomes, according to the 
ANNOVAR annotation output, overall (A), and by patient (B). Patients 1-5 experienced no hearing 
loss during treatment (Group A), while patients 6-11 developed severe ototoxicity (Group B). 
Frameshift and non-frameshift mutations include insertions, deletions and substitutions. 
A      B 
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Variants were classified as novel, or previously unreported, if they were not assigned a 
dbSNP identifier in the ANNOVAR output. Of the 257,831 coding region variants, 5.05% 
were considered novel by this definition. A higher proportion of novel mutations was 
observed in those variants which resulted in a loss of protein function, including insertions, 
deletions, substitutions and stop-gain or stop-loss mutations (Figure 4.5A). This was 
particularly true of the frameshift mutations, 82.0% of which were not included in the dbSNP 
database. The difference in distribution of novelty was statistically significant (Chi-squared 
test, p < 0.001).  
 
 
Figure 4.5: Proportion of novel mutations (A) and shared variants (B) for each consequence type in 






When considering the commonality of the variants, the loss of function variants were less 
likely to be shared between the patient groups, as a higher proportion of frameshift 
insertions, deletions and substitutions, and stop-gain or stop-loss mutations was unique to 
either patient group (Figure 4.5B). Only 44.5% of all frameshift variants, and 65.6% of stop-
gain or stop-loss variants were shared between Groups A and B, compared to 88.1% of non-
synonymous and 82.1% of synonymous SNVs. This may be because the higher proportion 
of novel variants was observed in these mutation types, and these may have been limited to 
a single patient, in which case they would have been identified as not shared in the analysis. 
 
  
A       B 
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4.3.2.1 Principal component analysis (PCA) 
 
The population structure of the extreme phenotype cohort was examined by PCA, in which 
genomic data from the 1000 Genomes Project was compared to the 11 patient exomes. A 
total of 86,672 exonic SNPs were extracted from the 1000 Genomes data, for all individuals, 
and merged with the experimental cohort, giving 2,515 samples for PCA. In the analysis, 
1,757 non-autosomal SNPs were excluded, as were 777 monomorphic or missing SNPs, 































Figure 4.6: Principal component analysis of the extreme phenotype cohort population structure in 
comparison to 1000 Genomes reference samples. Plotted are the first two principal components from 
the SNPRelate output, using 79,138 bi-allelic, autosomal SNPs from 2,515 individuals. Each circle 
represents an individual in the analysis: black circles indicate individuals from the 1000 Genomes 
African (AFR) populations, red circles indicate those from the 1000 Genomes admixed American 
(AMR) population, green circles indicate those from the 1000 Genomes East Asian (ASN) population, 
cyan circles indicate those from the 1000 Genomes European (EUR) populations, and yellow circles 
indicate those from the 1000 Genomes South Asian (SAN) populations. Dark blue and pink circles 
represent patients from the extreme phenotype patient cohort, indicating individuals of black African 
(BA) and mixed (MA) self-reported ancestries, respectively. 
 
 
The first two principal components distinguished three of the black African patients from the 
other populations; these clustered nearer to the 1000 Genomes African (AFR) population 














(Figure 4.6). The other self-reported black African in the extreme phenotype cohort was 
located nearer to the 1000 Genomes European (EUR) and admixed American (AMR) 
populations, and one of the mixed ancestry patients from the experimental cohort. The other 
mixed ancestry patients also demonstrated more complex ethnicity: three patients clustered 
relatively closely to the AFR population, while the remaining three were located between this 
population and the AMR group (Figure 4.6). When considering the second and third principal 
components, a similar distribution of individuals was observed (Figure 4.7). However, the 
mixed ancestry patients were more clustered between the AFR and 1000 Genomes South 
Asian (SAN) populations. In fact, one of the mixed ancestry patients clustered with the SAN 




















Figure 4.7: Principal component analysis of the extreme phenotype cohort population structure in 
comparison to 1000 Genomes reference samples. Plotted are the second and third principal 
components from the SNPRelate output, using 79,138 bi-allelic, autosomal SNPs from 2,515 
individuals. Each circle represents an individual in the analysis: black circles indicate individuals from 
the 1000 Genomes African (AFR) populations, red circles indicate those from the 1000 Genomes 
admixed American (AMR) population, green circles indicate those from the 1000 Genomes East 
Asian (ASN) population, cyan circles indicate those from the 1000 Genomes European (EUR) 
populations, and yellow circles indicate those from the 1000 Genomes South Asian (SAN) 
populations. Dark blue and pink circles represent patients from the extreme phenotype patient cohort, 
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4.3.2.2 Filtering of variants 
 
All the exonic variants were scored according to their functional annotation. Out of the 
257,831 variants, 7,632 had a score of at least 4 and were included in the filtering pipelines 
(Figure 4.8). In the variant-level analysis, 4,429 variants were identified as unique to either 
patient group (2,030 in Group A and 2,399 in Group B), 44 of which occurred in at least three 
patients (Table 4.6). According to the gene-level analysis, 2,589 genes were mutated 
uniquely in either group of patients (1,198 in Group A and 1,391 in Group B); 47 of these 








































Figure 4.8: Summary of the filtering pipelines applied to the WES data. Variants were scored 
according to their consequence type: synonymous, non-frameshift and unknown variants were scored 
0, frameshift, stop-gain and stop-loss variants were scored 8, and non-synonymous SNVs received a 




Table 4.6: Genetic variants enriched in Group A or B 
Gene Hg19 coordinates Ref  Var  Consequencea Score dbSNP ID DPb Q scoreb Patients Group MAF MAF (Afr) 
APC2 19:1457105 C A Stop-gain 8 - 203.67 40.85 6,8,11 B - - 
BORA 13:73317740 G GGTGA Frameshift insertion 8 rs10648315 47.67 215.97 6,8,11 B - - 
C3 19:6712379 T TGG Frameshift insertion 8 - 12 59.51 6,10,11 B - - 
CHAF1A 19:4422644 G GA Frameshift insertion 8 - 11.67 29.45 9,10,11 B - - 
CREB3L2 7:137593054 C CG Frameshift insertion 8 - 29.67 60.70 9,10,11 B - - 
CYFIP1 15:22993154 T TC Frameshift insertion 8 - 14 87.42 9,10,11 B - - 
DMGDH 5:78351635 GA G Frameshift deletion 8 - 37.33 133.46 6,8,11 B - - 
DNAH14 1:225239490 T TTA Frameshift insertion 8 - 13 111.77 1,2,3 A - - 
DYX1C1 15:55722882 C A Stop-gain 8 rs57809907 190 343.66 2,3,4 A 0.16 0.49 
EIF5B 2:99980798 T TA Frameshift insertion 8 - 35.67 257.28 6,10,11 B - - 
FCRL6 1:159785370 T C Stop-loss 8 rs4301626 145.67 693.21 6,9,10 B 0.18 0.40 
FREM2 13:39430313 A AT Frameshift insertion 8 - 14 81.52 6,8,11 B - - 
GP6 19:55526103 G GCAGA Frameshift insertion 8 rs138680589 137.67 196.59 6,8,10 B 0.06 0.08 
ING1 13:111368163 CT C Frameshift deletion 8 - 76.33 743.42 8,9,11 B - - 
KIAA1429 8:95547097 G A,GA Stop-gain/insertion 8 - 16.67 31.58 1,4,5 A - - 
LRRC10B 11:61277300 CCG C Frameshift deletion 8 - 83.33 349.47 8,10,11 B - - 
MUC5B 11:1269867 G GC Frameshift insertion 8 - 30.67 140.50 7,9,10 B - - 
MXD4 4:2252968 C CG Frameshift insertion 8 - 59.67 497.29 6,8,11 B - - 
NID2 14:52481916 C CT Frameshift insertion 8 - 24.33 818.33 2,3,4 A - - 
OR52H1 11:5566550 GA G Frameshift deletion 8 rs374926660 341 674.58 1,3,5 A 0.01 0.02 
PDE4DIP 1:144873957 CT C Frameshift deletion 8 rs11341221 251 359.70 6,8,11 B - - 
PER1 17:8045707 GCC GC Frameshift deletion 8 - 33.67 220.58 8,9,10 B - - 
RELA 11:65423198 C CG,CGG Frameshift insertion 8 - 16.33 114.30 3,4,5 A - - 
REXO1 19:1827083 G GGC Frameshift insertion 8 - 12 31.80 1,4,5 A - - 
SF3A2 19:2248449 T TC Frameshift insertion 8 - 15.67 110.28 6,8,10 B - - 
SLC6A18 5:1225702 GA G Frameshift deletion 8 - 361.67 2890.97 1,4,5 A - - 
SPTA1 1:158655035 CG C Frameshift deletion 8 - 145.67 1391.27 7,8,11 B - - 
ZFYVE19 15:41099899 T TGGGGC Frameshift insertion 8 rs142730574 25.67 42.29 7,8,11 B 0.34 0.39 
ZNF80 3:113955187 A C Stop-gain 8 rs3732781 157.20 404.91 6,7,9-11 B 0.19 0.03 
BCKDHA 19:41929001 G A Non-synonymous 7 rs375957868 151 377.58 2,3,4 A - - 
EP300 22:41574697 T C Non-synonymous 6 rs200876858 9.67 63.00 6,7,11 B < 0.01 < 0.01 
AQP7 9:33385689 C G Non-synonymous 5 - 226 100.27 1,2,3 A - - 
CUBN 10:17171176 C T Non-synonymous 5 rs12259370 28.33 55.11 6,8,11 B 0.03 0.11 
FOXO3 6:108882487 A T Non-synonymous 5 - 384 1559.17 8,9,11 B - - 
KRT4 12:53207619 C A Non-synonymous 5 - 32.67 105.40 2,3,4 A - - 
SDHC 1:161332153 A C Non-synonymous 5 - 9.33 82.70 1,2,3 A - - 
a consequence types in bold are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 
Afr, 1000 Genomes Project African population; DP, read depth; ID, identifier; MAF, minor allele frequency; Q score, quality score; Ref, reference allele; Var, variant allele 
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Table 4.6: Genetic variants enriched in Group A or B 
Gene Hg19 coordinates Ref  Var  Consequencea Score dbSNP ID DPb Q scoreb Patients Group MAF MAF (Afr) 
COL9A1 6:70944257 T C Non-synonymous 4 rs6910140 149.33 293.18 1,4,5 A 0.07 0.11 
CTBP2 10:126715436 C T Non-synonymous 4 rs3781411 39.75 116.38 6-8,11 B 0.12 0.11 
DGKQ 4:954951 A C Non-synonymous 4 - 9 86.63 6,8,10 B - - 
DYSF 2:71788979 G A Non-synonymous 4 - 195.67 246.79 3,4,5 A - - 
DYTN 2:207559599 T C Non-synonymous 4 rs16838593 122 251.16 9,10,11 B 0.07 0.28 
FOXH1 8:145700346 T A Non-synonymous 4 rs112028242 74 180.88 6,8,9 B 0.02 0.10 
OR4B1 11:48239071 C A Non-synonymous 4 rs12292056 328.67 446.02 1,3,4 A 0.1 0.22 
TJP1 15:30008977 T G Non-synonymous 4 rs2291166 144.67 249.53 3,4,5 A 0.04 0.01 
a consequence types in bold are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 




4.3.2.2.1 Variant-based filtering 
 
Of the 44 variants identified as enriched in Group A or B (Table 4.6), 30 had known gene-
disease relationships according to OMIM® or MalaCards (Appendix K), and 29 were 
identified as indirectly related to the phenotype according to VarElect (Table 4.7). Five of the 
variants occurred in genes associated with diseases which affect cisplatin-sensitive organs 
(Table 4.8). In Group A, these included a novel non-synonymous variant in AQP7, and 
DYX1C1 rs57809907. The Group B variants were novel frameshift insertions in FREM2 and 
C3, and the non-synonymous SNP CUBN rs12259370. Of these, AQP7, C3 and CUBN were 
indicated as indirectly associated with the phenotype, through their associations with genes 
involved in cisplatin response and/or ototoxicity (Table 4.7).  
 
Comparative genomic analysis of the novel non-synonymous SNVs indicated that the AQP7 
variant occurs at a highly conserved region of the genome, as did the SNV in FOXO3 
(Figure 4.9). Similar results were observed for the other variants (data not shown). 
 
Table 4.7: VarElect prioritisation of genes containing the enriched variants  
Gene Implicating gene(s) Score 
RELA MAPK8, CASP3, LRP2, GSTP1, CAT 26.21 
EP300 MAPK8, CASP3, TPMT, COMT, LRP2 25.97 
FOXO3 MAPK8, CASP3, CAT, GSTP1, LRP2 25.86 
CREB3L2 MAPK8, CASP3, COMT, LRP2, GSTP1 25.64 
APC2 MAPK8, CASP3, LRP2, GSTP1, ABCB1 25.59 
TJP1 MAPK8, CASP3, LRP2, NTF3, BDNF 25.58 
CTBP2 MAPK8, CASP3, GSTP1, CAT, NTF3 25.57 
C3 MAPK8, CASP3, LRP2, NTRK2, BDNF 25.54 
SDHC MAPK8, CASP3, TPMT, COMT, LRP2 25.52 
PER1 MAPK8, CASP3, COMT, GSTP1, GSTM3 25.51 
COL9A1 MAPK8, CASP3, LRP2, NTF3, NTRK2 25.50 
DGKQ MAPK8, CASP3, TPMT, COMT, LRP2 25.49 
FOXH1 MAPK8, CASP3, LRP2, NTF3, NTRK2 25.48 
CUBN LRP2, TPMT, COMT, GSTP1, CAT 25.43 
CYFIP1 MAPK8, CASP3, NTF3, BDNF, NTRK2 25.39 
AQP7 MAPK8, CASP3, ABCB1, NTF3, BDNF 25.32 
BCKDHA TPMT, COMT, LRP2, GSTP1, CAT 25.19 
DMGDH TPMT, COMT, LRP2, GSTP1, CAT 25.18 
OR52H1 MAPK8, CASP3, LRP2, NTRK2 24.58 
OR4B1 MAPK8, CASP3, LRP2, NTRK2 24.58 
MUC5B MAPK8, TGFA, EIF2AK3 21.66 
NID2 CASP3, LRP2 19.67 
SLC6A18 ABCB1, SLC12A1 18.28 
KRT4 MAPK8 13.29 
GP6 MAPK8 13.27 
SPTA1 MAPK8 13.27 
BORA GSTP1 12.84 
REXO1 MT-RNR1 11.84 
EIF5B EIF2AK3 11.30 
Unrelated genes: DNAH14, DYSF, DYX1C1, KIAA1429, CHAF1A, DYTN, FCRL6, FREM2, ING1, LRRC10B, 






Table 4.8: Select gene-disease relationships of genes enriched in the variant-level pipeline 
Gene OMIM® disorder(s) MalaCards disease(s) 





C3 C3 deficiency 
Haemolytic uremic syndrome, atypical, 
susceptibility to, 5 
Macular degeneration, age-related, 9 
Age related macular degeneration 
Arteriolosclerosis 
Atypical haemolytic-uraemic syndrome 
C3 deficiency     
Capillary leak syndrome     
Dense deposit disease 
Haemolytic uraemic syndrome, atypical 5    
Retinal drusen        
CUBN Megaloblastic anaemia-1, Finnish type 
Megaloblastic anaemia-1, Norwegian type 
Dent's disease     
Megaloblastic anaemia     
Megaloblastic anaemia-1, Finnish type     
Megaloblastic anaemia-1, Norwegian type 
Nephropathic cystinosis 
DYX1C1 Ciliary dyskinesia, primary, 25 
Dyslexia, susceptibility to, 1 
Articulation disorder 
Ciliary dyskinesia, primary, 11 
Ciliary dyskinesia, primary, 25 
Dyslexia 1 
FREM2 Fraser syndrome Fraser syndrome 
Unilateral renal agenesis 
OMIM®, Online Mendelian Inheritance in Man® 
 
 







Figure 4.9: Comparative alignment of mammalian genomic regions to the human hg19 genome 
construct at positions AQP7 9:33385679-33385699 (A) and FOXO3 6:108882477-108882497 (B), 
using the Ensembl genome browser (http://ensembl.org; accessed 16.09.2015). Red bases indicate 
the nucleotides which are variant in the WES data. Mammalian genomes not included did not align at 
the specified positions. 
 
 
4.3.2.2.2 Gene-based filtering 
 
In the gene-level pipeline, 47 genes were identified as mutated in ≥ 3 patients in only one of 
the groups (Tables 4.9 and 4.10). Of these, 24 genes were already identified in the variant-
level investigation (Table 4.6), so the analyses were limited to the remaining 23 genes. Only 
one additional gene, WFS1, was identified through the gene-disease relationship analysis 
(Appendix K), which was associated with Wolfram syndrome, and 11 genes were indirectly 
associated with the phenotype (Table 4.11). 
Human     GGTGAAGATGCGGGGGGGCAG 
Orangutan GGTGAAGATGCGGGGGGGCAG 
Macaque   GGTGAAGACGCGAGGGGGCAG 
Marmoset  GGTGAAGATACGGGGGGGCAG 
Cow       GGTGAAGAAGCGGGGAGGCAG 
Sheep     GGTGAAGAAGCGGGGAGGCAG 
Dog       AGTGAAGAAGCGGGGAGGCAG 
Cat       AGTGAAGAAGCGGGGAGGCAG 
Horse     GGTGAAGAAGCGCGGAGGCAG 
Human       CGAGCCCCAGAGCCGTCCGCG 
Chimpanzee  CGAGCCCCAGAGCCGTCCGCG 
Gorilla     CGAGCCCCAGAGCCGTCCGCG 
Orangutan   CGAGCCCCAGAGCCGTCCGCG 
Macaque     CGAGCCCCAGAGCCGTCCGCG 
Marmoset    CGAGCCCCAGAGCCGGCCGCG 
Mouse       CGAGCCACAGAGTCGGCCACG 
Rabbit      CGAGCCCCAGAGCCGACCGCG 
Cow         CGAGCCCCAGAGCCGGCCGCG 
Pig         CGAGCCCCAGAGCCGTCCGCG 
Dog         CGAGCCCCAGAGCCGGCCGCG 
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Table 4.9: Genes uniquely mutated in at least three Group A patients 



































































DYX1C1 15:55722882 C A Stop-gain 8 rs57809907 190 343.66 2,3,4 0.16 0.49 




































































































BCKDHA 19:41929001 G A Non-synonymous 7 rs375957868 151 377.58 2,3,4 - - 
AQP7 9:33385689 C G Non-synonymous 5 - 226 100.27 1,2,3 - - 

























































































a consequence types in bold are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 













Table 4.10: Genes uniquely mutated in at least three Group B patients 
Gene Hg19 coordinates Ref Var Consequencea Score dbSNP ID DPb Q scoreb Patient(s) MAF MAF (Afr) 
BORA 13:73317740 G GGTGA Frameshift insertion 8 rs10648315 47.67 215.97 6,8,11 - - 





































































































































































































































































































































a consequence types in bold are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 
Afr, 1000 Genomes Project African population; DP, read depth; ID, identifier; MAF, minor allele frequency; Q score, quality score; Ref, reference allele; Var, variant allele 
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Table 4.10 (cont.): Genes uniquely mutated in at least three Group B patients 
























































































































































































































































































a consequence types in bold are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 




Table 4.11: VarElect prioritisation of the enriched genes not identified in variant-level pipeline 
Gene Implicating gene(s) Score 
ERBB2 MAPK8, CASP3, COMT, GSTP1, LRP2 26.27 
CACNA1F MAPK8, CASP3, COMT, LRP2, NTF3 25.77 
SLC22A1 ABCB1, COMT, TPMT, LRP2, GSTP1 25.51 
CNGB1 MAPK8, CASP3, LRP2, NTF3, GSR 25.51 
COL19A1 MAPK8, CASP3, NTF3, BDNF, NTRK2 25.34 
WFS1 MAPK8, GSTP1, CAT, ABCB1, NTRK2 25.21 
OR4Q3 MAPK8, CASP3, LRP2, NTRK2 24.58 
TRPM2 ABCB1, NTF3, BDNF, NTRK2, SLC12A1 24.22 
FBXO32 MAPK8, CAT 19.33 
TUBA3E MAPK8, NOX3 16.12 
KRT79 GSR 12.56 




4.3.2.2.2.1 Panel-based gene-level analysis  
 
The deafness, ADME, DNA repair and cisplatin response gene panels were applied to all the 
genes which contained variants scoring ≥ 4 in more than one patient in either group (Figure 
4.8). Two genes were identified in the deafness panel, COCH and WFS1, which are 
associated with non-syndromic dominant hearing loss and Wolfram syndrome, respectively 
(Table 4.12). WFS1 was previously identified in the gene-level analysis, as three Group B 
patients had variants in this gene (Table 4.10), while two other patients in this group had 
variation in COCH.  
 
In the ADME gene analysis, two transporter genes were identified, ABCC6 and SLCO4A1, of 
which ABCC6 is part of the ABC family of multidrug resistance associated proteins (MRPs) 
(Table 4.12). The variant is a known non-synonymous SNV (rs41278174) and was observed 
in two of the resistant patients. Other ADME genes were those encoding phase I enzymes, 
including DDO, PON3 and NOS3, and the modifier genes CFTR and NR1I2. CFTR was also 
included in the cisplatin response panel; two non-synonymous SNVs, rs1800076 and 
rs121908759, occurred in Group A patients. A novel homozygous frameshift insertion in 
NOS3 occurred in two of the Group B patients. 
 
Regarding the DNA repair gene panel, homozygous 4 bp deletions in POLI were observed in 
two of the susceptible patients (Table 4.12). BIVM-ERCC5 was also included in the cisplatin 
response panel, and is involved in the NER pathway. Four mutations in three Group B 
patients occurred in PER1. This gene was also identified in the gene- and variant-level 
analyses, and was implicated here as a checkpoint protein involved in the detection of DNA 
damage. Similarly, SLX4, in which two mutations occurred, is a checkpoint protein and 
functions in the cellular response to DNA adducts and other lesions. 
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Table 4.12: Gene panel analysis 
Gene Coordinates Ref  Var  Consequencea Score dbSNP ID DPb Q scoreb Patient(s) Group MAF MAF (Afr) 
Deafness-related gene panel 
COCH 14:31355311 T G Non-synonymous 7 rs61759484 296 724.06 10 B - - 
14:31358897 A G Non-synonymous 4 rs17097468 52 211.99 6 B 0.01 0.05 
WFS1 4:6304133 G A Non-synonymous 4 rs71532874 170 360.70 7 B < 0.01 < 0.01 
4:6302502 T C Non-synonymous 5 - 25 46.46 8 B - - 
4:6304118 G A Non-synonymous 4 rs3821945 80 198.01 9 B 0.008 0.01 
ADME gene panel 
ABCC6 16:16259596 G A Non-synonymous 6 rs41278174 257.5 625.49 3,4 A 0.01 < 0.01 
CFTR 7:117149147 G A Non-synonymous 7 rs1800076 121 225.00 1 A 0.01 < 0.01 
7:117232086 G A Non-synonymous 7 rs121908759 102 212.50 2 A < 0.01 < 0.01 
DDO 6:110734521 C T Non-synonymous 7 rs147873486 268 565.67 1 A - - 
6:110714357 C T Non-synonymous 4 rs147072212 148 329.05 3 A < 0.01 0.01 
PON3 7:94996689 T C Non-synonymous 4 rs140234471 49 89.39 2,4 A - - 
7:94993334 G T Non-synonymous 4 rs17883013 8 15.55 10 A 0.01 0.05 
SLCO4A1 20:61287937 T TCG Frameshift insertion 8 - 54.5 144.94 1,3 A - - 
20:61297803 C T Non-synonymous 4 rs147153778 371 552.70 9 A < 0.01 < 0.01 
NOS3 7:150696110 A AG Frameshift insertion 8 - 117.5 696.35 6,11 B - - 
NR1I2 3:119526203 G A Non-synonymous 4 rs12721607 219 468.13 7,11 B 0.01 < 0.01 
DNA repair gene panel 
BIVM-ERCC5 13:103527848 A AC Frameshift insertion 8 - 20 168.40 1 A - - 
13:103510736 C T Non-synonymous 4 rs56255799 65 125.62 5 A < 0.01 < 0.01 
PER1 17:8045707 GCC GC Frameshift deletion 8 - 33.67 220.58 8,9,10 B - - 
17:8053361 G A Non-synonymous 4 rs139241830 99 105.20 9 B - - 
POLI 18:51795957 ACGAC A Frameshift deletion 8 - 176.5 1553.09 6,11 B - - 
SLX4 16:3647623 G GGC Frameshift insertion 8 - 9 20.24 7 B - - 
16:3656625 G A Non-synonymous 4 rs79842542 166 503.64 11 B 0.06 0.07 
Cisplatin response gene panel 
BIVM-ERCC5 13:103527848 A AC Frameshift insertion 8 - 20 168.40 1 A - - 
13:103510736 C T Non-synonymous 4 rs56255799 65 125.62 5 A < 0.01 < 0.01 
CFTR 7:117149147 G A Non-synonymous 7 rs1800076 121 225.00 1 A 0.01 < 0.01 
7:117232086 G A Non-synonymous 7 rs121908759 102 212.50 2 A - - 
a consequence types in bold are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 






Numerous other genes were identified at the individual level when the gene panel analysis 
was not limited to those genes mutated in more than one patient (Appendix L). For example, 
variants in five Usher syndrome genes were noticed in three of the patients: CDH23 and 
CIB2 variants in one Group A patient, and CLRN1, DFNB31 and MYO7A variants in two 
Group B patients. Similarly, various high-scoring ABC MRP transporter gene variants were 
observed in the cohort; most notable was ABCB6 rs111677240, which was a homozygous 
non-synonymous SNV which scored 8 in the analysis, and occurred in a Group B patient. 
Regarding the cisplatin response panel, three patients in the cohort had variation in NOX3. 
The variant NOX3 rs3749930 occurred in one Group A patient, and NOX3 rs142268682 was 
observed in two of the Group B patients. Both of the SNVs were non-synonymous and had a 
score of 5. 
 
4.3.2.2.2.2 Pathway gene-level analysis 
 
All of the genes which contained one or more variant with a score of at least 4 were 
interrogated using CPDB to identify pathways over-represented in each of the patient 
groups. A total of 55 pathways were identified: 26 which were enriched in Group A, and 29 
which were enriched in Group B (Appendix M). The full gene set of each of the pathways 
was downloaded, giving a pathway panel of 2,404 genes, which was then applied to the total 
dataset (Appendix N). Many of the pathways were similarly mutated in both patient groups 
(Figure 4.10); however, three were uniquely affected in Group A, and six in Group B (Table 
4.13). In particular, variation in the ERBB2 signalling pathway (pathway 25) was observed in 
five of the six Group B patients, with seven mutations occurring in the genes ERBB2, ERBB3 
and NRG1. Similarly, the pathway involved in the activation of C3 and C5 (pathway 1) 
contained variation in four Group B patients, implicating the genes C2, C5, CFB and C3, of 
which C3 was identified in the previous variant- and gene-level analyses (Tables 4.6 and 
4.10). EP300 is another gene which was also identified in the variant-level pipeline (Table 
4.6). This gene was implicated in two pathways involving IFN production (pathway 30) and 
oestrogen receptor regulation (pathway 38), and three patients contained the homozygous 
non-synonymous SNV rs200876858. 
 
The pathway which was most affected in Group A was the p53 signalling pathway (pathway 
36), which contained frameshift deletions in three of the five patients. Of these, BCL2 was 
included in the cisplatin response panel (Appendix J). This gene contained a homozygous 
frameshift deletion in the patient, although coverage of this locus was low (5X), and the 




Table 4.13: Details of affected genes identified in the uniquely mutated pathways 
Gene Coordinates Ref  Var  Consequencea Score dbSNP ID DPb Q scoreb Patient(s) Group MAF MAF (Afr) 
Activation of C3 and C5 
C2 6:31912522 G GC Frameshift insertion 8 - 276 2231.56 10 B - - 
C3 19:6712379 T TGG Frameshift insertion 8 - 12 59.51 6,10,11 B - - 
C5 9:123792679 C T Non-synonymous 4 rs112959008 108 279.71 6 B < 0.01 < 0.01 
CFB 6:31914024 T A Non-synonymous 4 rs4151667 45 135.87 7 B 0.03 0.01 
Aripiprazole metabolic pathway 
CYP2D6 22:42526694 G A Non-synonymous 5 rs1065852 225.5 485.09 1,4 A 0.24 0.11 
CYP3A43 7:99434077 TA T Frameshift deletion 8 rs61469810 43 91.7 4 A 0.11 0.32 





























































ERBB3 12:56490612 T G Non-synonymous 5 - 7 15.63 10 B - - 
NRG1 8:32611970 G T Non-synonymous 4 rs74942016 141 324.22 7 B 0.01 < 0.01 
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production 
EP300 22:41574697 T C Non-synonymous 6 rs200876858 9.67 63.00 6,7,11 B < 0.01 < 0.01 
CREBBP 16:3779222 C CGC Frameshift insertion 8 - 6 16.32 11 B - - 
LRRFIP1 2:238672699 AGGGC AGGC Substitution 8 - 29 166.92 8 B - - 
Opsins 
OPN1MW X:153459074 C CT Frameshift insertion 8 - 6 20.88 2 A - - 
OPN3 1:241757758 ACTT AT Substitution 8 - 11 80.4 4 A - - 
RHO 3:129247728 G C Non-synonymous 4 rs149079952 107 391 2 A < 0.01 0.02 
p53 signalling pathway 
CCND1 11:69465965 CCA C Frameshift deletion 8 - 10 57.89 2 A - - 
TP53 17:7579579 CG C Frameshift deletion 8 - 20 73.38 4 A - - 
BCL2 18:60985775 GCCCCCG GCCCC Frameshift deletion 8 - 5 36.81 4 A - - 
TIMP3 22:33253290 TCC TC Frameshift deletion 8 - 263 1781.98 5 A - - 
PELP1 modulation of oestrogen receptor activity 
EP300 22:41574697 T C Non-synonymous 6 rs200876858 9.67 63.00 6,7,11 B < 0.01 < 0.01 
CREBBP 16:3779222 C CGC Frameshift insertion 8 - 6 16.32 11 B - - 
PELP1 17:4607229 TTG T Frameshift deletion 8 - 138 36.84 9 B - - 
Purine deoxyribonucleosides degradation 
ADA 20:43255233 G A Non-synonymous 7 rs121908736 14 45.7 8 B < 0.01 0.01 
PNP 14:20943408 G A Non-synonymous 4 rs138702206 72 103.52 9 B 0.01 0.02 
Purine ribonucleosides degradation to ribose-1-phosphate 
ADA 20:43255233 G A Non-synonymous 7 rs121908736 14 45.7 8 B < 0.01 0.01 
PNP 14:20943408 G A Non-synonymous 4 rs138702206 72 103.52 9 B 0.01 0.02 
PGM2 4:37857332 A G Non-synonymous 7 rs139469063 94 283.29 10 B < 0.01 < 0.01 
a consequence types in bold are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 








Figure 4.10: Number of variants identified in pathways 1 to 27 (A) and 28 to 55 (B). Blue bars indicate 
the frequency of variation in Group A, and grey bars indicate variation in Group B patients. Pathways 
which contained variant counts > 100 (pathways 18, 32 and 52) were excluded. The pathway 







Hearing loss is a permanent adverse reaction to cisplatin therapy which can affect treatment 
outcomes and patient quality-of-life. Although its high prevalence is widely reported 
(Kopelman et al, 1988; Knight et al, 2005; Kushner et al, 2006; Coradini et al, 2007; Yancey 
et al, 2012; Choeyprasert et al, 2013; Peleva et al, 2014; Whitehorn et al, 2014a), inter-
individual variability in drug response amongst patients has implicated the role of various 
clinical and non-clinical risk factors in the development of ototoxicity. Patients who are 
exposed to similar treatment regimens can have very different responses to therapy, and this 
difference has been demonstrated to have a heritable component (Dolan et al, 2004; Shukla 
et al, 2008). Consequently, the identification of the genetic factors which play a role in 
ototoxicity would be beneficial and assist in the future personalisation of treatment plans for 
cancer. 
 
In this investigation, 11 patients who demonstrated an extreme audiological reaction to 
cisplatin were selected for WES analysis. Six of these patients developed significant hearing 
loss after a single cycle of treatment and were included in the extreme susceptibility category 
(Group B). In contrast, five patients demonstrated an increased resistance to cisplatin’s 
ototoxic effect (Group A). These patients received multiple doses of the drug, reaching total 
doses above the average for the cohort (median cumulative dose: 200 mg/m2). Cumulative 
cisplatin dose is a well characterised risk factor of ototoxicity (Bokemeyer et al, 1998; 
Bertolini et al, 2004; Li et al, 2004; Whitehorn et al, 2014b), and the high doses these 
patients were exposed to indicates their resistance to drug-induced hearing loss. Other 
factors such as patient age and sex were not different between the two groups of patients, 
and have been shown to have no effect on ototoxicity in SA or other populations (Bokemeyer 
et al, 1998; De Jongh et al, 2003; Chen et al, 2006; Choeyprasert et al, 2013; Whitehorn et 
al, 2014a). Because all the patients included in this investigation were head and neck, 
osteosarcoma or lymphoma cancer patients, they were treated with a similar strategy. The 
differences in treatment outcome can therefore not be attributed to differences in clinical 
parameters such as cisplatin infusion rates or method of administration. 
 
Four of the six Group B patients were of black African self-reported ethnicity; indeed, this 
population has been found to be more susceptible to ototoxicity than SA Caucasian and 
mixed ancestry patients (Chapter 2). Three of these individuals clustered together in the 
PCA, as expected, while the fourth clustered more closely with the mixed ancestry and 
European populations. This indicates that the ancestry of this individual may be more 
complex than reported. All the other individuals in the investigation, including the five who 
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demonstrated an increased resistance to cisplatin-induced ototoxicity, were of mixed 
ancestry; their positioning in the PCA reflected this self-reported complex ethnicity. The 
indigenous African and Cape mixed ancestry populations are relatively unexplored in 
pharmacogenomic studies of ototoxicity, and their investigation may yield novel findings. A 
review of available genotypes for previously associated genetic modifiers of ototoxicity 
indicated that the majority were unable to predict these patients’ reactions to cisplatin 
treatment. The protective variants OTOS rs2291767 and rs77124181 were only observed in 
patients who displayed resistance to cisplatin’s ototoxicity, while the COMT rs4646316 
variant alleles were limited to the susceptible patient group. These were the only variants 
which occurred in the direction in which they were originally reported (Ross et al, 2009; 
Spracklen et al, 2015), indicating that genotypic information from the other modifiers could 
not explain the extreme phenotypic response demonstrated by these patients. NGS analysis 
of this cohort of patients may therefore yield new insights into the genetics of cisplatin-
induced ototoxicity.  
 
The exonic regions of all 11 patients were successfully captured and sequenced, generating 
a total of 257,831 coding region variants for the analysis. When applying this exomic data to 
the cisplatin response panel, which included all the genes which have been previously 
implicated as modifiers of cisplatin-induced ototoxicity, few noteworthy results were 
obtained. In fact, no variants were identified in any of the previous modifiers in the filtering 
pipelines, although other genes which were previously implicated in cisplatin response, such 
as cystic fibrosis transmembrane conductance regulator (CFTR) and NADPH oxidase 3 
(NOX3), had potentially modifying variants which occurred at low frequencies. The inability 
of the cisplatin response gene panel to generate conclusive results indicates the need for 
hypothesis-generating approaches such as WES in the study of the pharmacogenomics of 
cisplatin’s ototoxicity. By targeting coding regions of the genome for NGS, WES is a strategy 
which allows functional variants to be prioritised in the study of complex traits. In this 
investigation, variants which were common to both groups of patients were excluded in order 
to select those variants with a greater possibility of being implicated in individual cisplatin 
response. Initial analyses indicated that stop-gain, stop-loss and frameshift variants, which 
are more likely to be functional due to their effects on the protein product, were shared 
between groups less often than other variants. These variants also presented a higher rate 
of novelty, however, which increases the possibility of them being false positives. Therefore, 
variants which occurred in multiple individuals were prioritised in the analysis, although 
genes which had multiple hits in one group were also included. To further focus on 
functionally relevant variants, the exomes were also interrogated for gene-disease 
relationships, pathway over-representations, and representation on various gene panels.  
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In the gene-disease relationship analysis, all genes which were associated with disorders 
which affect any of the cisplatin-sensitive organs in the body were considered. Six such 
genes were identified, of which aquaporin 7 (AQP7) and Wolfram syndrome 1 (WFS1) have 
their effects in the inner ear. AQP7 encodes an aquaporin (AQP) which was associated with 
Ménière’s disease and endolymphatic hydrops, two disorders involving dysregulation of 
endolymph levels in the cochlea and vestibular apparatus. The gene was also identified in 
the prioritisation analysis through its associations with genes involved in cisplatin response. 
AQPs are membrane transporters of water which are typically expressed in cells of the 
kidney, where they regulate body water homeostasis (Kortenoeven and Fenton, 2014). They 
are also expressed in the inner ear, where they regulate the water content of the endolymph 
and perilymph (Eckhard et al, 2012). In rats, cisplatin treatment reduced renal protein 
expression of AQP1, AQP2, and AQP3 (Kishore et al, 2000; Kim et al, 2001; Kang et al, 
2004), and differential expression of AQP1, AQP3, AQP5, and AQP8 has been observed 
after treating ovarian carcinoma cells with the drug (Yang et al, 2012; Xuejun et al, 2014). 
Furthermore, the sensitivity of ovarian cancer cells to cisplatin could be increased in vitro 
through incubation with mercuric chloride, an AQP inhibitor (Xuejun et al, 2014), while 
silencing AQP5 expression sensitised colon cancer cells to cisplatin treatment (Shi et al, 
2014b). Together, these results suggest that the permeability of cells may be important in 
cisplatin’s cytotoxicity. Polymorphisms in AQP2 and AQP9 have been associated with the 
response to platinum-based chemotherapy in 338 Chinese lung cancer patients (Wang et al, 
2014a), indicating that AQP genetic variation may play a role in variable treatment 
outcomes. In this investigation, AQP7 was identified as a potential modifier of ototoxicity, 
because a single non-synonymous SNV was observed in three of the patients who were 
resistant to cisplatin-induced ototoxicity One of the patients, however (patient 1), was 
observed to develop renal dysfunction during treatment. AQPs have previously been 
associated with inner ear-related disorders, such as Ménière’s disease (Ishiyama et al, 
2010), age-related hearing loss (Christensen et al, 2009), and non-syndromic deafness (Li 
and Verkman, 2001; Nicchia et al, 2011). Although little is known about the function of 
AQP7, the gene is expressed in the cochlea and vestibular apparatus (Huang et al, 2002), 
and homozygous deletion of the gene caused a renal phenotype similar to cisplatin-induced 
nephrotoxicity (Sohara et al, 2005). This indicates that AQP7 may be involved in the 
mediation of cisplatin-induced inner ear damage, although its precise role in hearing is 
currently unclear.  
 
In contrast, WFS1 has been thoroughly implicated in non-syndromic dominant hearing loss 
(Pennings et al, 2003; Bramhall et al, 2008; Rendtorff et al, 2011; Bai et al, 2014; Häkli et al, 
2014) and Wolfram syndrome, an autosomal recessive condition in which subjects often 
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present progressive high-frequency hearing loss (Haghighi et al, 2013; Lopez de Heredia et 
al, 2013; Matsunaga et al, 2014). Additionally, the gene was prioritised by VarElect due to its 
associations with GSTP1 and catalase (CAT), two enzymes which may be involved in the 
antioxidant response to cisplatin. In this cohort, three different non-synonymous WFS1 
variants were observed in three of the susceptible patients. Due to the link between WFS1 
and hearing, it may be that these variants were predisposing factors. Indeed, the disease 
phenotype which is the most related to cisplatin-induced ototoxicity is deafness. For this 
reason, a deafness gene panel was included in the analysis, and incorporated all genes 
which have been implicated in syndromic and non-syndromic forms of hearing impairment. 
Similar to the cisplatin response panel, the deafness gene panel did not offer many potential 
candidate genes beyond WFS1. An additional gene was cochlin (COCH), which encodes an 
extracellular protein with unclear functions (Bae et al, 2014). Mutations in COCH have been 
associated with autosomal dominant hearing loss (de Kok et al, 1998; Nagy et al, 2004; 
Tsukada et al, 2015) and it is therefore uncertain if the variants identified here would be 
functionally relevant. When considering other forms of syndromic hearing loss, variants in 
five Usher syndrome genes were noted. Usher syndrome is a recessive condition which is 
characterised by hearing and visual impairment (Mathur and Yang, 2015), and it may be 
hypothesised that individuals heterozygous for variants in these genes are predisposed to 
drug-induced hearing loss. Unfortunately, no phenotypic data was available for any of the 
known variation, and because the variants occurred at an individual basis, the role of the 
Usher syndrome genes in predisposition to cisplatin-induced ototoxicity is unclear at this 
stage. A previous study which considered deafness genes failed to find any association 
between variants in GJB2, SLC26A4, and the mitochondrial genome, and cisplatin-induced 
ototoxicity (Knoll et al, 2006); however, no work beyond this pilot investigation has been 
conducted to date, and the role of deafness genes in ototoxicity cannot be conclusively 
rejected. 
 
Cisplatin is also known to affect the kidneys, erythrocytes and nervous system (McKeage, 
1995). Mutations in the genes complement component 3 (C3), cubilin (CUBN), dyslexia 
susceptibility 1 candidate 1 (DYX1C1), and FRAS1 related extracellular matrix protein 2 
(FREM2) have been associated with disorders which affect some of these organs or tissues. 
FREM2, for instance, has been implicated in Fraser syndrome, a developmental disorder 
which can affect the formation of the kidneys and ears (van Haelst et al, 2007). Homozygous 
1 bp insertions were observed in this gene in three of the patients who were susceptible to 
cisplatin-induced ototoxicity. A gene ontology (GO) term associated with FREM2 is “inner 
ear development” (GO identifier: 0048839, http://www.ebi.ac.uk; accessed 08.04.2015), and 
it is possible that variation in the gene may predispose patients to cisplatin ototoxicity at a 
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developmental level; however, there is currently no data on the role of FREM2 in drug-
induced or any other form of hearing impairment. DYX1C1 is another gene with a 
developmental function, playing a role in neuronal migration (Wang et al, 2006; Tammimies 
et al, 2013). A single variant in DYX1C1, rs57809907, occurred in three of the resistant 
patients. This is a stop-gain SNP which is prevalent in the 1000 Genomes project African 
populations, and a reported risk factor of dyslexia (Taipale et al, 2003). Dyslexia is a 
cognitive disorder which primarily affects reading ability, although auditory processing may 
be affected in some individuals (Christmann et al, 2015). Homozygous deletion of the gene 
in rats caused both disrupted neuronal migration and deficient auditory processing (Wang et 
al, 2006; Rosen et al, 2007; Szalkowski et al, 2013), indicating the role of DYX1C1 in the 
development of the nervous system. Furthermore, DYX1C1 was also associated with ciliary 
dyskinesia according to the gene-disease output (Tarkar et al, 2013). The role of DYX1C1 in 
the development and function of ciliated cells has been demonstrated in zebrafish, when 
loss of the gene resulted in ciliary defects (Chandrasekar et al, 2013; Tarkar et al, 2013). 
DYX1C1 gene expression was also detected in murine tracheal cells undergoing 
differentiation in cell culture (Hoh et al, 2012), and in transcriptomic data from ciliated 
epithelia found in human tissues including the brain, tracheae, lungs and fallopian tubes 
(Ivliev et al, 2012). Hair cells of the cochlea possess stereocilia, and it is unknown if these 
require DYX1C1 in the same way. Nevertheless, the role of DYX1C1 in auditory processing 
and neuronal development indicates it may be a candidate similar to FREM2; however, in 
the case of this gene, the variant was enriched in the patients resistant to ototoxicity. 
Another possible risk factor was the non-synonymous SNP CUBN rs12259370, which 
occurred in three Group B patients. The gene was identified as a potential risk candidate 
through its association with megaloblastic anaemia (Tanner et al, 2004), and kidney-related 
disorders such as Dent’s disease and nephropathic cystinosis (Gaide Chevronnay et al, 
2014; Raggi et al, 2014). Although the role of the gene in cisplatin response and hearing is 
so far unknown, CUBN scored highly in the VarElect prioritisation analysis, and was 
associated with GSTP1 and CAT, similar to DYX1C1.  
 
The final gene from the gene-disease relationship analysis was C3. Associated with dense 
deposit disease and haemolytic uraemic syndrome (Frémeaux-Bacchi et al, 2008; Martínez-
Barricarte et al, 2010), the gene C3 encodes a component and central regulator of the 
complement cascade. The complement system is an innate inflammatory immune response 
which can be induced by three distinct pathways which all converge on the activation of C3 
and subsequent activation of C5 (Cook and Botto, 2006). C3 has been associated with both 
hearing and cisplatin response, when increased levels of activated C3 were observed in 
individuals with sudden unilateral deafness (Nordang et al, 1998), and up-regulation of C3 
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expression was reported in models of cisplatin-induced ovarian failure in rats (Li et al, 2013). 
Further experiments in rats demonstrated that cisplatin exposure increases serum 
complement activity and, in animals which were unable to produce C5, significantly less 
nephrotoxicity than wild type rats was observed (Pan et al, 2009). These results indicate that 
complement proteins may play a role in targeting and clearing cisplatin-damaged cells, and 
they can have their effects in the inner ear. Here, a novel 2 bp insertion in the gene was 
identified in three of the Group B patients. Additionally, the genes C2, C5, and complement 
factor B (CFB) also had variation in this group of patients. Together with C3, these genes 
occurred in the pathway involved in the activation of C3 and C5, which further suggests the 
role of complement deficiencies in predisposition to cisplatin-induced ototoxicity.  
 
The investigation of pathways is another approach to the analysis of WES data which 
investigates groups of genes, rather than individual genes, for their contribution to a 
phenotype, on the basis that those genes are all involved in the same process. Pathways 
which were affected in the susceptible patient group were involved in immune response, 
signalling, and purine metabolism. Immune response pathways which were potentially 
compromised in Group B patients were the activation of C3 and C5, which is discussed 
above, and the production of interferon (IFN). IFNs are cytokines which are involved in the 
regulation of the immune response and cell proliferation (de Andrea et al, 2002). Cancer 
cells in which IFN over-expression was forced were sensitised to cisplatin (Mecchia et al, 
2000), and those co-treated with IFNs and cisplatin displayed greater apoptosis compared to 
cells exposed to cisplatin alone (Mecchia et al, 2000; Meister et al, 2007). Variation in the 
IFN production pathway was observed in four of the susceptible patients, implicating the 
genes leucine rich repeat interacting protein 1 (LRRFIP1), CREB binding protein (CREBBP), 
and E1A binding protein p300 (EP300). LRRFIP1 encodes a transcription factor which has 
been associated with cisplatin resistance in various cancer cell lines (Shen et al, 2012), 
while EP300 has been implicated in the recognition of and response to DNA damaging 
agents, and the modulation of apoptosis in cisplatin-treated cells (Van Den Broeck et al, 
2012; Wang et al, 2013; Cao et al, 2014). The non-synonymous variant EP300 rs200876858 
occurred in three of the susceptible Group B patients. Although the functional effect of this 
SNV is unknown, its homozygosity in affected patients, as well as the role of EP300 in 
cisplatin response, indicates its potential as a candidate variant.  
 
Other pathways of interest in Group B concerned Erb-B2 receptor tyrosine kinase 2 (ERBB2) 
signalling and purine degradation. Although very few genes occurred in the purine 
degradation pathways, cisplatin is a DNA damaging agent which preferentially targets purine 
deoxyribonucleotides (Plooy et al, 1984; Fichtinger-Schepman et al, 1985), which makes the 
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role of adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and 
phosphoglucomutase 2 (PGM2) somewhat compelling. In particular, ADA may be involved in 
the response to cisplatin, since its activity and expression increased in rat models of 
cisplatin-induced nephrotoxicity (Söğüt et al, 2004; Gulec et al, 2006; Cure et al, 2014). The 
role of ERBB2 (also referred to as HER2) signalling in breast cancer is well documented, as 
HER2-positive breast cancers can be targeted with the drug trastuzumab (trade name 
Herceptin) (Molina et al, 2001; Slamon et al, 2001). ERBB2 belongs to a family of epidermal 
growth factor receptors which are involved in the regulation of cell proliferation and survival, 
amongst other cellular processes (Seshacharyulu et al, 2012). ERBB2 was the highest 
scoring gene in the gene prioritisation analysis, although this was at least partly because of 
its associations with the genes COMT and LRP2, which may not be involved in cisplatin-
induced ototoxicity (Riedemann et al, 2008; Choeyprasert et al, 2013; Yang et al, 2013; 
Hagleitner et al, 2014; Lanvers-Kaminsky et al, 2014; Whitehorn et al, 2014b). Nevertheless, 
expression of ERBB2 has been associated with the response to cisplatin therapy, for 
instance in lung (Kuyama et al, 2008; Calikusu et al, 2009), oesophageal (Akamatsu et al, 
2003), bladder (Koga et al, 2011; Inoue et al, 2014), cervical (Kim et al, 1999), and head and 
neck cancers (Shiga et al, 2000), where expression of the gene typically reduces the efficacy 
of the drug. Notably, ERBB2, ERBB3 and neuregulin 1 (NRG1) proteins are expressed in 
various cells in the inner ear (Zhang et al, 2002; Stankovic et al, 2004), and it was these 
components of the pathway which were affected in the Group B patients. The disruption of 
ERBB2 signalling in mice, through the expression of mutant erbB2, erbB3 and erbB4 genes, 
was associated with severe hearing impairment (Zhang et al, 2002; Stankovic et al, 2004). 
Furthermore, incubation of rat inner ear cells with NRG1 (also referred to as heregulin) could 
ameliorate the ototoxic effects of the aminoglycoside gentamicin (Zheng et al, 1999), while 
an ERBB inhibitor proved ototoxic in zebrafish and mouse models (Tang et al, 2015). These 
findings strongly suggest that deficiencies in ERBB2 signalling may confer susceptibility to 
cisplatin-induced ototoxicity, although more research is required to confirm this. 
 
The pathway which was most implicated in Group A was the p53 signalling pathway, which 
contained variation in three of the five resistant patients. This is one of the pathways 
whereby cisplatin induces apoptosis in affected cells (Müller et al, 1998; Park et al, 2000), as 
p53 is a transcriptional activator and key regulator of DNA repair, cell cycle arrest and 
apoptosis in the response to many cellular stresses (Budanov, 2014). A reduction of this 
pathway’s ability to induce apoptosis may be protective against cell death in cisplatin-
damaged cells (Guntur et al, 2010; Tang et al, 2013; Yang et al, 2015). In this investigation, 
a novel 1 bp deletion in tumour protein P53 (TP53), the gene which encodes p53, was only 
observed in one of the Group A patients; the other variants occurred in the genes B-cell 
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CLL/lymphoma 2 (BCL2), cyclin D1 (CCND1), and TIMP metallopeptidase inhibitor 3 
(TIMP3), although all of the identified variants were also frameshift deletions. While these 
may have been cancer predisposing events in these patients, TIMP3 genetic variation has 
been associated with survival rates amongst adenocarcinoma patients treated with cisplatin 
and 5-FU combination therapy (Bashash et al, 2013), while a reduced expression of BCL2 
increased the susceptibility of gastric cancer cells to cisplatin-induced apoptosis (Hu et al, 
2014b; Wang et al, 2014b). Similarly, CCND1 deletion could sensitise tumour cells to 
cisplatin exposure (Kornmann et al, 1998; Noel et al, 2010), and over-expression of the gene 
has been associated with resistance to cisplatin treatment (Biliran et al, 2005; Noel et al, 
2010).  
 
Because cisplatin is a DNA-damaging agent, one of the panels applied to the WES dataset 
was a DNA repair gene panel. Genes of interest were SLX4 structure-specific endonuclease 
subunit (SLX4), which is involved in the detection of DNA crosslinks, double-strand breaks, 
and other lesions including those associated with cisplatin exposure (Muñoz et al, 2009; 
Hodskinson et al, 2014), and period 1 (PER1). PER1 encodes a period protein which 
functions in the maintenance of circadian rhythm in mammalian cells, and was identified 
here through its role as a cell cycle checkpoint protein which may control the recognition of 
DNA damage (Gery et al, 2006). The circadian rhythm has previously been implicated in 
chemotherapy response, because of its ubiquitous effects on cellular processes such as 
drug metabolism, cellular proliferation and the response to genotoxic stress (Kondratov and 
Antoch, 2007). In lung cancer patients, the timing of cisplatin administration has been 
associated with the incidence of ADRs such as neutropaenia and gastrointestinal toxicity, 
although no effect on cisplatin efficacy was noted (Li et al, 2015). This may be due to the 
role of circadian cycles in DNA repair (Kang and Sancar, 2009). Murine cells had differing 
NER abilities depending on the time of day: optimal DNA repair capacity was observed 
during the afternoon and evening (Kang et al, 2009), the time at which cisplatin-induced 
toxicity was reportedly reduced in the study of lung cancer patients (Li et al, 2015). 
Accordingly, interference of aryl hydrocarbon receptor nuclear translocator-like (Arntl, also 
known as Bmal1), another component of the circadian cycle, reduced the expression Tp53, 
and attenuated DNA damage by cisplatin in murine colon cancer cells (Zeng et al, 2010). In 
the extreme phenotype cohort, a novel 1 bp deletion was detected in three of the susceptible 
patients. Silencing of PER1 expression by siRNA in human oral cancer cells increased 
apoptosis in response to cisplatin treatment, indicating that the gene may have anti-apoptotic 




The final gene panel investigated the role of ADME genes in cisplatin-induced ototoxicity. 
ABCC6 and CFTR are transporter genes which were variant in Group A patients, of which 
CFTR was also included in the cisplatin response panel. CFTR is a chloride ion channel, 
mutations in which have been associated with cystic fibrosis (Riordan et al, 1989). It also 
mediates glutathione efflux, and may therefore be involved in the cellular response to 
oxidative stress (I’Hoste et al, 2010; Duranton et al, 2012). Inhibition of CFTR in renal cells 
and rat models of nephrotoxicity caused significant protection against apoptosis upon 
treatment with cisplatin, and reduced ROS accumulation without affecting cisplatin uptake 
(Rubera et al, 2013). In this cohort, non-synonymous SNVs were found in CFTR in two of 
the protected patients, indicating that these deleterious variants may confer protection 
through a reduced transport of glutathione out of inner ear cells. Also involved in the 
oxidative stress response, homozygous 1 bp insertions were observed in nitric oxide 
synthase 3 (NOS3) in two of the Group B patients. Nitric oxide is a free radical, and promoter 
region and non-synonymous variation within NOS3 has been associated with treatment 
outcomes in breast cancer patients receiving combination chemotherapy, not including 
cisplatin (Choi et al, 2009). The role of NOS3 variation in cisplatin response has not yet been 
reported. However, a reduction in NOS3 expression was noted when treating cisplatin-
sensitive ovarian cancer cells with the drug, while cisplatin-resistant cells were characterised 
by unchanged NOS3 levels (Leung et al, 2008). Variation in NOS3 has been associated with 
sudden hearing loss (Teranishi et al, 2013), and increased levels of NOS3 in the inner ear 
were detected after exposure of guinea pigs to noise (Heinrich et al, 2005) and gentamicin 
(Heinrich et al, 2006). These results indicate that NOS3 may play a role in the response to 
trauma in the inner ear. 
 
Other genes of interest which were not identified in any of the panels include solute carrier 
family 22, member 1 (SLC22A1), inhibitor of growth family, member 1 (ING1), and V-rel 
avian reticuloendotheliosis viral oncogene homologue A (RELA). SLC22A1 encodes a 
member of the OCT family, OCT1, which is a paralogue of OCT2 (SLC22A2). OCT2 
variation was reported as protective against cisplatin-induced ototoxicity in the prospective 
cohort (Chapter 3) as well as a cohort of German cancer patients (Lanvers-Kaminsky et al, 
2015). SLC22A1, in which two variants were observed in three of the Group B patients, is 
expressed in mouse cochleae, although at a level 2.2 times less than SLC22A2 (Ciarimboli 
et al, 2010). The variants included a 1 bp deletion which occurred in two patients, and the 
non-synonymous SNP rs2282143. OCT1 is a reported transporter of cisplatin, although its 
ability to transport the drug is lower when compared to OCT2 (Yonezawa et al, 2006). These 
mutations may therefore confer susceptibility to ototoxicity through an altered transport of 
cisplatin in the inner ear. ING1 was also mutated in three of the Group B patients; in this 
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instance, the same 1 bp deletion was observed. ING1 encodes a tumour suppressor which 
was up-regulated in response to cisplatin-induced DNA damage in glioblastoma cells, and 
those in which ING1 expression was reduced by siRNA were more sensitive to cisplatin-
induced apoptosis (Tallen et al, 2008). Similarly, expression of ING1 was shown to prevent 
oxidative stress-induced apoptosis in a colon cancer cell line (Rotte et al, 2014), which may 
explain its relation with cisplatin response. RELA encodes p65, a component of the nuclear 
factor-kappaB (NF-κB) transcription factor, which is involved in the regulation of diverse 
cellular processes such as cell proliferation and survival in response to genotoxic stresses 
(Wang et al, 2002). NF-κB is activated following the exposure of cells to cisplatin, and its 
inhibition typically confers increased sensitivity of cells to the drug (Yeh et al, 2004; 
Venkatraman et al, 2005; He et al, 2010; El-Kady et al, 2011; Hong et al, 2012; Yang et al, 
2015). In this investigation, three of the resistant patients carried heterozygous 1 or 2 bp 
deletions in RELA, which may be in a direction opposite to what is expected, given that 
reduction in NF-κB activity is associated with cytotoxicity (Venkatraman et al, 2005; He et al, 
2010; Hong et al, 2012). Nevertheless, the role of NF-κB in cisplatin response indicates its 
potential as a genetic modifier of ototoxicity.  
 
Although this study has produced various potential genetic modifiers of cisplatin-induced 
ototoxicity, two key limitations are a lack of validation and the small sample size investigated. 
The WES data was generated using the Ion TorrentTM NGS platform, which requires 
validation of genotype calls. Because this has not yet been performed, some of the variants 
discussed here may be false positives, particularly those with relatively low sequence 
coverage. Although all of the variants passed CAF’s quality control procedures, validation of 
the variants will have to be conducted on all the potential candidates before applying this 
information to the rest of the prospective patient cohort. The small number of patients 
included in this investigation indicates that the patients selected may not represent the total 
patient population, and that meaningful statistical analyses could not be performed on the 
data as any statistical tests would likely be underpowered. However, the extreme phenotype 
cohort described here was utilised for the discovery of new candidate genes rather than the 
description of statistically significant genetic modifiers of ototoxicity. It is demonstrated here 
that NGS analysis of a well-phenotyped subset of the patient cohort may yield potential 
candidate genes, as numerous promising genes were identified, many of which are 









In this investigation, an extreme phenotype cohort of cisplatin-receiving cancer patients was 
described and subjected to WES analysis. Numerous potential modifiers of cisplatin-induced 
ototoxicity were identified through pipelines which were designed to focus on variants more 
likely to be functionally linked to cisplatin and its ototoxicity. Promising results were obtained 
in genes involved in various biological processes, including transmembrane transport 
(AQP7, CFTR, SLC22A1), development (DYX1C1, FREM2), hearing (COCH, WFS1), and 
the response to DNA damage (ING1, PER1, SLX4). Considering development and hearing, 
it may be suggested that variation in these genes can confer an altered risk of drug-induced 
hearing loss at a developmental level, while those genes involved in transport and DNA 
damage modify at the level of response to cisplatin exposure. Also implicated in cisplatin 
response were genes involved in immune reactions such as the complement cascade and 
interferon production, as well as the ERBB2, p53 and NF-κB signalling pathways. These 
have all been demonstrated to play a role in cisplatin’s cytotoxicity before, and variation in 
these pathways may well confer resistance or susceptibility to cisplatin’s ototoxic effects. 
 
Notably, few candidates were obtained when considering known cisplatin response and 
deafness genes. While this validates the need for hypothesis-generating approaches such 
as WES, this alone cannot conclusively resolve the role of these genes in cisplatin-induced 
ototoxicity. Further research is recommended to include an analysis of the genes and 
pathways identified in this investigation for their role in predisposition to ototoxicity, or 





5. Conclusion and future perspectives 
 
The results reported in this submission indicate the potential of genotypic information to 
identify cisplatin-receiving cancer patients who are at an altered risk of developing 
ototoxicity. In particular, the variants NFE2L2 rs6721961 and SLC22A2 rs316019 are the 
most promising genetic modifiers, as both genes have been demonstrated to play a role in 
the cellular processing of cisplatin, and the protective effects of these SNPs were maintained 
after correction for patient ethnicity. This study also demonstrates the inability of the variants 
EIF3A rs10787899 and rs3824830, ABCB5 rs10950831 and ABCC3 rs1051640 to predict 
hearing loss in the SA patient population, while CDH13 rs11646213 was potentially 
associated with TUNE-defined ototoxicity. Further studies are recommended to validate the 
role of NFE2L2, SLC22A2 and CDH13 genetic polymorphisms in cisplatin response and the 
onset of drug-induced hearing impairment.  
 
The response to cisplatin is a clinically heterogeneous phenotype which is likely influenced 
by multiple genetic factors (Dolan et al, 2004; Shukla et al, 2008; Boddy, 2013). Due to this 
polygenic nature, as well as the limited knowledge of cisplatin’s mechanism of action, future 
research should also consider new genes for their role in cisplatin-induced ototoxicity. These 
investigations would be better aided by genome-scale techniques such as GWAS, WES and 
whole genome sequencing, which allow novel loci to be considered for their contribution to 
the phenotype. In this study, a pilot WES investigation of eleven cisplatin-receiving cancer 
patients is described, in which many potential new loci are identified and may play a role in 
the development of ototoxicity amongst SA indigenous African and mixed ancestry cancer 
patients. As such, research aims in the prospective patient cohort should include the 
validation of these genetic variants, for example through direct cycle sequencing of the 
relevant loci, and the selection of novel candidates for screening in the rest of the patient 
cohort. Previous work by our research group reported novel genetic modifiers of cisplatin’s 
ototoxicity in OTOS (Spracklen et al, 2014), suggesting that the local patient population may 
provide an environment in which new genetic modifiers may be identified. This notion is 
supported by the identification of NFE2L2 genetic variation in association with hearing loss in 
this study, as the NFE2L2 rs6721961 variant has not, to our knowledge, been reported in 
association with cisplatin-induced ototoxicity before.  
 
An additional consideration of future research should be the long term audiometric follow-up 
of cisplatin-receiving patients. Because a high proportion of the patients in this study 
displayed signs of hearing loss immediately following cisplatin exposure (in the retrospective 
analysis, approximately 40% of patients attending GSH between 2006 and 2015 developed 
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Chang grade > 0 ototoxicity), the audiological effects of cisplatin may be more pronounced 
when considering a longer timeframe. If available for a subset of the surviving patient cohort, 
this data may enable the long term impact of cisplatin treatment on cancer patients to be 
ascertained. Indeed, platinum-based chemotherapy regimens can have several quality-of-life 
implications, of which hearing impairment may be severe and potentially disabling. While 
ototoxicity resulting from other drugs such as loop diuretics can be reversible, the effects of 
cisplatin on the inner ear appear to be permanent. Therefore, because there are currently no 
effective methods of preventing this ADR, there is a need for a better means of predicting 
treatment outcomes in order to avoid patient morbidity. This would be particularly valuable in 
developing countries such as SA, where the burden of cancer and the economic impacts of 
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Hello, I am a researcher in the Division of Human Genetics, here at UCT/Groote Schuur Hospital.  
I am doing research as part of contributing to improving cancer treatment and invite you to 
participate in this research project. I would be very grateful for your participation. Before agreeing 
to participate, it is important that you read the following explanations of the purpose of the study, 
the study procedures, benefits, risks, discomforts, and precautions as well as your right to 
withdraw from the study at any time. This information leaflet is to help you to decide if you would 
like to participate. You should fully understand what is involved before you agree to participate. 
 
Purpose of the study 
 
You have been diagnosed with cancer and your doctor has advised you of the treatment. Like 
any other treatment, some patients respond well while others do not respond so well. In some 
instances a treatment of one part of the body may affect another part of the body.  In this 
instance, we know that an anticancer drug such as cisplatin, in some individuals might result in 
hearing impairment. We stress that this occurs only in some individuals, and we have reason to 
believe that this might be because of hereditary factors. The aim of the study is to determine the 
role of what we inherit from our parents in the differences in response to anticancer medication. 
DNA is what each of us inherits from our parents and this DNA can be extracted from blood. If 
you decide to participate, you will not be asked to take any additional drugs except what your 




If you agree to participate, your medical information including demographic information will be 
accessed from the clinic files. A qualified nurse will draw 9 ml of blood, or a saliva sample, from 
you for the extraction of DNA that will be used for genetic analysis. This will be done only once. 
Possible side effects which may be associated with obtaining a blood sample include pain, 
bruising, light-headedness and on rare occasions infection. Precautions will be taken to avoid 
these difficulties. The entire procedure should take less than 5 minutes.   
 
Unforeseen risks and potential benefits 
 
You will continue on your regular medication, but you should contact your prescribing doctor 
immediately if you experience any side effects. There are no direct benefits for you arising from 
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participating in this study; however, the findings may help future patients in the choice and doses 
of their medication.   
 
Rights as a participant in the study: It is up to you to decide whether or not to take part in this 
study. Your participation is voluntary. If you decide to take part, you are still free to withdraw from 
the study at any time and without giving reason. This will not affect the standard of care that you 
receive or the relationship you have with your doctor. You are free to refuse to participate or 
withdraw your consent at any time. The results of the tests will be made available to you on your 
request. The results will be strictly confidential and if the data are published your name will not be 
used. There will be no costs to you from the study and there are no risks attached to this study.  
 
Ethical approval: This clinical study protocol has been submitted to the University of Cape 
Town, Human Research Ethics Committee (HREC) and written approval has been granted by 
that committee.  
 
Source of additional information: For the duration of the study you are still under the care of 
your prescribing doctor, who you should contact at any time should you feel that any of your 
symptoms are causing you problems. For questions relating to the study, you can contact Dr 
Sameera Dalvie at the Radiation and Oncology Clinic any time or alternatively on the following 
telephone number: 021 404 4261 or email: S.Dalvie@uct.ac.za. 
 
Prof. Raj S Ramesar (Supervisor) (021) 406 6297   Raj.Ramesar@uct.ac.za 
Dr. Lebogang Ramma (Supervisor) (021) 406 6954  Lebogang.Ramma@uct.ac.za  
Timothy Spracklen (Researcher) (021) 406 6501   sprtim002@myuct.ac.za 
Gameda Benefeld (Nurse)      Gameda.Benefeld@uct.ac.za 
 
University of Cape Town, Faculty of Health Sciences , Human Research Ethics Committee: 
A/Prof. Marc Blockman      Marc.Blockman@uct.ac.za 
 
If you agree to participate, please sign the consent form. 
 
Thank you 





APPENDIX C: Informed consent form for access to patient records 
 
RESEARCH FOLDER REVIEW 
Informed Consent 
 
Division of Human Genetics  
Faculty of Health Sciences  
University of Cape Town 
Anzio Road, Observatory 7925 
Cape Town, South Africa 




      
 
This is to certify that I, _________________________________________, hereby agree to be a 
participant in this study which has been authorised by the University of Cape Town, and that I 
have given permission for my patient folder to be reviewed after each visit to the Audiology 
Outpatients’ Department. The study and my participation in it have been clearly explained to me 
in full by the researcher, and I understand all the explanations given to me. The questions that I 
asked were answered to my satisfaction, and I understand that I can stop participating in the 







I the undersigned have defined and fully explained the study to the above participant. I have also 









APPENDIX D: Informed consent for the collection, analysis and storage of patient biological 
samples 
 
  REQUEST FOR MOLECULAR STUDIES            
 
Molecular Laboratory 
Division of Human Genetics 
IIDMM, Level 3 
UCT Medical School, 
Observatory 7925 




Please fill in all the information requested: 
 
Surname: ___________________ First Name(s):__________________________________ 
New Family:  Yes    No    
Family name: ____________________________________ 
Medical Aid: __________________________Medical Aid No: ________________________ 
Sex:     M        F    Date of Birth:  Year: _______  Month: _______________  Day: _____ 
Ethnic Origin:  Black    Indian   Mixed ancestry  Caucasian  Other  
 
Contact Address:  __________________________________________________________                
Tel:  __________________  Fax:____________________   Cell:_____________________ 
Email: ______________________         
Referring Doctor/Sister: ________________________  Fax: 
Hospital or Address:  _________________ Town:  ____________ Tel: _________________ 
Blood tissue taken for: Research  
Date of follow up: ______________________________ 
 
Blood should be drawn in 2 plastic EDTA Tubes  
(Purple top) +/- 5 ml each using a plastic barrel. 
Each tube should be inverted to mix and should be 
clearly labelled with the patient's code name or 
number.  
Keep blood in fridge at 4°C until able to send to 
laboratory. 





For Laboratory use only: 
DNA number: ____________________________ Vol. Blood/Saliva: ________________(ml)      
Date Received: Year: ________  Month: _________________  Day:  _____________        
Computer Index No:__________________ 
 





I, ____________________________________________  , consent 
to my/my child’s biological material (blood/saliva sample) being used for research 
aimed at  studying the genetic factors that may contribute to cisplatin ototoxicity in 
cancer patients undergoing chemotherapy treatment, as outlined to me and as per 
the information sheet handed to me, provided that any information from such 
research will remain anonymous and that anonymised/non-identifiable data can 
be deposited in public databases as required for publication in international 
journals, as per international standards in research. 
 
2 I request that no portion of the sample be stored for later use.   (MARK IF 
APPLICABLE) 
  Or 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE 
NOT APPLICABLE): 
(a)  possible re-analysis 
(b)  Research purposes, subject to the approval of the University of Cape Town 
Research Ethics Committee, provided that any information from such research will 
remain anonymous and that anonymised/non-identifiable data can be deposited in 
public databases as required for publication in international journals, as per 
international standards in research. 
  
3 I authorise / do not authorise my doctor(s) (DELETE WHERE NOT APPLICABLE) 
to provide relevant clinical details to the Division of Human Genetics, UCT. 
  
4 I have been informed that:  
(a) The analysis procedure is specific to the current study and cannot determine 
the complete genetic makeup of an individual. 
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(b) The genetics laboratory is under an obligation to respect medical 
confidentiality. 
(c) Where biological material is used for research purposes, there may be no 
direct benefit to me. 
  
5 I understand that I may withdraw my consent for any aspect of the above at any 
time without this affecting my/my child future medical care. 
  
6 ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I 
UNDERSTAND AND MY QUESTIONS ANSWERED BY: 
  
    ____________________________    DATE:     __________________                               
 
 
Patient signature _____________________    
 
 















APPENDIX F: Analysis of threshold changes in all prospective and retrospective patients 
 
 
Average sensitivity threshold changes were calculated at each test frequency for each 
patient, irrespective of cancer diagnosis. Similar to when this analysis was limited to patients 
with head and neck cancer, lymphoma or osteosarcoma, significant differences were 
observed between the different ethnic groups, where black Africans demonstrated greater 
hearing loss than Caucasian and mixed ancestry patients (Figure F1). Again, these changes 
































Figure F1: Average threshold changes at each test frequency in the total patient cohort. Orange, 
purple and grey represent the Caucasians, indigenous Africans and mixed ancestry patients, 
respectively. The distributions of hearing sensitivity changes are represented by box-and-whisker 
plots, in which the boxes delineate the upper and lower quartiles, and the whiskers indicate the 
minimum and maximum values. Lines within the boxes are the median values. Statistical outliers are 
indicated by circles (1.5-3.0 interquartile ranges from the whisker) and stars (> 3.0 interquartile ranges 
from the whisker). Hearing sensitivity changes are measured on the y-axis, in which a greater value 









Caucasian Mixed ancestry Indigenous African p-valuea 
0.25 5.00 0.00 5.00 0.041 
0.5 0.00 0.00 5.00 0.616 
1.0 0.00 0.00 2.50 0.161 
2.0 0.00 0.00 5.00 0.239 
3.0 5.00 5.00 10.00 0.007 
4.0 5.00 10.00 25.00 0.002 
6.0 5.00 15.00 30.00 < 0.001 
8.0 10.00 20.00 35.00 < 0.001 
a Determined by Kruskal-Wallis test 
 
 
Similar results were observed when focussing on the indigenous African patients: hearing 
threshold changes between 3.0 kHz and 8.0 kHz were significantly higher in this group of 
patients than the Caucasian and mixed ancestry patients combined (Table F2). Conversely, 
Caucasian patients had threshold changes which were, on average, lower than the other 
principal ethnic groups. This difference was limited to the frequencies 4.0 kHz to 8.0 kHz, 
however (Table F3). 
 
Table F2: Median threshold shifts per test frequency in indigenous Africans compared to other 
ethnicity groups 





0.25 0.00 5.00 0.059 
0.5 0.00 5.00 0.340 
1.0 0.00 2.50 0.056 
2.0 0.00 5.00 0.096 
3.0 5.00 10.00 0.003 
4.0 10.00 25.00 0.001 
6.0 12.50 30.00 0.001 
8.0 15.00 35.00 0.001 
a Determined by Kruskal-Wallis test 
 
 
Table F3: Median threshold shifts per test frequency in Caucasians compared to other ethnicity 
groups 
Test frequency (kHz) Black African and mixed 
ancestry patients 
Caucasian patients p-valuea 
0.25 0.00 5.00 0.249 
0.5 0.00 0.00 0.994 
1.0 0.00 0.00 0.634 
2.0 0.00 0.00 0.468 
3.0 5.00 5.00 0.067 
4.0 10.00 5.00 0.029 
6.0 20.00 5.00 < 0.001 
8.0 30.00 10.00 0.001 





APPENDIX G: DNA extraction protocols 
 
 




1. invert ORAgene saliva tube (supplied with kit) to mix the sample 
2. incubate in water bath at 50°C for 1 hour 
3. transfer 4 ml sample to a 15 ml tube 
4. add 1/25th volume (approximately 180 µl) ORAgene DNA Purifier (supplied with kit) and mix 
for a few seconds  
5. incubate at -20°C for 10 mins 
6. centrifuge for 10 mins at 2 400 rpm 
7. transfer supernatant to a fresh 15 ml tube 
8. add double that volume of absolute ethanol (Sigma-Aldrich®) and mix by inversion 
9. centrifuge at 2 400 rpm for 10 mins 
10. decant supernatant and resuspend the pellet in 1 ml ice-cold 70% ethanol 
11. mix by inversion 
12. recover the pellet by centrifuging at 2 400 rpm for 10 mins 
13. decant the supernatant and air-dry the pellet for a minimum of 2 hours 
14. reconstitute the DNA in 200 µl 1X TE buffer for at least 2 days 
Saliva DNA extraction and purification using Norgen Kit (Norgen Biotek Corp.) 
Procedure 
1. incubate saliva sample in water bath at 55°C for 30 mins 
2. mix by inversion 
3. transfer sample to a fresh 15 ml tube 
4. add 1 600 mg proteinase K and mix 
5. incubate at 55°C for 1 hour 
6. add an equal volume of room temperature isopropanol 
7. invert the tube 10 times 
8. centrifuge at 3 500 rcf/g for 10 mins 
9. decant supernatant and add 1 ml 70% ethanol to the pellet 
10. leave the tube to stand at room temperature for 1 min 
11. centrifuge at  3500 rcf/g for 10 mins  
12. decant supernatant and air-dry the pellet for a minimum of 30 mins 
13. reconstitute the DNA in 500 μl 1X TE buffer for 2 hours at 55°C 
14. centrifuge at 5 000 g for 10 mins and transfer the supernatant to a fresh tube 
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Red blood cell (RBC) lysis solution: 
- 8.28 g NAH4Cl (Sigma-Aldrich®) 
- 0.79 g NAH4HCO3 (Sigma-Aldrich®) 
- 0.5 M EDTA (pH 7.4) (Melford Laboratories Ltd., Ipswich, UK) 
- make to final volume of 1 L using sdH2O and filter sterilise using 0.2 µM micropore filter 
 
Cell lysis solution: 
- 25 ml of 1 M Tris-HCl (pH 7.5) (Melford Laboratories Ltd.) 
- 16.7 ml of 3 M NaCl (Merck Chemicals) 
- 1 ml of 0.5 M EDTA (Melford Laboratories Ltd.) 




1. obtain buffy coat by centrifuging blood sample for 10 mins at 2 000 rpm 
2. remove 500 µl buffy and plasma 
3. add 900 µl RBC lysis solution and incubate at 37°C for 1 hour 
4. centrifuge for 10 mins at 2 500 rpm 
5. remove supernatant and add 1 000 µl RBC lysis solution to the pellet 
6. centrifuge at 2 500 rpm for 10 mins 
7. decant supernatant and resuspend the pellet in residual RBC lysis solution 
8. add 300 µl cell lysis solution, 10 µl 20% SDS (Sigma-Aldrich®) and 2 µl Proteinase K (Roche 
Applied Science) 
9. mix well   
10. incubate overnight or at room temperature until the solution clears (approximately 2 hours) 
11. add 200 µl saturated 6 M NaCl (Merck Chemicals) and vigorously mix by vortexing 
12. incubate at 4°C for 5 mins 
13. centrifuge at 2500 rpm for 15 mins 
14. remove 500 µl supernatant and add to a new tube containing 900 µl ice-cold absolute ethanol 
(Sigma-Aldrich®) 
15. mix by inversion (50X) and centrifuge for 2 mins at 10 000 rpm 
16. decant the solution and add 400 µl ice-cold 70% ethanol 
17. resuspend the pellet by vortexing 
18. recover DNA by centrifuging at 10 000 rpm for 2 mins 
19. pour off the ethanol and allow to air-dry for 2 hours 
20. resuspend in 100 µl 1X TE for at least 2 days  
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10X TE (stock): 
- 10 mM Tris (Melford Laboratories Ltd.) 
- 1 mM EDTA (Melford Laboratories Ltd.) 
- pH 8.0 
 
1X TE (working): 
- Made by a 1:10 dilution of stock 10X TE buffer, with sterile distilled water 
 
Agarose gel electrophoresis 
 
Tris/Borate/EDTA (TBE) buffers 
10X TBE (stock):  
- 0.89 M Tris (Melford Laboratories Ltd.) 
- 0.89 M Boric acid (Melford Laboratories Ltd.) 
- 0.04 M EDTA (Melford Laboratories Ltd.) 
- Made to a total volume of 2 L with sterile distilled water (Adcock Ingram) 
 
1X TBE (working): 
- Made by a 1:10 dilution of stock  10X TBE buffer, with sterile distilled water 
 
Agarose gels 
1% agarose gel: 
- 0.5 g SeaKem® LE Agarose (Lonza, Basel, Switzerland) 
- 50 ml 1X TBE 
- 1X SYBR® Safe DNA gel stain (Life TechnologiesTM) 
 
2.5% agarose gel: 
- 2.5 g SeaKem® LE Agarose (Lonza) 
- 100 ml 1X TBE 









Molecular weight marker 
GeneRulerTM 100 bp Plus DNA ladder: 
 
 
(Adapted from https://static.fishersci.ca/images/F100438~wl.jpg; accessed 10.09.2015)  
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Appendix I: Tests of association and regression between genotypic and allelic information 
and ototoxicity in the total patient cohort 
 
Table I1: Association of variants with ASHA-grade ototoxicity in all patients 
Variant No ototoxicity Ototoxicity p-value Odds ratio (95% CI) Regressionc 













1.197 (0.627; 2.283) 
0.829 (0.460; 1.492) 








a 1.054 (0.696; 1.597) 0.185 













0.976 (0.516; 1.847) 
0.928 (0.478; 1.801) 








a 0.914 (0.526; 1.589) 0.951 













1.305 (0.725; 2.349) 
0.744 (0.407; 1.360) 








a 1.151 (0.738; 1.794) 0.222 













0.745 (0.403; 1.376) 
1.139 (0.631; 2.057) 








a 0.806 (0.530; 1.227) 0.348 













0.951 (0.529; 1.710) 
1.277 (0.701; 2.325) 








a 1.084 (0.686; 1.713) 0.615 













0.449 (0.193; 1.049) 









a 0.439 (0.197; 0.978) 0.035 













1.163 (0.567; 2.384) 
0.744 (0.351; 1.577) 








a 1.021 (0.535; 1.948) 0.902 


















Table I2: Association of variants with Chang-grade ototoxicity in all patients  
Variant No ototoxicity Ototoxicity p-value Odds ratio (95% CI) Regressionc 













1.212 (0.632; 2.323) 
0.804 (0.451; 1.433) 








a 1.045 (0.695; 1.573) 0.034 













1.193 (0.639; 2.229) 
0.805 (0.423; 1.533) 








a 1.120 (0.650; 1.931) 0.472 













1.229 (0.688; 2.198) 
0.712 (0.396; 1.279) 








a 1.046 (0.678; 1.613) 0.175 













0.827 (0.457; 1.497) 
1.065 (0.594; 1.911) 








a 0.857 (0.565; 1.302) 0.765 













0.714 (0.399; 1.276) 
1.129 (0.622; 2.050) 








a 0.709 (0.448; 1.123) 0.251 













0.604 (0.239; 1.523) 









a 0.588 (0.241; 1.434) 0.144 













0.491 (0.230; 1.047) 









a 0.479 (0.236; 0.976) 0.034 





Table I3: Association of variants with CTCAE-grade ototoxicity in all patients  
Variant No ototoxicity Ototoxicity p-value Odds ratio (95% CI) Regressionc 













1.003 (0.536; 1.875) 
0.870 (0.495; 1.529) 








a 0.935 (0.628; 1.392) 0.337 













1.081 (0.585; 1.997) 
0.894 (0.474; 1.688) 








a 1.039 (0.608; 1.775) 0.681 













1.248 (0.710; 2.195) 
0.820 (0.462; 1.455) 








a 1.152 (0.754; 1.759) 0.181 













0.869 (0.486; 1.554) 
1.075 (0.609; 1.897) 








a 0.905 (0.604; 1.356) 0.612 













0.727 (0.414; 1.278) 
1.410 (0.790; 2.515) 








a 0.829 (0.536; 1.282) 0.375 













0.419 (0.175; 1.001) 









a 0.416 (0.181; 0.957) 0.036 













0.838 (0.426; 1.650) 









a 0.735 (0.397; 1.361) 0.383 






Table I4: Association of variants with TUNE-grade ototoxicity in all patients 
Variant No ototoxicity Ototoxicity p-value Odds ratio (95% CI) Regressionc 













0.960 (0.470; 1.959) 
0.769 (0.404; 1.463) 








a 0.849 (0.541; 1.334) 0.581 













1.046 (0.520; 2.103) 
0.780 (0.372; 1.638) 








a 0.903 (0.497; 1.640) 0.882 













0.836 (0.439; 1.589) 
1.020 (0.533; 1.952) 








a 0.829 (0.517; 1.331) 0.879 













0.772 (0.395; 1.510) 
0.817 (0.426; 1.565) 








a 0.708 (0.449; 1.116) 0.242 













0.785 (0.414; 1.488) 
1.638 (0.858; 3.129) 








a 0.995 (0.606; 1.633) 0.712 













0.714 (0.288; 1.771) 









a 0.643 (0.277; 1.493) 0.195 













0.574 (0.277; 1.192) 









a 0.499 (0.263; 0.947) 0.023 






Appendix J: Gene panels used in analysis of WES data 
 
 
Table J1: Deafness-associated gene panel 
Gene symbol Gene name Type(s) of deafness 
ACTG1 Actin gamma 1 Baraitser-Winter syndrome 2 
DFNA20 
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit 
B1 
Renal tubular acidosis with deafness 
BSND Barttin CLCNK-type chloride channel accessory beta 
subunit 
Bartter syndrome 4A  
DFNB 
CATSPER2 Cation channel, sperm associated 2 Deafness-infertility syndrome 
CACNA1D Calcium channel, voltage-dependent, L type, alpha 1D 
subunit 
Sinoatrial node dysfunction and deafness 
CCDC50 Coiled-coil domain containing 50 DFNA44 
CDH23 Cadherin-related 23 DFNB12 
USH1D, USH1DF 
CEACAM16 Carcinoembryonic antigen-related cell adhesion molecule 
16 
DFNA4B 
CIB2 Calcium and integrin binding family member 2 DFNB48 
USH1J 
CLDN14 Claudin 14 DFNB29   
CLPP Caseinolytic mitochondrial matrix peptidase proteolytic 
subunit 
Perrault syndrome 3 
CLRN1 Clarin 1 USH3A 
COCH Cochlin DFNA9 
COL11A2 Collagen, type XI, alpha 2 DFNA13, DFNB53 
Stickler syndrome 3 
DIABLO Diablo, IAP-binding mitochondrial protein DFNA64 
DFNA5 Deafness, autosomal dominant 5 DFNA5 
DFNB31 Deafness, autosomal recessive 31 DFNB31 
USH2D 
DFNB59 Deafness, autosomal recessive 59 DFNB59 
DIAPH1 Diaphanous-related formin 1 DFNA1 
EDN3 Endothelin 3 Waardenburg syndrome 4B 
EDNRB Endothelin receptor type B ABCD syndrome  
Waardenburg syndrome 4A 
ESPN Espin DFNB36 
ESRRB Oestrogen-related receptor beta DFNB35 
EYA1 EYA transcriptional coactivator and phosphatase 1 Branchiootic syndrome 1 
Branchiootorenal syndrome 1 
Otofaciocervical syndrome 1 
EYA4 EYA transcriptional coactivator and phosphatase 4 DFNA10 
GIPC3 GIPC PDZ domain containing family, member 3 DFNB15 




Ichthyosis hystrix-like with deafness 
syndrome 
GJB6 Gap junction protein, beta 6, 30kDa DFNA3B, DFNB1B 
GPR98 Adhesion G protein-coupled receptor V1 USH2C 
GPSM2 G-protein signalling modulator 2 Chudley-McCullough syndrome 
GRHL2 Grainyhead-like 2 (Drosophila) DFNA28 
GRXCR1 Glutaredoxin, cysteine rich 1 DFNB25 
HARS2 Histidyl-tRNA synthetase 2, mitochondrial Perrault syndrome 2 
HSD17B4 Hydroxysteroid (17-beta) dehydrogenase 4 Perrault syndrome 1 
HGF Hepatocyte growth factor (hepapoietin A; scatter factor) DFNB39 
ILDR1 Immunoglobulin-like domain containing receptor 1 DFNB42 
KARS Lysyl-tRNA synthetase DFNB89 
KCNE1 Potassium channel, voltage gated subfamily E regulatory 
beta subunit 1 
Jervell and Lange-Nielsen syndrome 2 
KCNQ1 Potassium channel, voltage gated KQT-like subfamily Q, 
member 1 
Jervell and Lange-Nielsen syndrome 1 
KCNQ4 Potassium channel, voltage gated KQT-like subfamily Q, 
member 4 
DFNA2A 




         Table J1 continued on p153 
155 
 
Table J1 (cont.): Deafness-associated gene panel 
Gene symbol Gene name Type(s) of deafness 
LARS2 Leucyl-tRNA synthetase 2, mitochondrial Perrault syndrome 4 
LHFPL5 Lipoma HMGIC fusion partner-like 5 DFNB67 
LOXHD1 Lipoxygenase homology domains 1 DFNB77 
LRTOMT Leucine rich transmembrane and O-methyltransferase 
domain containing 
DFNB63 
MARVELD2 MARVEL domain containing 2 DFNB49 
MIR96 MicroRNA 96 DFNA50 
MITF Microphthalmia-associated transcription factor Tietz syndrome  
Waardenburg syndrome 2A 
Waardenburg syndrome 2, with ocular 
albinism, autosomal recessive  
MSRB3 Methionine sulfoxide reductase B3 DFNB74 
MTRNR1 Mitochondrially encoded 12S RNA Mitochondrial non-syndromic sensorineural 
deafness 
MT-TS1 Mitochondrially encoded tRNA serine 1 (UCN) Mitochondrial non-syndromic sensorineural 
deafness 
MYH14 Myosin, heavy chain 14, non-muscle DFNA4A 
MYH9 Myosin, heavy chain 9, non-muscle Alport syndrome  
DFNA17 
Epstein syndrome  
Fechtner syndrome 
MYO15A Myosin XVA DFNB3 
MYO3A Myosin IIIA DFNB30 
MYO6 Myosin VI DFNA22, DFNB37 
Deafness, sensorineural, with hypertrophic 
cardiomyopathy 
MYO7A Myosin VIIA USH1B 
DFNA11, DFNB2 
OTOA Otoancorin DFNB22 
OTOF Otoferlin DFNB9 
OTOG Otogelin DFNB18B 
OTOGL Otogelin-like DFNB84B 
P2RX2 Purinergic receptor P2X, ligand gated ion channel, 2 DFNA41 
PAX3 Paired box 3 Craniofacial-deafness-hand syndrome 
Waardenburg syndrome 1 
Waardenburg syndrome 3 
PCDH15 Protocadherin-related 15 DFNB23 
USH1F 
POU3F4 POU class 3 homeobox 4 DFNX2 
POU4F3 POU class 4 homeobox 3 DFNA15 
PRPS1 Phosphoribosyl pyrophosphate synthetase 1 ARTS syndrome  
DFNX1 
RDX Radixin DFNB24 
SERPINB6 Serpin peptidase inhibitor, clade b (ovalbumin), member 6 DFNB91 
SIX1 SIX homeobox 1 DFNA23 
SLC26A4 Solute carrier family 26 (anion exchanger), member 4 DFNB4 
Pendred syndrome 
SMPX Small muscle protein, X-linked DFNX4 
SOX10 SRY (Sex Determining Region Y)-box 10 Waardenburg syndrome 2E 
Waardenburg syndrome 4C 
STRC Stereocilin Deafness-infertility syndrome  
DFNB16 
SYNE4 Spectrin repeat containing, nuclear envelope family 
member 4 
DFNB76 
TBC1D24 TBC1 domain family, member 24 Deafness, onychodystrophy, osteodystrophy, 
mental retardation, and seizures syndrome 
DFNA65, DFNB86 
TECTA Tectorin alpha DFNA12, DFNB21 
TIMM8A Translocase of inner mitochondrial membrane 8 
homologue A (Yeast) 
Jensen syndrome  
Mohr-Tranebjaerg syndrome 
 
TMC1 Transmembrane channel-like 1 DFNA36, DFNB7 
TMIE Transmembrane inner ear DFNB6 
TMPRSS3 Transmembrane protease serine 3 DFNB8 
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Table J1 (cont.): Deafness-associated gene panel 
Gene symbol Gene name Type(s) of deafness 
TPRN Taperin DFNB79 
TRIOBP TRIO and F-actin binding protein DFNB28 
TSPEAR Thrombospondin-type laminin G domain and EAR repeats DFNB98 
USH1C Usher syndrome 1C (autosomal recessive, severe) DFNB18A  
USH1C  
USH1G Usher syndrome 1G (autosomal recessive) USH1G 
USH2A Usher syndrome 2A (autosomal recessive, mild) USH2A 
WFS1 Wolfram syndrome 1 (wolframin) DFNA6 
Wolfram syndrome 1 




TableJ2: ADME gene panel 
Gene symbol Gene name Class 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 Transporter 
ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 Transporter 
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Transporter 
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 Transporter 
ABCB5 ATP-binding cassette, sub-family B (MDR/TAP), member 5 Transporter 
ABCB6 ATP-binding cassette, sub-family B (MDR/TAP), member 6 Transporter 
ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 7 Transporter 
ABCB8 ATP-binding cassette, sub-family B (MDR/TAP), member 8 Transporter 
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Transporter 
ABCC10 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 Transporter 
ABCC11 ATP-binding cassette, sub-family C (CFTR/MRP), member 11 Transporter 
ABCC12 ATP-binding cassette, sub-family C (CFTR/MRP), member 12 Transporter 
ABCC13 ATP-binding cassette, sub-family C (CFTR/MRP), member 13 Transporter 
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Transporter 
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Transporter 
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 Transporter 
ABCC6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 Transporter 
ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 Transporter 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 Transporter 
ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 Transporter 
ADH1A Alcohol dehydrogenase 1A (class I), alpha polypeptide Phase I 
ADH1B Alcohol dehydrogenase IB (class I), beta polypeptide Phase I 
ADH1C Alcohol dehydrogenase 1C (class I), gamma polypeptide Phase I 
ADH4 Alcohol dehydrogenase 4 (class II), pi polypeptide Phase I 
ADH5 Alcohol dehydrogenase 5 (class III), chi polypeptide,methionyl aminopeptidase 1 Phase I 
ADH6 Alcohol dehydrogenase 6 (class V) Phase I 
ADH7 Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide Phase I 
ADHFE1 Alcohol dehydrogenase, iron containing, 1 Phase I 
AHR Aryl hydrocarbon receptor Modifier 
ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 Phase I 
ALDH1A2 Aldehyde dehydrogenase 1 family, member A2 Phase I 
ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 Phase I 
ALDH1B1 Aldehyde dehydrogenase 1 family, member B1 Phase I 
ALDH2 Aldehyde dehydrogenase 2 family (mitochondrial) Phase I 
ALDH3A1 Aldehyde dehydrogenase 3 family, memberA1 Phase I 
ALDH3A2 Aldehyde dehydrogenase 3 family, member A2 Phase I 
ALDH3B1 Aldehyde dehydrogenase 3 family, member B1 Phase I 
ALDH3B2 Aldehyde dehydrogenase 3 family, member B2 Phase I 
ALDH4A1 Aldehyde dehydrogenase 4 family, member A1 Phase I 
ALDH5A1 Aldehyde dehydrogenase 5 family, member A1 Phase I 
ALDH6A1 Aldehyde dehydrogenase 6 family, member A1 Phase I 
ALDH7A1 Aldehyde dehydrogenase 7 family, member A1 Phase I 
ALDH8A1 Aldehyde dehydrogenase 8 family, member A1 Phase I 
ALDH9A1 Aldehyde dehydrogenase 9 family, member A1 Phase I 
AOX1 Aldehyde oxidase 1 Phase I 
ARNT Aryl hydrocarbon receptor nuclear translocator Modifier 
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ARSA Arylsulfatase A Modifier 
ATP7A ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome) Modifier 
ATP7B ATPase, Cu++ transporting, beta polypeptide Modifier 
CAT Catalase Modifier 
CBR1 Carbonyl reductase 1 Phase I 
CBR3 Carbonyl reductase 3 Phase I 
CDA Cytidine deaminase Modifier 
CES1 Carboxylesterase 1 (monocyte/macrophage serine esterase 1) Phase I 
CES2 Carboxylesterase 2 (intestine, liver) Phase I 
CFTR Cystic fibrosis transmembrane conductance regulator Modifier 
CHST1 Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 Phase II 
CHST10 Carbohydrate sulfotransferase 10 Phase II 
CHST11 Carbohydrate (chondroitin 4) sulfotransferase 11 Phase II 
CHST12 Carbohydrate (chondroitin 4) sulfotransferase 12 Phase II 
CHST13 Carbohydrate (chondroitin 4) sulfotransferase 13 Phase II 
CHST2 Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 Phase II 
CHST3 Carbohydrate (chondroitin 6) sulfotransferase 3 Phase II 
CHST4 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4 Phase II 
CHST5 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 Phase II 
CHST6 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 Phase II 
CHST7 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 Phase II 
CHST8 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 Phase II 
CHST9 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 Phase II 
CYB5R3 Cytochrome B5 reductase 3 Phase I 
CYP11A1 Cytochrome P450, family 11, subfamily A, polypeptide 1 Phase I 
CYP11B1 Cytochrome P450, family 11, subfamily B, polypeptide 1 Phase I 
CYP11B2 Cytochrome P450, family 11, subfamily B, polypeptide 2 Phase I 
CYP17A1 Cytochrome P450, family 17, subfamily A, polypeptide 1 Phase I 
CYP19A1 Cytochrome P450, family 19, subfamily A, polypeptide 1 Phase I 
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 Phase I 
CYP20A1 Cytochrome P450, family 20, subfamily A, polypeptide 1 Phase I 
CYP20A1 Cytochrome P450, family 20, subfamily A, polypeptide 1 Phase I 
CYP21A2 Cytochrome P450, family 21, subfamily A, polypeptide 2 Phase I 
CYP24A1 Cytochrome P450, family 24, subfamily A, polypeptide 1 Phase I 
CYP26A1 Cytochrome P450, family 26, subfamily A, polypeptide 1 Phase I 
CYP26C1 Cytochrome P450, family 26, subfamily C, polypeptide 1 Phase I 
CYP27A1 Cytochrome P450, family 27, subfamily A, polypeptide 1 Phase I 
CYP27B1 Cytochrome P450, family 27, subfamily B, polypeptide 1 Phase I 
CYP2A13 Cytochrome P450, family 2, subfamily A, polypeptide 13 Phase I 
CYP2A7 Cytochrome P450, family 2, subfamily A, polypeptide 7 Phase I 
CYP2C18 Cytochrome P450, family 2, subfamily C, polypeptide 18 Phase I 
CYP2D7P1 Cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 1 Phase I 
CYP2F1 Cytochrome P450, family 2, subfamily F, polypeptide 1 Phase I 
CYP2J2 Cytochrome P450, family 2, subfamily J, polypeptide 2 Phase I 
CYP2R1 Cytochrome P450, family 2, subfamily R, polypeptide 1 Phase I 
CYP2S1 Cytochrome P450, family 2, subfamily S, polypeptide 1 Phase I 
CYP39A1 Cytochrome P450, family 39, subfamily A, polypeptide 1 Phase I 
CYP3A43 Cytochrome P450, family 3, subfamily A, polypeptide 43 Phase I 
CYP3A7 Cytochrome P450, family 3, subfamily A, polypeptide 7 Phase I 
CYP46A1 Cytochrome P450, family 46, subfamily A, polypeptide 1 Phase I 
CYP4A11 Cytochrome P450, family 4, subfamily A, polypeptide 11 Phase I 
CYP4B1 Cytochrome P450, family 4, subfamily B, polypeptide 1 Phase I 
CYP4F11 Cytochrome P450, family 4, subfamily F, polypeptide 11 Phase I 
CYP4F12 Cytochrome P450, family 4, subfamily F, polypeptide 12 Phase I 
CYP4F2 Cytochrome P450, family 4, subfamily F, polypeptide 2 Phase I 
CYP4F3 Cytochrome P450, family 4, subfamily F, polypeptide 3 Phase I 
CYP4F8 Cytochrome P450, family 4, subfamily F, polypeptide 8 Phase I 
CYP4Z1 Cytochrome P450, family 4, subfamily Z, polypeptide 1 Phase I 
CYP51A1 Cytochrome P450, family 51, subfamily A, polypeptide 1 Phase I 
CYP7A1 Cytochrome P450, family 7, subfamily A, polypeptide 1 Phase I 
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Gene symbol Gene name Class 
CYP7B1 Cytochrome P450, family 7, subfamily B, polypeptide 1 Phase I 
CYP8B1 Cytochrome P450, family 8, subfamily B, polypeptide 1 Phase I 
DDO D-aspartate oxidase Phase I 
DHRS1 Dehydrogenase/reductase (SDR family) member 1 Phase I 
DHRS12 Dehydrogenase/reductase (SDR family) member 12 Phase I 
DHRS13 Dehydrogenase/reductase (SDR family) member 13 Phase I 
DHRS2 Dehydrogenase/reductase (SDR family) member 2 Phase I 
DHRS3 Dehydrogenase/reductase (SDR family) member 3 Phase I 
DHRS4 Dehydrogenase/reductase (SDR family) member 4 Phase I 
DHRS4L1 Dehydrogenase/reductase (SDR family) member 4 like 1 Phase I 
DHRS4L2 Dehydrogenase/reductase (SDR family) member 4 like 2 Phase I 
DHRS7 Dehydrogenase/reductase (SDR family) member 7 Phase I 
DHRS7B Dehydrogenase/reductase (SDR family) member 7B Phase I 
DHRS7C Dehydrogenase/reductase (SDR family) member 7C Phase I 
DHRS9 Dehydrogenase/reductase (SDR family) member 9 Phase I 
DHRSX Dehydrogenase/reductase (SDR family) X-linked Phase I 
DPEP1 Dipeptidase 1 (renal) Phase I 
EPHX1 Epoxide hydrolase 1, microsomal (xenobiotic) Phase I 
EPHX2 Epoxide hydrolase 2, cytoplasmic Phase I 
FMO1 Flavin containing monooxygenase 1 Phase I 
FMO2 Flavin containing monooxygenase 2 Phase I 
FMO3 Flavin containing monooxygenase 3 Phase I 
FMO4 Flavin containing monooxygenase 4 Phase I 
FMO5 Flavin containing monooxygenase 5 Phase I 
FMO6P Flavin containing monooxygenase 6 Phase I 
GPX1 Glutathione peroxidase 1 Phase I 
GPX2 Glutathione peroxidase 2 (gastrointestinal) Phase I 
GPX3 Glutathione peroxidase 3 (plasma) Phase I 
GPX4 Glutathione peroxidase 4 (phospholipid hydroperoxidase) Phase I 
GPX5 Glutathione peroxidase 5 (epididymal androgen-related protein) Phase I 
GPX6 Glutathione peroxidase 6 (olfactory) Phase I 
GPX7 Glutathione peroxidase 7 Phase I 
GSR Glutathione reductase Phase I 
GSS Glutathione synthetase Phase I 
GSTA1 Glutathione S-transferase A1 Phase II 
GSTA2 Glutathione S-transferase A2 Phase II 
GSTA3 Glutathione S-transferase A3 Phase II 
GSTA4 Glutathione S-transferase A4 Phase II 
GSTA5 Glutathione S-transferase A5 Phase II 
GSTCD Glutathione S-transferase, C-terminal domain containing Phase II 
GSTK1 Glutathione S-transferase kappa 1 Phase II 
GSTM2 Glutathione S-transferase M2 (muscle), Glutathione S-transferase M4 Phase II 
GSTM3 Glutathione S-transferase M3 (brain) Phase II 
GSTM4 Glutathione S-transferase M4 Phase II 
GSTM5 Glutathione S-transferase M5 Phase II 
GSTO1 Glutathione S-transferase omega 1, Glutathione S-transferase omega 2 Phase II 
GSTO2 Glutathione S-transferase omega 2 Phase II 
GSTT2 Glutathione S-transferase theta 2 Phase II 
GSTZ1 Glutathione transferase zeta 1 (maleylacetoacetate isomerase) Phase II 
HAGH Hydroxyacylglutathione hydrolase Phase I 
HNF4A Hepatocyte nuclear factor 4, alpha Modifier 
HNMT Histamine N-methyltransferase Phase II 
HSD11B1 Hydroxysteroid (17-beta) Dehydrogenase 11 Phase I 
HSD17B11 Hydroxysteroid (17-beta) Dehydrogenase 11 Phase I 
HSD17B14 Hydroxysteroid (17-beta) Dehydrogenase 14 Phase I 
IAPP Islet amyloid polypeptide Modifier 
KCNJ11 Potassium inwardly-rectifying channel, subfamily J, member 11 Modifier 
LOC728667 Similar to Dehydrogenase/reductase (SDR family) member 2 isoform 1 Phase I 
LOC731356 Similar to Dehydrogenase/reductase (SDR family) member 4 like 2 Phase I 
LOC731931 Similar to Dehydrogenase/reductase (SDR family) member 2 isoform 1 Phase I 
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MAT1A Methionine adenosyltransferase I, alpha Modifier 
METAP1 Methionyl aminopeptidase 1 Phase I 
MGST1 Microsomal glutathione S-transferase 1 Phase II 
MGST2 Microsomal glutathione S-transferase 2 Phase II 
MGST3 Microsomal glutathione S-transferase 3 Phase II 
MPO Myeloperoxidase Modifier 
NNMT Nicotinamide N-methyltransferase Phase II 
NOS1 Nitric oxide synthase 1 (neuronal) Phase I 
NOS2A Nitric oxide synthase 2A (inducible, hepatocytes) Phase I 
NOS3 Nitric oxide synthase 3 (endothelial cell) Phase I 
NR1I2 Nuclear receptor subfamily 1, group I, member 2 Modifier 
NR1I3 Nuclear receptor subfamily 1, group I, member 3 Modifier 
PDE3A Phosphodiesterase 3A, cGMP-inhibited Phase I 
PDE3B Phosphodiesterase 3B, cGMP-inhibited Phase I 
PLGLB1 Plasminogen-like B1 Phase I 
PNMT Phenylethanolamine N-methyltransferase Phase II 
PON1 Paraoxonase 1 Phase I 
PON2 Paraoxonase 2 Phase I 
PON3 Paraoxonase 3 Phase I 
POR P450 (cytochrome) oxidoreductase Modifier 
PPARA Peroxisome proliferator-activated receptor alpha Modifier 
PPARD Peroxisome proliferative activated receptor, delta Modifier 
PPARG Peroxisome proliferative activated receptor, gamma Modifier 
RXRA Retinoid X receptor, alpha Modifier 
SERPINA7 Serpin peptidase inhibitor, clade A, member 7 Modifier 
SLC10A1 Solute carrier family 10 (sodium/bile acid cotransporter family), member 1 Transporter 
SLC10A2 Solute carrier family 10 (sodium/bile acid cotransporter family), member 2 Transporter 
SLC13A1 Solute carrier family 13 (sodium/sulfate symporters), member 1 Transporter 
SLC13A2 Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 Transporter 
SLC13A3 Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 Transporter 
SLC15A1 Solute carrier family 15 (oligopeptide transporter), member 1 Transporter 
SLC16A1 Solute carrier family 16 (monocarboxylic acid Transporter), member 1 Transporter 
SLC19A1 Solute carrier family 19 (folate transporter), member 1 Transporter 
SLC22A10 Solute carrier family 22 (organic anion/cation transporter), member 10 Transporter 
SLC22A11 Solute carrier family 22 (organic anion/cation transporter), member 11 Transporter 
SLC22A12 Solute carrier family 22 (organic anion/cation transporter), member 12 Transporter 
SLC22A13 Solute carrier family 22 (organic cation transporter), member 13 Transporter 
SLC22A14 Solute carrier family 22 (organic cation transporter), member 14 Transporter 
SLC22A15 Solute carrier family 22 (organic cation transporter), member 15 Transporter 
SLC22A16 Solute carrier family 22 (organic cation transporter), member 16 Transporter 
SLC22A17 Solute carrier family 22 (organic cation transporter), member 17 Transporter 
SLC22A18 Solute carrier family 22 (organic cation transporter), member 18 Transporter 
SLC22A18AS Solute carrier family 22 (organic cation transporter), member 18 antisense Transporter 
SLC22A3 Solute carrier family 22 (extraneuronal monoamine transporter), member 3 Transporter 
SLC22A4 Solute carrier family 22 (organic cation transporter), member 4 Transporter 
SLC22A5 Solute carrier family 22 (organic cation transporter), member 5 Transporter 
SLC22A7 Solute carrier family 22 (organic anion transporter), member 7 Transporter 
SLC22A8 Solute carrier family 22 (organic anion transporter), member 8 Transporter 
SLC22A9 Solute carrier family 22 (organic anion/cation transporter), member 9 Transporter 
SLC27A1 Solute carrier family 27 (fatty acid transporter), member 1 Transporter 
SLC28A1 Solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 Transporter 
SLC28A2 Solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 Transporter 
SLC28A3 Solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 Transporter 
SLC29A1 Solute carrier family 29 (nucleoside Transporter), member 1 Transporter 
SLC29A2 Solute carrier family 29 (nucleoside Transporter), member 2 Transporter 
SLC2A4 Solute carrier family 2 (facilitated glucose transporter), member 4 Transporter 
SLC2A5 Solute carrier family 2 (facilitated glucose/fructose transporter), member 5 Transporter 
SLC5A6 Solute carrier family 5 (sodium-dependent vitamin transporter) Transporter 
SLC6A6 Solute carrier family 6 (neurotransmitter transporter, taurine), member 6 Transporter 
SLC7A5 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 Transporter 
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SLC7A7 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 Transporter 
SLC7A8 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 Transporter 
SLCO1A2 Solute carrier organic anion transporter family, member 1A2 Transporter 
SLCO1C1 Solute carrier organic anion transporter family, member 1C1 Transporter 
SLCO2A1 Solute carrier organic anion transporter family, member 2A1 Transporter 
SLCO2B1 Solute carrier organic anion transporter family, member 2B1 Transporter 
SLCO3A1 Solute carrier organic anion transporter family, member 3A1 Transporter 
SLCO4A1 Solute carrier organic anion transporter family, member 4A1 Transporter 
SLCO4C1 Solute carrier organic anion transporter family, member 4C1 Transporter 
SLCO5A1 Solute carrier organic anion transporter family, member 5A1 Transporter 
SLCO6A1 Solute carrier organic anion transporter family, member 6A1 Transporter 
SOD1 Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) Modifier 
SOD2 Superoxide dismutase 2, mitochondrial Modifier 
SOD3 Superoxide dismutase 3, extracellular precursor Modifier 
SULF1 Sulfatase 1 Phase I 
SULT1A2 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 Phase II 
SULT1A3 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 Phase II 
SULT1B1 Sulfotransferase family, cytosolic, 1B, member 1 Phase II 
SULT1C1 Sulfotransferase family, cytosolic, 1C, member 1 Phase II 
SULT1C2 Sulfotransferase family, cytosolic, 1C, member 2 Phase II 
SULT1E1 Sulfotransferase family 1E, estrogen-preferring, member 1 Phase II 
SULT2A1 Sulfotransferase family, cytosolic, 2A, DHEA preferring, member 1 Phase II 
SULT2B1 Sulfotransferase family, cytosolic, 2B, member 1 Phase II 
SULT4A1 Sulfotransferase family 4A, member 1 Phase II 
TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) Transporter 
TAP2 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) Transporter 
UGT1A10 UDP glucuronosyltransferase 1 family, polypeptide A10 Phase II 
UGT1A3 UDP glucuronosyltransferase 1 family, polypeptide A3 Phase II 
UGT1A4 UDP glucuronosyltransferase 1 family, polypeptide A4 Phase II 
UGT1A5 UDP glucuronosyltransferase 1 family, polypeptide A5 Phase II 
UGT1A6 UDP glucuronosyltransferase 1 family, polypeptide A6 Phase II 
UGT1A7 UDP glucuronosyltransferase 1 family, polypeptide A7 Phase II 
UGT1A8 UDP glucuronosyltransferase 1 family, polypeptide A8 Phase II 
UGT1A9 UDP glucuronosyltransferase 1 family, polypeptide A9 Phase II 
UGT2A1 UDP glucuronosyltransferase 2 family, polypeptide A1 Phase II 
UGT2B10 UDP glucuronosyltransferase 2 family, polypeptide B10 Phase II 
UGT2B11 UDP glucuronosyltransferase 2 family, polypeptide B11 Phase II 
UGT2B28 UDP glucuronosyltransferase 2 family, polypeptide B28 Phase II 
UGT2B4 UDP glucuronosyltransferase 2 family, polypeptide B4 Phase II 
UGT8 UDP glycosyltransferase 8 (UDP-galactose ceramide galactosyltransferase) Phase II 
XDH Xanthine Dehydrogenase Phase I 
 
 
Table J3: DNA repair gene panel 
Gene symbol Gene name Function 
ALKBH2 AlkB, alkylation repair homologue 2 (E. Coli) Reversal of damage 
ALKBH3 AlkB, alkylation repair homologue 3 (E. Coli) Reversal of damage 
APEX1 APEX nuclease 1 BER 
APEX2 APEX nuclease 2 BER 
APLF Aprataxin and PNKP like factor BER 
APTX Aprataxin Processing of SS-DNA interruptions 
ATM ATM serine/threonine kinase Sensitivity to DNA damaging agents 
ATR ATR serine/threonine kinase ATM- and PI-3K-like essential kinase 
ATRIP ATR interacting protein ATR-interacting protein 
BLM Bloom syndrome, RecQ helicase-like Sensitivity to DNA damaging agents 
BRCA1 Breast cancer 1, early onset Homologous recombination 
BRCA2 Breast cancer 2, early onset Repair of DNA crosslinks and adducts 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 Repair of DNA crosslinks and adducts 
BER, base excision repair; MMR, mismatch repair; NER, nucleotide excision repair; SS, sinlge-stranded 
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Gene symbol Gene name Function 
C19orf40 Chromosome 19 open reading frame 40 Repair of DNA crosslinks and adducts 
C1orf86 Chromosome 1 open reading frame 86 Repair of DNA crosslinks and adducts 
CCNH Cyclin H NER 
CDK7 Cyclin-dependent kinase 7 NER 
CETN2 Centrin, EF-hand protein, 2 NER 
CHAF1A Chromatin assembly factor 1, subunit A (P150) Chromatin assembly 
CHEK1 Checkpoint kinase 1 Effector kinase 
CHEK2 Checkpoint kinase 2 Effector kinase 
CLK2 CDC-like kinase 2 S-phase check point 
DCLRE1A DNA cross-link repair 1A DNA crosslink repair 
DCLRE1B DNA cross-link repair 1B Related to SNM1 
DCLRE1C DNA cross-link repair 1C Non-homologous end-joining 
DDB1 Damage-specific DNA binding protein 1, 127kDa NER 
DDB2 Damage-specific DNA binding protein 2, 48kDa NER 
DMC1 DNA meiotic recombinase 1 Homologous recombination 
DUT Deoxyuridine triphosphatase Modulation of nucleotide pools 
EME1 Essential meiotic structure-specific endonuclease 1 Homologous recombination 
EME2 Essential meiotic structure-specific endonuclease 2 Homologous recombination 
ENDOV Endonuclease V Nuclease 
ERCC1 Excision repair cross-complementation group 1 NER 
ERCC2 Excision repair cross-complementation group 2 NER 
ERCC3 Excision repair cross-complementation group 3 NER 
ERCC4 Excision repair cross-complementation group 4 NER 
ERCC5 Excision repair cross-complementation group 5 NER 
ERCC6 Excision repair cross-complementation group 6 NER 
ERCC8 Excision repair cross-complementation group 8 NER 
EXO1 Exonuclease 1 5` exonuclease 
FAN1 FANCD2/FANCI-associated nuclease 1 5` nuclease 
FANCA Fanconi anaemia, complementation group A Repair of DNA crosslinks and adducts 
FANCB Fanconi anaemia, complementation group B Repair of DNA crosslinks and adducts 
FANCC Fanconi anaemia, complementation group C Repair of DNA crosslinks and adducts 
FANCD2 Fanconi anaemia, complementation group D2 Repair of DNA crosslinks and adducts 
FANCE Fanconi anaemia, complementation group E Repair of DNA crosslinks and adducts 
FANCF Fanconi anaemia, complementation group F Repair of DNA crosslinks and adducts 
FANCG Fanconi anaemia, complementation group G Repair of DNA crosslinks and adducts 
FANCI Fanconi anaemia, complementation group I Repair of DNA crosslinks and adducts 
FANCL Fanconi anaemia, complementation group L Repair of DNA crosslinks and adducts 
FANCM Fanconi anaemia, complementation group M Repair of DNA crosslinks and adducts 
FEN1 Flap structure-specific endonuclease 1 5` nuclease 
GEN1 GEN1 Holliday junction 5` flap endonuclease Homologous recombination 
GTF2H1 General transcription factor IIH, polypeptide 1, 62kDa NER 
GTF2H2 General transcription factor IIH, polypeptide 2, 44kDa NER 
GTF2H3 General transcription factor IIH, polypeptide 3, 34kDa NER 
GTF2H4 General transcription factor IIH, polypeptide 4, 52kDa NER 
GTF2H5 General transcription factor IIH, polypeptide 5 NER 
H2AFX H2A histone family, member X Phosphorylated after DNA damage 
HELQ Helicase, POLQ-like DNA helicase 
HLTF Helicase-like transcription factor E3 ubiquitin ligase 
HUS1 HUS1 checkpoint homologue (S. Pombe) Sensor of damaged DNA 
LIG1 Ligase I, DNA, ATP-dependent NER 
LIG3 Ligase III, DNA, ATP-dependent BER 
LIG4 Ligase IV, DNA, ATP-dependent Non-homologous end-joining 
MAD2L2 MAD2 mitotic arrest deficient-like 2 (Yeast) DNA polymerase catalytic subunit 
MBD4 Methyl-CpG binding domain protein 4 BER 
MDC1 Mediator Of DNA-damage checkpoint 1 Mediator of DNA damage checkpoint 
MGMT O-6-methylguanine-DNA methyltransferase Reversal of damage 
MLH1 MutL homologue 1 MMR 
MLH3 MutL homologue 3 MMR 
BER, base excision repair; MMR, mismatch repair; NER, nucleotide excision repair; SS, sinlge-stranded 
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MMS19 MMS19 nucleotide excision repair homologue (S. 
Cerevisiae) 
NER 
MNAT1 MNAT CDK-activating kinase assembly factor 1 NER 
MPG N-methylpurine-DNA glycosylase BER 
MPLKIP M-phase specific PLK1 interacting protein Sensitivity to DNA damaging agents 
MRE11A MRE11 meiotic recombination 11 homologue A (S. 
Cerevisiae) 
Homologous recombination 
MSH2 MutS homologue 2 MMR 
MSH3 MutS homologue 3 MMR 
MSH4 MutS homologue 4 MMR 
MSH5 MutS homologue 5 MMR 
MSH6 MutS homologue 6 MMR 
MUS81 MUS81 structure-specific endonuclease subunit Homologous recombination 
MUTYH MutY homologue BER 
NABP2 Nucleic acid binding protein 2 SS-DNA binding protein 
NBN Nibrin Homologous recombination 
NEIL1 Nei endonuclease VIII-like 1 (E. Coli) BER 
NEIL2 Nei endonuclease VIII-like 2 (E. Coli) BER 
NEIL3 Nei endonuclease VIII-like 3 (E. Coli) BER 
NHEJ1 Nonhomologous end-joining factor 1 Non-homologous end-joining 
NTHL1 Nth endonuclease III-like 1 (E. Coli) BER 
NUDT1 Nudix (nucleoside diphosphate linked moiety X)-type motif 1 Modulation of nucleotide pools 
OGG1 8-Oxoguanine DNA glycosylase BER 
PALB2 Partner and localiser Of BRCA2 Repair of DNA crosslinks and adducts 
PARP1 Poly (ADP-ribose) polymerase 1 Protects strand interruptions 
PARP2 Poly (ADP-ribose) polymerase 2 Protects strand interruptions 
PARP3 Poly (ADP-ribose) polymerase family, member 3 Protects strand interruptions 
PCNA Proliferating cell nuclear antigen DNA polymerase catalytic subunit 
PER1 Period circadian clock 1 S-phase check point 
PMS1 PMS1 postmeiotic segregation increased 1 (S. Cerevisiae) MMR 
PMS2 PMS2 postmeiotic segregation increased 2 (S. Cerevisiae) MMR 
PMS2P3 Postmeiotic segregation increased 2 pseudogene 3 MMR 
PNKP Polynucleotide kinase 3'-phosphatase BER 
POLB Polymerase (DNA directed), beta DNA polymerase catalytic subunit 
POLD1 Polymerase (DNA directed), delta 1, catalytic subunit DNA polymerase catalytic subunit 
POLE Polymerase (DNA directed), epsilon, catalytic subunit DNA polymerase catalytic subunit 
POLG Polymerase (DNA directed), gamma DNA polymerase catalytic subunit 
POLH Polymerase (DNA directed), eta DNA polymerase catalytic subunit 
POLI Polymerase (DNA directed), iota DNA polymerase catalytic subunit 
POLK Polymerase (DNA directed), kappa DNA polymerase catalytic subunit 
POLL Polymerase (DNA directed), lambda DNA polymerase catalytic subunit 
POLM Polymerase (DNA directed), mu DNA polymerase catalytic subunit 
POLN Polymerase (DNA directed), nu DNA polymerase catalytic subunit 
POLQ Polymerase (DNA directed), theta DNA polymerase catalytic subunit 
PRKDC Protein kinase, DNA-activated, catalytic polypeptide Non-homologous end-joining 
PRPF19 Pre-mRNA processing factor 19 DNA crosslink repair 
RAD1 RAD1 checkpoint DNA exonuclease Sensor of damaged DNA 
RAD17 RAD17 homologue (S. Pombe) Sensor of damaged DNA 
RAD18 RAD18 E3 ubiquitin protein ligase E3 ubiquitin ligase 
RAD23A RAD23 homologue A (S. Cerevisiae) NER 
RAD23B RAD23 homologue B (S. Cerevisiae) NER 
RAD50 RAD50 homologue (S. Cerevisiae) Homologous recombination 
RAD51 RAD51 recombinase Homologous recombination 
RAD51B RAD51 paralogue B Homologous recombination 
RAD51C RAD51 paralogue C Repair of DNA crosslinks and adducts 
RAD51D RAD51 paralogue D Homologous recombination 
RAD52 RAD52 homologue (S. Cerevisiae) Homologous recombination 
RAD54B RAD54 homologue B (S. Cerevisiae) Homologous recombination 
RAD54L RAD54-like (S. Cerevisiae) Homologous recombination 
RAD9A RAD9 homologue A (S. Pombe) Sensor of damaged DNA 
BER, base excision repair; MMR, mismatch repair; NER, nucleotide excision repair; SS, sinlge-stranded 
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Gene symbol Gene name Function 
RDM1 RAD52 motif containing 1 Similar to RAD52 
RECQL RecQ helicase-like DNA helicase 
RECQL4 RecQ protein-like 4 Sensitivity to DNA damaging agents 
RBBP8 Retinoblastoma binding protein 8 Homologous recombination 
RECQL5 RecQ protein-like 5 DNA helicase 
REV1 REV1, polymerase (DNA directed) DNA polymerase catalytic subunit 
REV3L REV3-like, polymerase (DNA directed), zeta, catalytic 
subunit 
DNA polymerase catalytic subunit 
RIF1 Replication timing regulatory factor 1 Suppressor of 5`-end-resection 
RNF168 Ring finger protein 168, E3 ubiquitin protein ligase E3 ubiquitin ligase 
RNF4 Ring finger protein 4 E3 ubiquitin ligase 
RNF8 Ring finger protein 8, E3 ubiquitin protein ligase E3 ubiquitin ligase 
RPA1 Replication protein A1, 70kDa NER 
RPA2 Replication protein A2, 32kDa NER 
RPA3 Replication protein A3, 14kDa NER 
RPA4 Replication protein A4, 30kDa Similar to RPA2 
RRM2B Ribonucleotide reductase M2 B (TP53 inducible) Modulation of nucleotide pools 
SETMAR SET domain and mariner transposase fusion gene Histone methylase and nuclease 
SHFM1 Split hand/foot malformation (ectrodactyly) type 1 Homologous recombination 
SHPRH SNF2 histone linker PHD RING helicase, E3 ubiquitin 
protein ligase 
E3 ubiquitin ligase 
SLX1A SLX1 structure-specific endonuclease subunit homologue A 
(S. Cerevisiae) 
Homologous recombination 
SLX1B SLX1 structure-specific endonuclease subunit homologue B 
(S. Cerevisiae) 
Homologous recombination 
SLX4 SLX4 structure-specific endonuclease subunit Repair of DNA crosslinks and adducts 
SMUG1 Single-strand-selective monofunctional uracil-DNA 
glycosylase 1 
BER 
SPO11 SPO11 meiotic protein covalently bound to DSB Endonuclease 
SPRTN SprT-like N-terminal domain Ubiquitination processing 
TDG Thymine-DNA glycosylase BER 
TDP1 Tyrosyl-DNA phosphodiesterase 1 Repair of topoisomerase crosslinks 
TDP2 Tyrosyl-DNA phosphodiesterase 2 Repair of topoisomerase crosslinks 
TOPBP1 Topoisomerase (DNA) II binding protein 1 DNA damage checkpoint control 
TP53 Tumour protein P53 Cell cycle regulation 
TP53BP1 Tumour protein P53 binding protein 1 Chromatin-binding checkpoint protein 
TREX1 Three prime repair exonuclease 1 3` exonuclease 
TREX2 Three prime repair exonuclease 2 3` exonuclease 
UBE2A Ubiquitin-conjugating enzyme E2A Ubiquitin conjugation 
UBE2B Ubiquitin-conjugating enzyme E2B Ubiquitin conjugation 
UBE2N Ubiquitin-conjugating enzyme E2N Ubiquitin conjugation 
UBE2V2 Ubiquitin-conjugating enzyme E2 variant 2 Ubiquitin conjugation 
UNG Uracil-DNA glycosylase BER 
UVSSA UV-stimulated scaffold protein A NER 
WRN Werner syndrome, RecQ helicase-like Sensitivity to DNA damaging agents 
XAB2 XPA binding protein 2 NER 
XPA Xeroderma pigmentosum, complementation group A NER 
XPC Xeroderma pigmentosum, complementation group C NER 
XRCC1 X-ray repair complementing defective repair in Chinese 
hamster cells 1 
BER 
XRCC2 X-ray repair complementing defective repair in Chinese 
hamster cells 2 
Homologous recombination 
XRCC3 X-ray repair complementing defective repair in Chinese 
hamster cells 3 
Homologous recombination 
XRCC4 X-ray repair complementing defective repair in Chinese 
hamster cells 4 
Non-homologous end-joining 
XRCC5 X-ray repair complementing defective repair in Chinese 
hamster cells 5 (double-strand-break rejoining) 
Non-homologous end-joining 
XRCC6 X-ray repair complementing defective repair in Chinese 
hamster cells 6 
Non-homologous end-joining 




Table J4: Cisplatin response gene panel 
Gene symbol Gene Name Nature of association 
ABCB1 ATP-binding cassette, sub-family B, member 1 Transmembrane drug transporter 
ABCC3 ATP-binding cassette, sub-family C, member 3 Transmembrane drug transporter 
ACYP2 Acylphosphatase 2, muscle type Potential modifier of ototoxicity 
ATP7A ATPase, Cu++ transporting, alpha polypeptide Transmembrane drug transporter 
ATP7B ATPase, Cu++ transporting, beta polypeptide Transmembrane drug transporter 
BCL2 B-cell CLL/lymphoma 2 Induction of apoptosis 
CDH13 Cadherin 13 Anti-oxidant response 
CFTR Cystic fibrosis transmembrane conductance regulator Anti-oxidant response 
COMT Catechol-O-methyltransferase Potential modifier of ototoxicity 
EIF3A Eukaryotic translation initiation factor 3, subunit A  DNA damage response 
ERCC1 Excision repair cross-complementation group 1 DNA damage response 
ERCC2 Excision repair cross-complementation group 2 DNA damage response 
ERCC4 Excision repair cross-complementation group 4 DNA damage response 
ERCC5 Excision repair cross-complementation group 5 DNA damage response 
ERCC6 Excision repair cross-complementation group 6 DNA damage response 
GDNF Glial cell derived neurotrophic factor Potential otoprotectant 
GSTA1 Glutathione S-transferase alpha 1 Drug detoxification or inactivation 
GSTM1 Glutathione S-transferase mu 1 Drug detoxification or inactivation 
GSTM3 Glutathione S-transferase mu 3 Drug detoxification or inactivation 
GSTP1 Glutathione S-transferase pi 1 Drug detoxification or inactivation 
GSTT1 Glutathione S-transferase theta 1 Drug detoxification or inactivation 
HMOX1 Haem oxygenase 1 Anti-oxidant response 
LRP2 Low density lipoprotein receptor-related protein 2 Transmembrane drug transporter 
NFE2L2 Nuclear factor, erythroid 2-like 2  Anti-oxidant response 
NOX1 NADPH oxidase 1 Mediator of oxidative stress 
NOX3 NADPH oxidase 3 Mediator of oxidative stress 
NOX4 NADPH oxidase 4 Mediator of oxidative stress 
NQO1 NAD(P)H dehydrogenase, quinone 1 Anti-oxidant response 
NTF3 Neurotrophin 3 Potential otoprotectant 
OTOS Otospiralin Potential modifier of ototoxicity 
REV1 REV1, polymerase DNA damage response 
REV3L REV3-like, polymerase, zeta, catalytic subunit DNA damage response 
SLC31A1 Solute carrier family 31, member 1 Transmembrane drug transporter 
SLC31A2 Solute carrier family 31, member 2 Transmembrane drug transporter 
SLC47A1 Solute carrier family 47, member 1 Transmembrane drug transporter 
TPMT Thiopurine S-methyltransferase Potential modifier of ototoxicity 
TRPA1 Transient receptor potential cation channel, subfamily A, member 1 Transmembrane drug transporter 
TRPV1 Transient receptor potential cation channel, subfamily V, member 1 Transmembrane drug transporter 
XIAP X-linked inhibitor of apoptosis Induction of apoptosis 
XPC Xeroderma pigmentosum, complementation group C DNA damage response 
XRCC1 X-ray repair complementing defective repair in Chinese hamster 
cells 1 





Appendix K: Gene-disease relationships for WES data 
 
 
Table K1: All diseases associated with the genes identified in the variant-level analysis 
Gene OMIM disorder(s) MalaCards disease(s) 
APC2 - Familial adenomatous polyposis 
AQP7 Glycerol QTL 
 
Meniere's disease     
Endolymphatic hydrops     
Morbid obesity     
Constipation 
Obesity     
Insulin resistance 
BCKDHA Maple syrup urine disease Maple syrup urine disease     
Pseudogout     
Bacteriuria     
Urethral syndrome 
BORA - - 
C3 C3 deficiency 
Haemolytic uremic syndrome, atypical, susceptibility 
to, 5 
Macular degeneration, age-related, 9 
Haemolytic uraemic syndrome, atypical 5    
C3 deficiency     
Age-related macular degeneration 9     
C3 deficiency, autosomal recessive 
C3-related atypical haemolytic-uremic syndrome     
Systemic lupus erythematosus     
Multiple sclerosis     
Age related macular degeneration 




Pneumococcal meningitis     
Capillary leak syndrome     
Paediatric systemic lupus erythematosus 
Dense deposit disease 
Tuberculosis     
Retinal drusen     
Atypical haemolytic-uraemic syndrome 
Afibrinogenaemia 
CHAF1A - Cornelia de Lange syndrome 
COL9A1 Epiphyseal dysplasia, multiple, 6 
Stickler syndrome, type IV 
Interstitial keratitis 
Stickler syndrome, type IV     
COL9A1-related multiple epiphyseal dysplasia 
Epiphyseal dysplasia, multiple, 6 




Pseudoachondroplasia     
Stickler syndrome type 1     
Stickler syndrome     
Multiple epiphyseal dysplasia 
Spinal stenosis     
Osteochondritis dissecans     
Multiple epiphyseal dysplasia, dominant     
Pierre Robin sequence 
CREB3L2 - Myxofibrosarcoma 
CTBP2 - - 
CUBN Megaloblastic anaemia-1, Finnish type 
Megaloblastic anaemia-1, Norwegian type 
Megaloblastic anaemia     
Megaloblastic anaemia-1, Finnish type     
Dent's disease     
Nephropathic cystinosis 
Megaloblastic anaemia-1, Norwegian type 
3 methylglutaconic aciduria type I 
CYFIP1 - Angelman syndrome 
Fragile X syndrome 
DGKQ - Dominant optic atrophy 
DMGDH Dimethylglycine dehydrogenase deficiency Dimethylglycine dehydrogenase deficiency 
Sarcosinemia 
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Table K1 (cont.): All diseases associated with the genes identified in the variant-level analysis 
Gene OMIM disorder(s) MalaCards disease(s) 
DYSF Muscular dystrophy, limb-girdle, type 2B 
Myopathy, distal, with anterior tibial onset 
Miyoshi muscular dystrophy 1 
Miyoshi muscular dystrophy 1     
Miyoshi myopathy     
Limb-girdle muscular dystrophy     
Dysferlinopathy 
Limb-girdle muscular dystrophy, type 2b     
Myopathy, distal, with anterior tibial onset     
Congenital myopathy, paradas type     
Distal muscular dystrophy 
Muscular dystrophy     
Rippling muscle disease     
Sarcoglycanopathies     
Dystrophinopathies 
Myopathy 
DYTN - - 
DYX1C1 Dyslexia, susceptibility to, 1 
Ciliary dyskinesia, primary, 25 
Ciliary dyskinesia, primary, 25     
Dyslexia 1     
Dyslexia     
Articulation disorder 
Ciliary dyskinesia, primary, 11 
EIF5B - - 
EP300 Colorectal cancer, somatic 
Rubinstein-Taybi syndrome 2  
Rubinstein-Taybi syndrome 2 




Acute monocytic leukaemia 
Monocytic leukaemia 
Colorectal cancer, somatic 
Breast cancer 
FCRL6 - Viral pneumonia 
Chronic lymphocytic leukaemia 
FOXH1 - FOXH1-related holoprosencephaly 
Ventricular septal defect 
Septopreoptic holoprosencephaly 
Midline interhemispheric variant of holoprosencephaly 
Alobar holoprosencephaly 
Single median maxillary central incisor 
Semilobar holoprosencephaly 
Lobar holoprosencephaly 
FOXO3 - Acute leukaemia 
Rhabdomyosarcoma 
Neuroblastoma 
FREM2 Fraser syndrome Unilateral renal agenesis 




GP6 Bleeding disorder, platelet-type, 11 Cervix uteri carcinoma in situ 
Glycoprotein 1a deficiency     
Bleeding disorder, platelet-type, 11 
Gray platelet syndrome 
Coronary thrombosis 
ING1 Squamous cell carcinoma, head and neck, somatic Squamous cell carcinoma of the head and neck 
Squamous cell carcinoma, head and neck, somatic 
KIAA1429 - Oxyphilic adenoma 
KRT4 White sponge nevus 1 Hereditary mucosal leukokeratosis 
Leukoplakia     
White sponge nevus 1     
White sponge nevus of cannon, krt4-related 
Hymenolepiasis     
Oral leukoplakia     
Basaloid squamous cell carcinoma 
Epidermodysplasia verruciformis 
Pterygium     
Oral lichen planus 
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Table K1 (cont.): All diseases associated with the genes identified in the variant-level analysis 
Gene OMIM disorder(s) MalaCards disease(s) 
MUC5B Pulmonary fibrosis, idiopathic, susceptibility to Idiopathic pulmonary fibrosis 





Pulmonary fibrosis, familial 
MXD4 - - 
NID2 - - 
OR4B1 - - 
OR52H1 - - 
PDE4DIP - Eosinophilia 
PER1 - Advanced sleep phase syndrome 
Delayed sleep phase syndrome 
RELA - Ependymoma 
Hypersplenism 
REXO1 - - 
SDHC Gastrointestinal stromal tumour 
Paraganglioma and gastric stromal sarcoma 
Paragangliomas 3 
Paragangliomas 3     
SDHC-related paraganglioma and gastric stromal 
sarcoma     
Gastrointestinal stromal tumour     
Carotid body tumour 
Chondroma     
Carney triad     
Pheochromocytoma     
Hereditary paraganglioma-pheochromocytoma 
syndromes 
Paraganglioma     
Extra-adrenal pheochromocytoma     
Paragangliomas 4     
Paraganglioma and gastric stromal sarcoma 
Gastrointestinal stromal tumour, somatic 
Gastrointestinal stromal tumours, familial 
Familial medullary thyroid carcinoma 
Cowden syndrome 1 
Neural crest tumour     
Familial renal cell carcinoma     
Multiple endocrine neoplasia     
Von Hippel-Lindau disease 
SF3A2 - - 





Spherocytosis, type 3 
Elliptocytosis 2     
Pyropoikilocytosis     
Common hereditary elliptocytosis 
SPTA1-related spherocytosis 
Spherocytosis, type 3 
Pyropoikilocytosis hereditary     
Hereditary elliptocytosis     
Homozygous hereditary elliptocytosis 
Hereditary spherocytosis 
Hypophosphatasia 
TJP1 - Malaria 
ZFYVE19 - - 















Table K2: All diseases associated with the new genes identified in the gene-level analysis 
Gene OMIM disorders MalaCards diseases 
AATK - Neuroblastoma 
ASPM Microcephaly 5, primary, autosomal recessive Microcephaly 
Primary autosomal recessive microcephaly type 5 
Primary autosomal recessive microcephalies and seckel 
syndrome spectrum disorders     
Oculocerebrorenal syndrome 
C4orf33 - - 
CACNA1F Aland Island eye disease  
Cone-rod dystropy, X-linked, 3  
Night blindness, congenital stationary 
(incomplete), 2A, X-linked 
Aland island eye disease     
Eye disease     
CACNA1F-related X-linked congenital stationary night 
blindness     
Night blindness, congenital stationary , 2a, x-linked 
CDHR5 - - 
CNGB1 Retinitis pigmentosa 45 Retinitis pigmentosa 45     
CNGB1-related retinitis pigmentosa     
Retinitis pigmentosa     
Achromatopsia 
COL19A1 - - 
ERBB2 Adenocarcinoma of lung, somatic  
Gastric cancer, somatic  
Glioblastoma, somatic  
Ovarian cancer, somatic 
Breast scirrhous carcinoma     
Lipid-rich carcinoma     
Ductal carcinoma in situ     
Transitional cell carcinoma 
FAM171B - - 
FBXO32 - Myopathy of critical illness     
Acquired Immunodeficiency Syndrome 
KRT79 - - 
KRTAP5-2 - - 
OR4Q3 - - 
PCSK1N - Amyotrophic lateral sclerosis-parkinsonism/dementia complex 
1     
Obesity     
Amyotrophic lateral sclerosis-parkinsonism/dementia complex 
SLC22A1 - Chronic myeloid leukaemia 
SLC25A45 - - 
SRPK3 - - 
TBC1D21 - - 
TPST2 - - 
TRPM2 - - 
TUBA3E - - 
WFS1 ?Cataract 41  
Deafness, autosomal dominant 6/14/38 
Wolfram syndrome 
Wolfram-like syndrome, autosomal dominant  
Diabetes mellitus, noninsulin-dependent, 
association with 
Chromosome 4p deletion     
WFS1-related disorders     





Appendix L: Panel-based analysis of all unique variants scoring ≥ 4 
 
Table L1: Deafness gene panel analysis of all variants with score ≥ 4 in uniquely mutated genes 
Gene Coordinates Ref  Var  Consequencea Score dbSNP ID DPb Q scoreb Patient(s) Group MAF MAF (Afr) 
CDH23 10:73567085 G A Non-synonymous 6 rs376189742 393 717.97 4 A - - 
CIB2 15:78401595 A AT Frameshift insertion 8 - 17 36.92 4 A - - 

























COL11A2 6:33136310 G T Non-synonymous 6 rs2229784 76 263.99 10 B 0.06 0.09 
DFNB31 9:117168688 C T Non-synonymous 4 rs138767834 306 590.02 6 B < 0.01 < 0.01 
ESRRB 14:76957918 A C Non-synonymous 5 - 487 631.58 1 A - - 
GPSM2 1:109465165 ACTTCTT ACTTC Frameshift deletion 8 - 33 287.79 3 A - - 
KCNQ1 11:2608893 C G Non-synonymous 5 rs28730756 15 73.80 3 A 0.01 0.02 
LOXHD1 18:44109144 C T Non-synonymous 4 rs187587197 256 427.69 1 A < 0.01 < 0.01 
MYO3A 10:26434455 G T Non-synonymous 6 rs33947968 25 105.31 3 A 0.03 0.01 
MYO7A 11:76890902 G A Non-synonymous 7 rs371029653 128 507.65 7 B - - 
PAX3 2:223158963 G T Non-synonymous 4 rs376921556 111 326.53 6 B - - 





































a consequence types in bold type are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 

















Table L2: ADME gene panel analysis of all variants with score ≥ 4 in uniquely mutated genes 
Gene Coordinates Ref  Var  Consequencea Score dbSNP ID DPb Q scoreb Patient(s) Group MAF MAF (Afr) 
ABCA1 9:107574883 C G Non-synonymous 4 rs147743782 26 39.21 4 A < 0.01 < 0.01 
ABCB11 2:169783728 C T Non-synonymous 6 rs1521808 138 329.52 6 B 0.01 0.04 
ABCB6 2:220078890 C T Non-synonymous 8 rs111677240 131 1249.81 6 B - - 
ABCC10 6:43400685 G A Non-synonymous 6 rs140348023 580 936.79 2 A < 0.01 < 0.01 
ABCC12 16:48122456 C T Non-synonymous 7 rs77775459 102 241.95 1 A 0.02 0.06 
ABCC5 3:183696402 AG A Frameshift deletion 8 - 37 166.46 10 B - - 
ABCC6 16:16259596 G A Non-synonymous 6 rs41278174 257.5 625.49 3,4 A 0.01 < 0.01 
ABCG1 21:43640145 GAC G Frameshift deletion 8 - 78 231.89 8 B - - 
ADH1B 4:100229017 G A Non-synonymous 4 rs2066702 128 234.16 5 A 0.05 0.19 
ADH4 4:100062706 G A Non-synonymous 4 rs111700010 132 268.48 4 A < 0.01 < 0.01 

























CHST13 3:126260696 G C Non-synonymous 4 - 7 15.78 7 B - - 
CHST3 10:73767863 GC G Frameshift deletion 8 - 9 84.69 9 B - - 
CYP1B1 2:38301588 A G Non-synonymous 4 rs112059845 107 240.23 3 A - - 
CYP11B1 8:143958274 C G Non-synonymous 6 - 159 297.07 11 B - - 
CYP2A7 19:41381646 GA G Frameshift deletion 8 - 55 522.51 7 B - - 
CYP2C18 10:96447562 T A Stop-gain 8 rs41291550 177 127.97 2 A 0.03 0.08 






























































DHRS4 14:24424366 C CA Frameshift insertion 8 - 299 2565.30 3 A - - 
DHRS4L2 14:24459477 C T Non-synonymous 4 rs61729874 141 252.16 8 B 0.02 0.07 
GSTA2 6:52621101 C T Non-synonymous 4 rs75013911 52 118.82 11 B < 0.01 0.01 
GSTA3 6:52767205 T G Non-synonymous 5 rs1052661 43 171.48 8 B 0.04 0.14 
GSTA4 6:52852179 CTTTT C Frameshift deletion 8 - 51 78.08 4 A - - 
HAGH 16:1859304 A C Non-synonymous 8 - 45 129.05 7 B - - 
HSD17B11 4:88258483 T TC Frameshift insertion 8 - 14 123.53 10 B - - 
MPO 17:56356527 T TA Frameshift insertion 8 - 27 169.49 2 A - - 
NOS3 7:150696110 A AG Frameshift insertion 8 - 117.5 696.35 6,11 B - - 
NR1I2 3:119526203 G A Non-synonymous 4 rs12721607 219 468.13 7,11 B 0.01 < 0.01 
PDE3B 11:14666054 CCG C Frameshift deletion 8 - 71 24.33 11 B - - 
a consequence types in bold type are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 
Afr, 1000 Genomes Project African population; DP, read depth; ID, identifier; MAF, minor allele frequency; Q score, quality score; Ref, reference allele; Var, variant allele 
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Table L2 (cont.): ADME gene panel analysis of all variants with score ≥ 4 in uniquely mutated genes 

























RXRA 9:137320963 A AC Frameshift insertion 8 - 14 32.39 7 B - - 
SERPINA7 X:105280779 C T Non-synonymous 5 - 143 1366.51 1 A - - 





























































SLC22A14 3:38347916 G A Non-synonymous 6 - 164 363.63 4 A - - 
SLC22A16 6:110752377 TG TA Non-synonymous 8 - 72 377.12 7 B - - 
SLC2A4 17:7186627 C CG Frameshift insertion 8 - 12 16.22 7 B - - 
SLC7A7 14:23282121 C A Non-synonymous 7 - 66 234.57 11 B - - 

























SULT1C2 2:108924881 GA G Frameshift deletion 8 rs143858235 189 276.46 6 B 0.01 0.05 
TAP2 6:32803106 G A Non-synonymous 6 rs138586326 220 420.14 2 A < 0.01 0.02 
UGT2A1/2 4:70462042 C T Non-synonymous 5 rs4148301 52 93.55 8 B 0.07 0.06 
UGT2B11 4:70066322 G A Non-synonymous 4 rs150196832 222 664.94 2 A < 0.01 0.01 
a consequence types in bold type are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 




Table L3: DNA repair gene panel analysis of all the unique variants scored at least 4 in the filtering pipeline 
Gene Coordinates Ref  Var  Consequencea Score dbSNP ID DPb Q scoreb Patient(s) Group MAF MAF (Afr) 
ATM 11:108143456 C G Non-synonymous 4 rs1800057 136 243.76 7 B 0.01 < 0.01 

























BLM 15:91346922 C CA Frameshift insertion 8 - 70 340.49 11 B - - 
C19orf40 19:33464178 C T Non-synonymous 4 - 38 150.99 3 A - - 
CHAF1A 19:4422644 G GA Frameshift insertion 8 - 15 29.45 9,10,11 B - - 
DCLRE1A 10:115609831 T A Stop-gain 8 - 342 37.31 1 A - - 
FANCC 9:97934359 C T Non-synonymous 4 rs1800362 43 72.52 8 B 0.01 0.05 
GFT2H1 11:18382239 G C Non-synonymous 4 - 27 43.60 1 A - - 
HELQ 4:84362474 C T Non-synonymous 5 rs142206532 51 99.09 5 A 0.01 0.02 
MPLKIP 7:40173878 AC A Frameshift deletion 8 - 6 63.24 2 A - - 
MSH3 5:79974821 C T Non-synonymous 6 rs143211109 37 142.12 4 A < 0.01 < 0.01 
MSH5 6:31725978 C G Non-synonymous 6 rs28399976 115 185.48 7 B 0.01 < 0.01 
OGG1 3:9796430 A G Non-synonymous 4 rs368423806 133 301.54 4 A - - 

























PMS1 2:190656614 G C Non-synonymous 8 rs5742973 96 151.21 3 A < 0.01 0.01 
POLE 12:133245280 A G Non-synonymous 4 - 7 15.16 5 A - - 
POLG 15:89860691 G A Non-synonymous 6 rs369544574 337 699.08 1 A < 0.01 < 0.01 
POLI 18:51795957 ACGAC A Frameshift deletion 8 - 176.5 1553.09 6,11 B - - 
POLM 7:44113786 TGG TG(GGT) Deletion/insertion 8 - 76 506.11 9 B - - 
POLN 4:2130959 A G Non-synonymous 5 - 21 141.43 8 B - - 
POLQ 3:121263697 A C Non-synonymous 4 - 13 29.82 2 A - - 
RAD23B 9:110084279 A AC Frameshift insertion 8 - 263 27.38 1 A - - 
RAD51B 14:68353913 T G Non-synonymous 4 rs33929366 48 56.96 8 B 0.01 0.03 
RAD54B 8:95390844 T TC Frameshift insertion 8 - 102 24.73 2 A - - 
RAD54L 1:46739409 C T Non-synonymous 6 rs28363240 367 664.35 3 A < 0.01 0.01 

























TOPBP1 3:133356733 G C Non-synonymous 4 rs142305736 85 148.46 8 B < 0.01 < 0.01 
TP53 17:7579579 CG C Frameshift deletion 8 - 20 73.38 5 A - - 
TREX1 3:48508608 G A Non-synonymous 5 - 28 43.48 5 A - - 
WRN 8:30924631 G A Non-synonymous 7 - 25 48.24 8 B - - 
XAB2 19:7689247 C T Non-synonymous 4 rs61761630 252 663.80 10 B < 0.01 < 0.01 
a consequence types in bold type are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 




Table L4: Cisplatin response gene panel analysis of all the unique variants scored at least 4 in the filtering pipeline 
Gene Coordinates Ref  Var  Consequencea Score dbSNP ID DPb Q scoreb Patient(s) Group MAF MAF (Afr) 
ABCC6 16:16259596 G A Non-synonymous 6 rs41278174 257.5 625.49 3,4 A 0.01 < 0.01 
ATP7A X:77268383 G T Non-synonymous 6 - 82 40.71 10 B - - 

















































REV1 2:100019495 C CG Frameshift insertion 8 - 66 399.79 1 A - - 
TRPA1 8:72984051   Frameshift deletion 8 -   7 B - - 
a consequence types in bold type are homozygous in at least one of the patients; b mean read depth and quality scores averaged over all patients with the variant 




Appendix M: Results of pathway analysis 
 
Table M1: Pathways enriched in Groups A and B 
Pathway name Pathway no. CPDB set size No. candidates Group p-value 
Activation of C3 and C5 1 7 4 (57.1%) B 0.000794 
Amoebiasis - Homo sapiens (human) 2 109 16 (14.7%) A 0.00108 
AMPK signalling pathway - Homo sapiens (human) 3 124 18 (14.6%) B 0.00311 
Aripiprazole metabolic pathway 4 2 2 (100.0%) A 0.00385 
Assembly of collagen fibrils and other multimeric structures 5 44 8 (18.2%) A 0.00512 
Benzodiazepine pathway, pharmacokinetics 6 11 4 (36.4%) A 0.00342 
Beta1 integrin cell surface interactions 7 66 12 (18.2%) A 0.00066 
Beta-oxidation of pristanoyl-CoA 8 8 4 (50.0%) A 0.000842 
Bile acid biosynthesis 9 53 9 (17.0%) A 0.00491 
cAMP signalling pathway - Homo sapiens (human) 10 200 24 (12.0%) B 0.00965 
Codeine metabolism pathway 11 4 3 (75.0%) A 0.000909 
Collagen biosynthesis and modifying enzymes 12 64 11 (17.2%) A 0.00177 
Collagen formation 13 87 16 (18.4%) A 0.0000767 
Complement activation, classical pathway 14 17 5 (29.4%) B 0.00579 
Constitutive androstane receptor pathway 15 32 7 (21.9%) B 0.00684 
Degradation of the extracellular matrix 16 84 14 (16.7%) A 0.000609 
Endochondral ossification 17 64 11 (17.5%) A 0.00155 
Extracellular matrix organisation 18 264 36 (13.7%) A 0.00000595 
Formation of senescence-associated heterochromatin foci (SAHF) 19 17 5 (29.4%) B 0.00579 
FoxO signalling pathway - Homo sapiens (human) 20 134 18 (13.5%) B 0.00716 
Glucose metabolism 21 72 12 (16.9%) B 0.00456 
Glucuronidation 22 26 6 (23.1%) B 0.00921 
Glycolysis / gluconeogenesis - Homo sapiens (human) 23 67 12 (17.9%) B 0.00279 
Glycolysis and gluconeogenesis 24 67 13 (19.7%) B 0.000754 
GRB7 events in ERBB2 signalling 25 5 3 (60.0%) B 0.00337 
Interaction between L1 and ankyrins 26 29 7 (24.1%) B 0.00383 
Ion channel transport 27 197 28 (14.2%) B 0.000424 
Ion transport by P-type ATPases 28 47 9 (19.1%) B 0.0058 
Lectin induced complement pathway 29 12 5 (41.7%) B 0.001 
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production 30 5 3 (60.0%) B 0.00337 
Mono-unsaturated fatty acid beta-oxidation 31 21 5 (23.8%) A 0.00804 
Olfactory transduction - Homo sapiens (human) 32 407 39 (9.6%) A 0.00426 
Omega-6 fatty acid metabolism 33 28 6 (21.4%) A 0.0065 
AMPK, AMP-activated protein kinase; C3, complement component 3; C5, complement component 5; cAMP, cyclic adenosine monophosphate; CPDB, ConsensusPathDB; 
ERBB2, Erb-B2 receptor tyrosine kinase; FLII, flightless I homologue (Drosophila); GRB7, growth factor receptor-bound protein 7; LRR, leucine rich repeat; no., number; 
PELP1, proline, glutamate and leucine rich protein 1 
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Table M1 (cont.): Pathways enriched in Groups A and B 
Pathway name Pathway no. CPDB set size No. candidates Group p-value 
Opsins 34 11 4 (36.4%) A 0.00342 
Other glycan degradation - Homo sapiens (human) 35 18 5 (27.8%) A 0.00395 
p53 signalling pathway 36 13 4 (30.8%) A 0.0067 
p73 transcription factor network 37 79 11 (14.1%) A 0.00843 
PELP1 modulation of oestrogen receptor activity 38 5 3 (60.0%) B 0.00337 
Pentose phosphate pathway - Homo sapiens (human) 39 29 7 (24.1%) B 0.00383 
Peroxisomal lipid metabolism 40 21 7 (33.3%) A 0.000186 
Pregnane X receptor pathway 41 33 7 (21.2%) B 0.00815 
Purine deoxyribonucleosides degradation 42 2 2 (100.0%) B 0.00522 
Purine ribonucleosides degradation to ribose-1-phosphate 43 3 3 (100.0%) B 0.000376 
Pyruvate metabolism - Homo sapiens (human) 44 40 9 (22.5%) B 0.00183 
Regulation of androgen receptor activity 45 51 12 (23.5%) B 0.000214 
Regulation of complement cascade 46 24 6 (25.0%) B 0.00609 
Regulation of nuclear SMAD2/3 signalling 47 78 12 (15.6%) B 0.00882 
Retinol metabolism 48 37 8 (21.6%) A 0.00164 
Role of nicotinic acetylcholine receptors in the regulation of apoptosis 49 17 5 (29.4%) B 0.00579 
Saturated fatty acids beta-oxidation 50 25 7 (28.0%) A 0.000618 
Stimuli-sensing channels 51 100 13 (13.0%) A 0.00873 
Transmembrane transport of small molecules 52 579 64 (11.1%) B 0.000361 
Trihydroxycoprostanoyl-CoA beta-oxidation 53 12 4 (33.3%) A 0.00488 
Validated nuclear oestrogen receptor alpha network 54 64 12 (18.8%) B 0.00186 
Vitamin A deficiency 55 37 8 (21.6%) A 0.00164 
AMPK, AMP-activated protein kinase; C3, complement component 3; C5, complement component 5; cAMP, cyclic adenosine monophosphate; CPDB, ConsensusPathDB; 
ERBB2, Erb-B2 receptor tyrosine kinase; FLII, flightless I homologue (Drosophila); GRB7, growth factor receptor-bound protein 7; LRR, leucine rich repeat; no., number; 








Appendix N: Pathway panels 
 
After identifying the 55 pathways enriched in Group A and Group B, the full gene sets from 
each pathway were downloaded from CPDB, to construct a pathway panel of genes for 
application to the total dataset. The gene sets used are provided below. 
 

























































































































































































































































4. Aripiprazole metabolic pathway (n = 2) 
CYP2D6 CYP3A43 
 
















































































































































































































































































































































































































11. Codeine metabolism pathway (n = 4) 
CYP2D6 CYP3A4 OPRM1 UGT2B7 
 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































42. Purine deoxyribonucleosides degradation (n = 2) 
ADA PNP 
 
43. Purine ribonucleosides degradation to ribose-1-phosphate (n = 3) 
ADA PGM2 PNP 
 








































































































































































































































































50. Saturated fatty acids beta-oxidation (n = 25) 
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